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ABSTRACT
Three-dimensional bicyclic and cage compounds have been used
extensively as polymers, polymer additives, medicinals, and pesticides.
Lesser applications have included fuels, fuel additives, lubricants,
lubricant additives, and perfumes. Several areas where further work
might be useful have been outlined. These are primarily in the areas
of polymers, polymer additives, medicinals, and synthetic lubricants.
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Chapter 1 - Introduction
Bicyclic compounds are compounds containing two rings fused together,
They may be made in any size beginning with four Atoms in the ring.
Since carbon is the only element that is known to extensively bond with
itself, most bicyclic compounds are organic. Some specific examples
of bicyclic compounds that have been made are shown in figure 1-1.
napthaiene bicyclobutane
A -pinene
norbornane
V
camphor
Figure 1-1. Some known bicyclic compounds.
Cage compounds are similar to bicyclic compounds except that they
are generally larger and have more rings fused together. The three
dimensional shape of cage compounds generally resemble that of a cage.
Some specific examples of known cage compounds are shown in figure 1-2.
adamantane prismane twistane
Figure 1-2. Some known cage compounds.
2The atoms where the rings are fused together are known as the bridge-
head atoms (e.g. bridgehead carbon atoms for most rings) for both
bicyclic and cage compounds.
ridgehead carbon atoms
Bicyclic and cage compounds are very common. Many natural products
contain bicyclic or cage systems. For example, gibberellin is a naturally
occuring plant growth regulator, that has been extensively studied. Many
OH
COOH
Gibberellin
of the terpenes and alkaloids found in natural products have similar
types of structures.
Studies of the chemical reactivity of these molecules suggest that
in general, most large bicyclic and cage compounds are similar to non
bicyclic compounds. Smaller systems, however, tend to exhibit special
behavior. Compounds containing very small ring systems tend to be highly
reactive because of the ring strain. Bicycloheptanes and bicyclooctanes
containing functional groups at the bridgehead, however, have been found
to be unusually stable. The unusual stability of these materials is
so striking that there should be many practical applications for them.
Definitions of the Problem
The present report represents the results of a literature survey
of the field of bicyclic and cage compounds. The objective of the
project was to identify those types of compounds that have unusual
physical and chemical stability, and to determine what practical applica-
tions have been found for these types of compounds.
Limitations of the Report
The scope of the project, as outlined above, is tremendous. There
have been literally thousands of papers written on bicyclic and cage
compounds. For this reason, it has been necessary to limit the scope
of the project to more specific areas. We have attempted to make the
limitations in such a manner that no significant areas were eliminated,
but at the same time, the bulk of the unnecessary material would not
have to be included. The specific limitations placed on the project
were:
1. Natural products were generally not considered.
2. Only three dimensional molecules (as opposed to planar
systems) were considered.
3. Highly olefinic systems were generally not considered.
4. Only articles pertaining to existing or potential applications
were included.
Natural products were eliminated because they really constitute a separate
field in themselves, and there have been many books and review articles
written on all areas of natural products. A few special cases have
been included when the compounds seemed to be particularly appropriate,
however.
Bicyclic compounds in which the bridgehead carbon atoms are bonded
to each other are not considered here. These compounds, while often
4exhibiting unique properties of their own, do not usually exhibit the
unusual stability associated with the molecules considered in this report.
These systems are most easily identified by their name as bicyclo [x.y.o]
systems. Examples are shown in figure 1-3.
bicyclo[4.4.0]decane bicyclo[2.1.Ojpentane
Figure 103. Examples of compounds with bridgehead
atoms bonded together,
Highly olefinic systems also tend to be more reactive than the
types of compounds of general interest here. For this reason, these
compounds have also been omitted from the present study.
Since the objective of the project is to determine practical
application for bicyclic and cage compounds, one of the most important
ways in which the project was restricted was to limit the study to
only papers that discussed existing applications, or obvious future
applications. For this reason, the chapters discussing theoretical
considerations are selective rather than comprehensive in scope.
Approach
The literature search consisted of a.search of chemical abstracts.
From the first Decennial index through the Eighth Collective Index^
the search was conducted by hand. A computer search was provided by the
Technical Applications Center at the University of New Mexico, Albuquerque,
5New Mexico 87133 for material published between 1972 and June, 1975.
The topics searched were
bicyclo dioxabicyclo
azabicyclo thiabicyclo
diazabicyclo cage
oxabicyclo adamantane
After the first couple of months work on the hand search, it became
obvious that there were so many duplicate listings for the same com-
pound that much time was being wasted looking up the same papers over
and over again. As a consequence, productivity was extremely low.
As the problem continued to get worse, it became obvious that a solution
would be necessary.
The solution finally reached was to have all of the pertinent
Chemical Abstract entries punched on computer cards and sorted. A
serial number was assigned to each entry so that it could be correlated
with the original source if necessary. This procedure brought all of
the duplicate entries together and made it possible to only look up the
abstract one time. A communication on this procedure was submitted to the
Journal of Chemical Education in October, 1975, andfis now in press (the
expected publication date is fall, 1976).
References
Two types of references are used in this report. These are listed
as References and Bibliography. The references are all discussed in the
body of the report. When only the abstract of the paper was available,
the chemical abstracts reference follows the main reference. When the
actual paper was used as the reference, no abstract reference is given.
The Bibliography section covers papers that are closely related, but
6not discussed in the text. The title of the paper is included in this
case as an aid to those interested in material in the Bibliography.
Chapter 2 - Reactivity of Bridgehead Systems
The reactivity of bicyclic systems varies considerably with ring
size. The small systems are generally highly reactive, Intermediate
sized systems (particulary bicycloheptane and octane) generally tend
to be unreactive. Reactivity generally increases again as ring size
increases until finally the systems tend to react much like normal
compounds,
Bicyclopentanes
The smallest molecule that qualifies as a three-dimensional bicyclic
molecule is bicyclofl,l.ljpentane.
Thermal decomposition of this material was carried out by Srinivasan.
The only product isolated between 553,0 and 582,0°K was 1,4-pentadiene.
The decomposition was first order and a free radical mechanism was
proposed.
O
Pyrolysis of l,3-dimethylbicyclo[l,l,l]pentane gave only 2,4-dimethyl-l,
4-pentadiene under similar conditions,
CH,
>
CH2 = C — CH2 - C = CH2
/-'TT /-'TJCH3 CH3
8Thermal decomposition of 2-phenylbicyclo[l.l.l]pentane-2-ol gave
l-phenyl-4-penten-l-one (65%) and cyclotru.t-ylphenyl ketone (35%) between
135 and 208°C. A mechanism involving a 1,5-H transfer from a diradical
Ph OH
0
II
Ph-C-CH2CH CH
0
II
-C-PH
intermediate was proposed. In acid solution, 2-phenylbicyclo[l.1.1]
pentane-2-ol was unstable and rearranged to 3-phenyl-3-cyclopenten-l-ol.
Ph OH
A bicyclo[2.1.0]pentyl cation intermediate was proposed for this reaction.
Bicyclohexanes
Bicyclohexanes are somewhat less reactive than bicyclopentanes.
The only three-dimensional version is bicyclo[2.1.l]hexane. Several
routes to the ring system have been devised. In general, these routes
have involved ring contraction reactions. For example, Wiberg carried
out the following sequence of reactions to obtain the ring system.
0 0
OH
\/
°
-CH, •OCOCH,
• OH OCOCH,
OH
H
10
When a chloro group was located at the bridgehead of the norbornane
starting material, it remained in the product.
CI
. , .COOH
>^ j » i -^ i i .r
0
HOAe
Once the bridgehead chloro compound was available, other deviatives
4 5
could be readily made. For example, Wiberg also carried out the
following reactions.
Li
Li
Br
ICO,
COOH
NaN5 LiAlH4,
Another interesting route to bicyclo[2.1.1 Jhexanes has been reported
by Cairncross and Blanchard. These authors obtained the bicyclohexane
ring system via a cycloaddition reaction between 3-methylbicyclo[l.1.0]
butanecarbonitrile and an appropriate olefin.
-CN "CN.
Olefins which were used included butadiene, acrylonitrile, maleonitrile,
fumaronitrile, ethylene, styrene, p-methoxystyrene, and l-(N,N-dimethyl-
amino)cyclopentene. Papers including additional routes to bicyclo[2.1.1]
11
hexanes are summarized as references 1 through 5 in the bibliography
for this chapter,
Thermal decomposition of bicyclo[2.1 . l]hexane in the gas phase
has been carried out by Srinivasan, The only detectable product
at 327 to 366°C was 1,5-hexadiene. The reaction followed a first order
rate law.
A study of hydrogen abstraction of bicyclo[2. 1 . l]hexane has been
Q
conducted by Srinivasan and Sonntag. They used methyl radicals as the
hydrogen abstracting agent. A high degree of selectivity for abstraction
of hydrogen from the number 2 position was observed.
Meinwold and coworkers have studied the solvolysis of 2-substituted
bicyclo[2.1 . l]hexenes. Their studies have shown a marked rate enhancement
compared with suitable reference models. On this basis they proposed
that a non-classical carbonium is involved as an intermediate.
I
i— •
HOAc
25"
OTs
OAc
Wiberg has studied the solvolysis of 5-substituted bicyclo[2.1 . 1]
hexanes. He concluded that the solvolysis reaction involves a concerted
rearrangement mechanism
HOAc
25'
OAc
+
OAc OTs
OTs 18% 12% 30 40%
12
11Solution photochemistry of bicyclo[2.1.l]hexane-2-one produced
bicycle[l.l.ljpentane (32%), 1,4-pentadiene (57%), bicyclo[2.1.0]pentane
(1%), and vinylcyclopropane (11%) .
32% 57% 1% 11
Bicyclohexenes
Bicyclo[2. 1 .l]hexenes have also been used in the study of strained
ring systems: They are generally made by first synthesizing a bicyclo
12[2. 1 . l]hexane followed by insertion of the double band.
Br
Solvolysis and carbonium ion rearrangement of other bicyclohexanes
has also been used. Recently, a new route involving the Ramberg-
14Backlund rearrangement has been developed.
Cl
In this procedure, the double bond is inserted at the same time that
the ring is formed.
13
Thermal decomposition of bicyclo[2.1.l]hexene has been studied
by Frey, Hopkins, and O'Niel. The reaction occurs readily between
149 and 190°C to produce bicyclo[3.1.0]hex-2-ene in quantitative yield
following a first order rate law.
149-190
A concerted reaction mechanism was proposed. Thermolysis of bicycle
13a[2.1.l]hex-2-en-5-ol derivatives gave similar results.
0
\J
This reaction was interpreted as a suprafacial[l,3]sigmatropic
rearrangement. The rearrangement was shown to be stereospecific when
an endomethyl group was placed on the five position .
56.5% 25.2%
H CH,
0.5% 98.5%
14
A study of the addition reactions of bicyclo[2.1.l]hex-2-ene
suggests that in general, eis addition is the rule.
ArS
15
Benzvalene
Photolysis of dialklbenzenes has been reported to lead to iso-
18
merization. Thus, photolysis of 0-xylene at 250 nm. gave a mixture
of ortho, meta, and para xylenes. The major product could be explained
by a 1,2 shift. Isotopic labeling experiments showed that a skeletal
19
rearrangement of the benzene ring occurred. For example, mesitylene-1,
14 143,5-C gave 1,2,4-trimethylbenzene-l,2,4-C on irradiation at 253.7 nm.
Benzvalene was proposed as an intermediate in the reaction.
20Later, photolysis of l,3,5-tri-t>butylbenzene was shown to produce the
corresponding benzvalene, Dewar benzene, and prismane. The yields in
the photostationary mixture are summarized in figure 2-1.
7.3%
Figure 2-1, Photostationary mixture
resulting from photolysis of 1,3,5-
tri-t-butylbenzene^O
64.8%
16
Irradiation of hexakis (trifluoromethyl) benzene was reported to give
similar products.
,22
54 :
The product ratio was significantly changed, however.
The isolation of unsubstituted benzvalene was finally reported''
in 1967. Rearomatization was reported to be slow at room temperature.
Bicycloheptanes
In contrast to the smaller bicyclic compounds, the bicycloheptanes
are generally stable. In fact, they often exhibit unusual stability.
The bicyclo[2.2.l]heptanes in particular show a remarkable degree of
stability.
Bicyclo[3.1.l]heptane
The bicyclo[3.1.l]heptane ring system is readily available from
naturally occurring <X- and /^-pinene.
<=K-pinene ,^ -pinene
These compounds are used extensively in the paint industry where they
are the principal constituents of turpentine. Since they are natural
products, they will not be discussed further here. Specific, unusual
applications are included later where appropriate.
17
Bicyclo[2.2.Ijheptane
The bridgehead position in the bicyclo[2.2.1]heptanes* has- been
23found to be unusually stable toward nucleophilic substitution. For
example, l-chloro-7,7-dimethylbicyclo[2.2.l]heptane has been reported
to be unreactive toward silver nitrate in aqueous ethanol. Further-
more, no chloride ion was observed when this compound was heated with
30% potassium hydroxide in 80% ethanol for 21 hours. These latter
conditions were vigorous enough to dissolve the flask even though the
bicyclic compound was inert.
This phenomenon has generally been explained in terms of the SN1
and SN2 reaction mechanisms. Backside attack of the nucleophile at
the reaction center is required by the SN2 reaction mechanism. This
is impossible with bicyclo[2.2.1] octane and similar compounds. A
carbonium ion is required in the SN1 mechanism. A carbonium ion,
however, has a strong tendency to have the groups attached to it be
planar because of its orbital hybridization (sp2). Bicyclo[2.2.1]
heptane is too small, however, for the formation of a planar carbonium
ion at the bridgehead position.
L
Bartlett and Knox estimated the strain energy for a carbonium ion
at the.bridgehead of bicyclo[2.2.2]octane to be 22.5 kcal and suggested
that for the bicyclo[2.2.1]heptane system it should be much higher.
In contrast to carbonium ion reactions, reactions of bicyclo[2.2.1]
heptane which involve free radicals and carbonium ions -proceed without undue
difficulty provided there is no steric inhibition toward resonance.
18
23
Free radical hydrogen abstraction, however, is inhibited at the bridge-
25head position. Koch and Gleicher, for example, studied hydrogen
abstractions from a series of polycyclic hydrocarbons. Using trichloro-
methyl radical as the radical source, they found no bridgehead hydrogen
abstraction from bicyclo[2.2.l]heptane. Their observations for other
hydrocarbons are summarized in Table 2-1. Normally, a tertiary position
is highly reactive toward hydrogen atom extraction.
Table 2-1. Free radical hydrogen abstraction
from bridgehead carbon atoms.25
Bridgehead reactions
Bicyclo[2,2.1]heptane 0%
Bicyclo[2.2.2]octane 8.8 t 2%
Bicyclo[3.2.1]octane Undeterminable
Bicyclo[3.3.1]nonane 100%
Adamantane 86.0 ± 2%
Homoadamantane* 73.5 1 2%
*Reaction only at the 3 position. No reaction at the 1 position.
The entire subject of bicyclic activity was reviewed by Applequist and
Roberts23 in 1954.
Bicyclooctanes
Owing to their somewhat larger size, bicyclooctanes are somewhat
more reactive than bicycloheptanes. The bridgehead position is still
quite unreactive, however.
Bicyclo[2.2.2]octane
l-Bromobicyclo[2,2,2]octane has been shown to be about 10 times
23less reactive than tertiary-butyl bromide toward nucleophilic substitution.
19
While this is faster than bicycloheptane, it is still a very slow
reaction. The addition of fused benzene rings to the bicyclic system
J f\decreased the reactivity by making the compound more rigid. Thus,
1-bromotriptycene was unreactive toward silver nitrate in aqueous
ethanol and similar conditions.
AgN05 No Reaction
. AqEtOH
\\ A 48 hr
The explanation for the lack of reactivity in this system is
similar to that for the bicyclo[2.2,Ijheptanes. Resonance stabilization
of the carbonium ion is not possible because of the Bredts Rule.
Bridgehead Reactivity
The determination of the relative reactivity of bridgehead systems
is difficult because bridgehead compounds tend to be highly unreactive
toward nucleophilic substitution. The reactivity of these compounds
has been increased somewhat by using more reaction leaving groups.
The most reactive leaving group found to date is the trifluoromethane-
sulfonate group, abbreviated triflate (Tf). Using this leaving group,
it has been found that the least reactive bicyclic compound toward
27
nucleophilic substitution is nortricyclyl triflate.
OTf
20
Bingham and Schleyer have taken a mathematical approach to the
problem. The results of their calculations on sixteen bicyclic compounds
are summarized in figure (2-2), The least reactive compound is the
nortricyclene derivative, as already observed.
29Olah and coworkers have prepared the l,4-bicyclo[2,2.2]octyl
dication.
The ion was found to be unusually stable. Nuclear magnetic resonance,
molecular mechanical and MINDO/3 techniques were used to explain the
stability,
21
10
2
-1 8x10
7x10-2 3x10-2 3x10
-3
6x10-4 3x10-4 4x10-7
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10
10-7
12
10-9
13
10-9
CH, :
14
10-11
15
10-14
16
10-19
Figure 2-2, Relative carbonium ion reactivities
of selected bicyclic compounds as „
calculated by Bingham and Schleyer.
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Chapter 3 - Synthetic Routes
to Bicyclic and Cage Compounds
As may be seen from the size of this report, a large number of .
bicyclic and cage compounds are known. Synthetic techniques leading
to these compounds are varied, The purpose of this chapter is to out-
line some of the common..techniques for synthesizing the major bicyclic
systems. In particular, emphasis has been placed on the bicycloheptane,
bicyclooctane and adamantane systems.
This is not an exhaustive treatment. Synthetic routes to specific
compounds that have been discussed elsewhere may be found by referring
to the reference for that compound,
Bicyclo[2,2.1]heptanes
The general route to bicyclo[2,2.1Jheptanes involves a 4+2 cyclo-
addition of cyclopentadiene to ethylene or
CH2=CH2
acetylene derivatives,
\\ //
+ HC=CH
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A common olefin that has been employed is maleic anhydride.
0 v
 0
0
Many examples of compounds prepared in this manner are found throughout
this report,
To place functional groups at the bridgehead position, it is necessary
to start with the functional group on the 1 or 1 and 4 positions.of the
cyclopentadiene molecule.
Y—/ \_X + CH2CH2
Once the bridgehead carbon atom has a functional group attached,
it may be converted into another functional group by reactions involving
a free radical or carbanion. Some examples that have'been used are:
RBr EMgQ > RMgBr -^U RCO°H
2
 %^ RHgOAc
OBr9
RCONH2 >
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Reactions involving carbonium ions generally do not work well.
Nortricyclenes are made by 1,4 addition to bicyclo[2.2.1]hepta-
2,5-diene.
Bicyclo[2.2.2]octanes
Like the bicycloheptanes, the bicyclooctanes are usually made by
a 4+2 cycloaddition reaction. Bridgehead substituents may be added
IX
CH,,
CH,
by starting with a 1,4-disubstituted cyclohexane.
l,4-Diamino[2.2.2]bicyclooctane has been made by treating 1,4-
diaminocyclohexane with acetylene in the presence of ditertiary butyl
2
peroxide.
+ HC=CH peroxide
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Bicyclo[2.2.2]octane-l-carboxylic acids containing substituents
in the 4-position have been synthesized from the corresponding 1,4-
3adicarboxylic acid ester.
COOH
X = CONH2,Br,NH2
CN,H,OH
COOH COOEt
l,4-Dihydroxybicyclo[2.2.2]octane has been prepared by the
4following sequence:
Cl
I
CLr^T- C-H,I 24 >
V4
Cl OH
Cl Cl
H20/Cu
Cl Cl Cl OH
Some compounds that have been derived from l,4-dihydroxybicyclo[2.2.2]-
octane are:
OH
SF,
HF
OH
NX
OTs
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The following sequence of reactions has also been reported.'
0
OAc
OAc
H
OAc OAc OAc
OAc OAc
OAc
OAc
v
OAc
OAc
COOH
<
COOH
OAc OAc 0
X = Cl,Br,I
OH
32
Adamantanes
The easiest way to.make adamantane is to.isomerize erido~trimethyl-
enenorbornane (obtained by hydrogenation of dicyclopentadiene) with
aluminum chloride or another Lewis acid, Polymethyladamantanes have
been made by treating perhydro tricyclic aromatic hydrocarbons in a
similar manner, 1,3,5,7-tetrasubstituted adamantanes, particularly
Q
the tetramethyl product have.been specifically reported,
1-Aminoadamantane is an important antiviral compound, Its synthesis
9
has been described by several authors. One route involved the addition
of nitrogen trichloride to adamantane in the presence of aluminum
chloride.
1,3-Dibromoadamantane has been prepared by reaction of adamantane or
1-bromoadamantane with bromine and aluminum bromide. Polyhaloadaman-
tanes have been made in a similar manner,
Bromination, chlorination, sulfonation, hydroxymethylation, nitra-
tion and air oxidation of adamantane have been studied by Smith and
12Williams. A high degree of selectivity for attack at the tertiary
position was observed.
13Bingham and Schleyer have looked at the chromic acid oxidation of
bridgehead compounds. While bicycloheptane and bicyclooctane reacted
33
slowly, attack at the bridgehead position of adamantane was considered
to be sufficiently rapid.and selective-that the.method could.be synthet-
ically useful,
34
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Chapter 4 - Theoretical Applications
of Bicyclic and Cage Compounds
The three-dimensional structures of bicyclic and cage compounds
makes them ideally suited for many theoretical studies. As a consequence,
they have been used extensively in studies related to bonding in organic
chemistry.
Studies of Strained Bonds
Bicyclic and cage compounds containing small rings have considerable
ring strain. As a consequence, they tend to show unusual reactivity.
This unusual reactivity has made them the subject of numerous studies
of ring strain and strained bonds. Some of these studies have been
summarized in Chapter 2. Major workers in this field have been Wiberg
2
and Meinwold. This area has grown to the point that a thorough review
by a neutral observer might be useful. •
Studies of Carbonium Ions
As indicated in Chapter 2, bicycloheptanes and bicyclooctanes form
carbonium ions at the bridgehead only with difficulty. Studies of
bridgehead carbonium ion reactions have added significantly to the
knowledge of the shape of carbonium ions and their reactivity. While
a planar carbonium ion is predicted by quantum mechanics, the extent
of the tendency for carbonium ions to achieve a planar configuration,
as discussed in Chapter 2, probably could not have been predicted with-
out the laboratory studies.
Carbonium ions formed at positions other than the bridgehead do
not show the unusual lack of reactivity associated with bridgehead carbon
atoms. On the contrary, they often show unusual reactivity, stereo-
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chemistry, and a tendency to undergo rearrangement reactions, These
phenomena have been rationalized by introducing the concept of non-
classical carbonium ions. This concept has been argued and reviewed
many times in the last fifteen years or so, and will not.be discussed
here, The main protagonists in.the area have been H, C. Brown,
S, Winstein, D, J, Cram, and.J, Roberts, although others including
P,v.R, Schleyer and G, Olah have also become involved. A few key
reviews are found in reference 3,
Bredt's Rule
4
Bredt, a specialist in camphor chemistry, suggested a rule relating
to bicyclic compounds .in 1924 that has since come to .bear his name.
In its most simple form, Bredt's Rule states that a double bond cannot
exist at the bridgehead position of a bicyclic compound unless the
rings are large enough to accommodate it without excessive strain.
Since that time, much effort has been expended to define the .limits
of the rule. Fawcett reviewed the subject in 1950 and suggested that
in three-dimensional systems a double bond at the bridgehead position
should be isolable if the sum of the atoms between the bridges is
greater than or equal to nine. This number was call the S value.
Transient intermediates were believed to be possible for S as low as
six.
This concept proved to be fairly accurate, and the subject rested
at this point until 1967 when Wiseman prepared bicyclo[3.3.1]non-l-ene
and suggested a refinement of the rule, Wiseman postulated that the
compound should be isolable if the largest ring contains at least eight
carbon atoms, and if the olefin is trans to the largest ring. He further
38
postulated that compounds containing a trans cycloheptene ring might
be found as transient intermediates. Since that time, the hypothesis
has been substantiated by evidence suggesting the transient existance
of bicyclo[3.2,2]non-l-ene,
Q
The subject was reviewed by Kobrich in 1973, The entire topic
9
was reviewed again in!974 by Buchanan.
Studies of Free Radicals
Free radicals normally attack tertiary positions preferentially.
As indicated in Chapter 2, however, the bridgehead positions in bicyclo-
heptanes are unreactive toward free radical attack, Danen, Tipton, and
Saunders studied the relative rate of abstraction of iodine from
compounds (4-1), (4-2), (4-3), and (4-4).
(OH3)3C-I
(4-1) (4-2)
I
(4-3)
I
(4-4)
The relative order of stability was found to be (4-1)> (4-2)> (4-3)>
(4-4).
The observation that free radicals may exist at the bridgehead
position has been used as evidence for the free radical nature of some
39
reactions, Decarbonmonoxylation is one example,
co
The reduction of 4-camphylmercuric chloride with sodium stannite is
also believed to involve a free radical intermediate.
HgCl
Carbanion Reaction^
Reactions involving carbanions have not been as well studied as
those involving carbonium ions, Nevertheless, it is generally accepted
3 12that a carbanion consists of a rapidly inverting sp species.
Bridgehead positions should have no problems with carbanion formation
except for inhibition to inversion.
This situation is generally true, Reactions which tend to proceed
via carbanion intermediates generally proceed without undue difficulty.
Reactions which might be included in this category are Grignard and
other organmetallic reactions, and the Hoffman Rearrangement. These
reactions are useful for interconversion of functional groups at the
bridgehead position.
40
In-Put Isomerism
Most bicyclic compounds have the bridgehead substituents located
outside the hydrocarbon cage. Small rings, of course, cannot exhibit
this phenomenon. Larger rings, however, can exist in three forms,
out-out, out-in, and in-in.
H—C H—C H—
out,out out, in in,in
There has not been a great deal of work on this phenomenon, but a
few compounds have been made. In particular, bicyclo[8.8.8]hexacosane
has been prepared in the in-in form.
C—H H—C
For this size ring system, it was suggested that the in-in form was the
14
most stable form of the molecule. Gassmann and Thummel in a
compa'riion paper, prepared (4-5) and (4-6).
41
-(CH,) (CH2)g
(4-6)
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Chapter 5 - Applications to Polymers x
At the research level, bicyclic and cage compounds have been
used rather extensively for polymers. Most of the common bicyclic
and cage systems have been synthesized and incorporated into polymers.
Polyamides and polyesters have probably received the most study, but
bicyclic analogs of the other common polymer types, such as polyolefins.
polyvinyls, polyethers, and polyurethanes have also been prepared.
These compounds are generally reported to have improved physical properties
such as thermal resistance.
The general procedure for making polymers containing bicyclic groups
has involved synthesis of the appropriate monomer followed by a classical
polymerization process. Two alternate routes have also been used in
.selected cases, however, which might find more extensive use. In the
first route, a preformed polymer containing a double bond is treated
with a cyclic diene to form bicyclic groups along the polymer chain by
a 4 + 2.cycloaddition reaction.
>CH=CH-—-— «~~»CH — CH
\J
This should be a good way to incorporate flame retardancy into the
polymer by using compounds like hexachlorocyclopentadiene as the diene.
The disadvantage of this procedure is that there is no assurance that all
of the olefinic sites in the polymer will be reacted.
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A more certain technique that assures that all sights are reacted
involves formation of the bicyclic compound as part of the polymerization
process. This has been accomplished in one instance by treating a
diimide containing a double bond at two sights with a cyclopentadiene.
The resulting cycloaddition product was a polymer containing a bicyclo-
[2.2.2]octane ring system as an integral part of the molecule.
In an alternate route to polymers, bicyclic lactams, lactones, and
similar compounds have been used as monomers. The resulting polymer does
not contain a bicyclic ring, however, even though the monomer was bicyclic.
OOC
In spite of the extensive research work on bicyclic polymers, and
the improved properties that they are reported to have, it is not obvious
that they have found any appreciable commercial market. This situation
is probably due to the high cost of the bicyclic monomers. Only highly
desirable and unusual properties could justify using an expensive polymer,
and a significant, high volume market probably could not be developed.
Polyamides
Polyamides are the main, but not the only, topic of one of the most
extensive patents in the area of bicyclic polymers. Polyamides, polyesters,
polyureas, and polyurethanes made from bridgehead substituted bicyclo-
[2.2.1]heptanes, bicyclo[2.2.2]octanes, bicyclo[3.2.2]nonanes, bicyclo-
[3.3.l]nonanes, adamantanes, and related bicyclic compounds are disclosed
in this patent. These polymers are reported to have improved mechanical
46
properties including thermal and oxidative stability. Their use in fibers
was suggested, and data on fiber properties were included. Some specific
polymers from the patent -are listed in Table 5-1. Other related polymers
Table 5-1. Some specific polymers disclosed
in U.S. Patent 3,301,827.
poly(bicyclo[2.2.2]oct-l,4-ylene sebacamide)
poly(l-bicyclo[2.2.2]octylene-4-carbonamide)
poly(bicyclo[2.2.2]oct-1,4-ylene suberamide)
poly(bicyclo[2.2.2]oct-1,4-ylene isophthalate)
poly(bicyclo[2.2.2]oct-1,4-ylene terephthalate)
poly(bicyclo[2.2.2]oct-1,4-ylene-m-terphenyl-4,4 -
dicarboxylate)
poly(adamant-1,3-ylene sebacamide)
polymer from adamantane-l,3-diisocyanate and
polytetramethylene ether glycol (M.W. about 2000)
polymer from adamantane-1,3-diisocyanate and
1,3-diaminocyclohexane
are included in the patent, as well as synthetic routes to some of the
monomers.
2
In related work, Martin has patented heat and oxidation stable
polyamides made from diamines of the type:
NH.
where 1, m, and n are 1, 2 or 3, and their sum is 5 to 9. The preferred
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diamines were bicycle[2.2. l]heptane-l-4-diamine, and bicyclo[.2.2.2]-
octane-1,4-diamine. The preferred diabasic acids were adipic acid,
suberic acid, azelaic acid, sebacic acid, isophthalic acid, and
terephthalic acid. In addition to the diamines, diols and amino
alcohols are used to make polyesters and combination polyester-polyamides.
Bicyclo[2.2.1]heptanes
Acrylonitrile is reported to form an interpolymer with the following
compounds:
:OOR y i :OOR
R = alkyl group with 1-4 carbon atoms
4Similar polymers are made from the corresponding imide.
M = H or -C-NRR1
R = -H,-CH3,-C2H5,-CH2CH2OH,-Ph
These materials are reported to be outstanding for fiber formation.
Bicyclo[2.2.l]heptane 2,3-dicarboxylic acid forms a polymer with
4atetramethylenediamine. This polymer is also a good fiber forming
material.
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Bicyclic polyimides (5-2) and polyimidazoles (5-1) derived from
furan have been used to make heat stable polymers.
n
(5-2) (5-1)
These polymers were reported to be stable up to 350-450° in air.
2-Azabicyclo[2.2.l]heptane-3-one has been used as a monomer for
.0
H
th.e formation of polyamides. In this case, the monomer is bicyclic,
but the resulting polymer is not. There are several examples of this
situation in the bicyclooctane systems discussed later in this chapter,
49
Another source of nonbicyclic polymers with a bicyclic origin is
the maleimides. N-substituted maleimides for polymers have been pre-
pared by the retro Diels-Alder (4+2 cycloaddition) reaction.
Insecticidal and fungicidal properties have also been attributed to some
Q
of these materials.
Formation of the bicyclic systems during polymer formation has
been achieved by carrying out a 1,3-dipolar addition between 5-oxazolone
q
and nonconjugated dienes.
R ° °
1 0 0
CH-Ph
0 I 2 o
—N -CH2CH2-
n
(5-3)
Other dienes that were used included the following:
COOH COOH y = CO, C=C(CN)2,
C02(CH2)402C
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These polymers were reported to have increased thermal stability.
Application to coatings were suggested. Polymer (5-3) was reported
to have a weight loss of 10% at 350°, 20% at 385°, and 50% at 500°.
Tricyclopentadiene has been used as a starting material for the
formation of diamines for use in polyamides via the Ritter's reaction.10
HCN
NHCHO
4HCHO
Bicyclo[2.2.2]octanes
Polyamides from bicyclo.[2.2.2]octan-trans-2,3-dicarboxylic acid
and piperazine were prepared by Overberger and coworkers in order
to study a structurally rigid, asymmetric polyamide that could not
hydrogen bond.
d COOH
COOH
A discussion of the special properties anticipated for these materials
was not included in the papers.
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Bicycle[2.2.2]oct-7-ene-2,3,5,6-tetracarboxylic acid dianhydride
has been prepared by treating 3,5-cyclohexadiene-l,2-trans-dicarboxylic
acid with maleic anhydride. Heat resistant polyimides having high
softening points and favorable electrical properties are made from this
monomer and an appropriate diamine such as 4,4 -diaminodiphenylmethane.
Lacquered coatings, molded articles, and film were proposed as uses
for these materials. When 4,4*-diaminodiphenylmethane-3,3'-dicarboxylic
acid was used as the diamine, the resulting polymer could be crosslinked
with toluene and diisocyanante to give an elastic crosslinked coating
,, . 13dfor wires.
An alternate route to these polymers involves using the tetracar-
14boxylic acid ester instead of the anhydride.
ROOC ^f^ COOR
ROOC
The saturated compound has also been prepared and used to make heat stable
polyimides for protective coatings and building elements.
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Polymerization of l,4,7,8-tetrachlorobicyclo[2.2.2]-7-octene-2,
3,5,6-tetracarboxylic dianhydride rubeanic acid to form a polymer suitable
Cl n
Cl 0
16for use as a copy sheet for the thermographic copy process. Sheets
made from this and other polymers reported in the patent are less subject
to aging.
A few rather exotic bicyclic compounds have been used as monomers
for polyamides, such as (5-4), (5-5), and (5-6).
xCOOH
COOH0
(5-5)
(5-6)
Polyimides derived from (5-4) are reported to have properties that are
superior to polyamides. They are proposed for use as coatings and elec-
trical insulation material. Compound (5-4) has been polymerized with
I Q
both aliphatic and aromatic diamines to give polymers that showed
heat resistance to 360°. Compound (5-6) is converted to a polyamide by
19
reaction with hexamethylenediamine.
53
Another series of bicyclic polyamides is obtained by treating
triethylenediamine (l,4-diazabicyclo[2,2.2]octane) with an appropriate
20 21
carboxylic acid. Acids such as maleic anhydride, phthalic anhydride,
22 23and linoleic dimer acid, or other higher fatty acids have been used.
The latter two compounds have been proposed as adhesives and potting
resins respectively.
The formation of a bicyclooctane ring system during the polymeri-
24
aztion process was reported by Kraiman.
0
0
-CO
CH,
n
25This procedure has been used for similar polymers.
A series of substituted bicyclo[2.2.2]oct-2-ene compounds have
been reported as intermediates in the production of heat resistant poly-
o s
amides. The following compounds are specifically included.
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CH.
OH
OCH,
OH
CH,
OCH,
CH,
OH OCH,
Ph
OCH, OCH,
OCH.
H,
CH,
OCH,
CH,
No details on how they were used were given in the patent abstracts,
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Several monomers have been made that can be used to make polyamides.
For example, 1 , 4-bis-(0-chlorobenzylamino)-bicyclo[2.2. 2] octane is
a suitable diamine. Similar 1,4 disubstituted bicyclo[2.2. 2] octanes
28 29 29 30
containing amides. ' carboxylic acids and amino groups have been
reported.
Adamantanes .
The adamantane ring has been incorporated into polyamides in several
ways. Adamantan-l,3-dicarbonyl chloride has been polymerized with
31diamines by either interfacial or solution polymerization. Hexa-
methylenediamine, ethylenediamine, m-phenylenediamine, and 1,3-adamantyl-
enediamine have been used. The products are reported to have good impact
resistance, a low coefficient of friction, a high softening point, good
tensil strength, and low water absorption.
321 , 3-Diamidoadamantanes have been prepared and found useful in
the preparation of polyamides and as antistatic agents for fibers and
moldings. Polyamides of this type are clear films and sheets. They are
useful as wrappings, displays and in structural design. They may be
drawn into fibers for textiles, carpeting, and tire cord.
CONHRNH—
Nonbicyclic polyamides from bicyclic monomers.
34Hall carried out a study in 1958 to determine which bicyclic rings
containing suitable functional groups (lactams, lactones, etc.) could be
57)
induced to polymerize. In general, he found when bicyclo[2.2.2]octanes
and bicyclo[3.2.2]nonanes containing a cyclohexane ring in a boat form
are used that polymerization occurs readily. Bicyclo[3.2.l]octanes
varied in polymerizability. When stable chair forms of cyclohexane
were present as with bicyclo[3.3.Ijnonane, no polymerization occurred.
Since Hall's pioneering work in this area, several bicyclic monomers
have been reported along with their corresponding polymers and copolymers.
2-Azabicyclo[2.2.2]oct-3-ane (5-7) has been used rather extensively to
(5-7)
•7 r 70
make copolymers with £ -caprolactam. ' Fibers made from these copoly-
35c
mers are said to exceed the quality of Nylon 6. Increased thermal
35e
and oxidative thermal stability were also reported. A copolymer
between (5-6) and the corresponding lactone (2-oxobicyclo[2.2.2]oct-3-ane)
has also been reported.
2-Azabicyclo[3.2.l]oct-3-ane (5-8) has also been used to prepare
(5-8)
37 38polyamides. ' Use in fibers was suggested because of the ability of
38
the polymer to absorb 6% water.
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3-Azabicyclo[3.2.2]nonan-2-one (5-9) has also been prepared for
40
use in polymers.
0
N-H
(5-9)
The polymers have good chemical resistance, heat resistance and mechanical
stability and are useful for machine parts, electrical parts, and tire
cords.40a
41Attempted synthesis of the lactam (5-10) gave only polymer.
(5-10)
It was suggested that the ether group was cleaved in the acidic medium
used in the synthesis.
59
Polyesters
Like the polyamides, bicyclic polyesters have been studied rather
extensively. Bicyclo[2.2.l]heptane and bicyclo[2.2.2]octane systems
have been thoroughly studied. Adamantane has also been incorporated
into polyesters.
Bicyclo[2.2.l]heptanes
The most common monomer of the bicyclo[2.2.1]heptane series that
has been used in polyesters is bicyclo[2.2.l]heptan-2,3-dicarboxylic
acid (5-11) and derivatives such as the anhydride. A copolymer made
Q
COOH
COOH
(5-11)
from the diethyleneglycol ester of (5-11), styrene, and maleic anhydride
42
has been suggested for impregnation of textiles and as a casting resin.
Other glycols were also used.
Copolymerization of a diester of (5-11) with vinyl chloride or
vinylidene chloride in the presence of a peroxide catalyst gave a poly-
mer with improved heat and light stability, and improved molding and
43a
extrusion characteristics. A series of esters of (5-11) such as the
octadienoate, crotonate, methacry-I.ate and acrylate have been reported
for use in paints, varnishes and coating compounds because they form
44tough films on exposure to air.
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The corresponding compound containing a double bond at the number
5 position (5-12) has been used even more extensively, probably because
(5-12)
it can be made by a Diels-Alder reaction between cyclopentadiene and
45 •
maleic anhydride. Chloromaleic anhydride has also been used to make
46 'the corresponding chlorocompound. The diallyl ester has been reported
47by Morris, Snider, and Horowitz for use in polymers and a copolymer
of the diallyl ester, ethylene glycol, maleic anhydride, and phthalic
48
anhydride has been reported by Agnew.
Compound (5-12) has been polymerized with dialcohols such as 2-ethyl-
1,3-hexanediol to form a polyester that is suitable as a plasticizer
49
for urea and melamine-formaldehyde resins. By mixing the polyesters
obtained from (5-12) and ethylene glycol, triethylene glycol, propylene
glycol, or dipropylene glycol with a drying oil, a wrinkle finish coating
was obtained. Another copolymer system was also suggested for coatings
or plasticizers depending on composition. The diallyl ester of (5-12)
.and similar compounds has been prepared and used to make polyesters
52afor surface coatings with good electrical insulating properties.
Fatty oils and vinyl monomers have been included in a polymer composition
r Ol»
using allyl derivatives.
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When furan was substituted for cyclopentadiene, a heterocyclic
, , 52
monomer resulted.
Polymerization occurs with peroxide or metal soaps between 35 and 160°.
Partial polymerization produced a product which could be shaped or molded
and which was infusible on further heating.
Bicyclo[2.2.l]hept-5-en-2-carbonic acid has been homopolymerized,
and copolymerized with maleic anhydride. The related bicyclo[2.2.1]-
hept-2-en-5-ylmethyl acrylate (5-13) and methacrylate (5-14) have also
CH2OOCCH=CH2
(5-13) (5-14)
been prepared. Useful polymers and coatings can result from poly-
merization of these monomers. A copolymer made from norborneol meth-
55a
acrylate and methyl methacrylate has also been reported. A Diels-
Alder adduct of cyclopentadiene and allyl alcohol has been polymerized
with methacrylic acid.
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Norbornene and tricycloheptene ether-esters have also been prepared
for use in polymers.
XR R X-^ N^^ x^  COOR
R = alkyl (C -C )
1
R = alkyl or haloalkyl
X = S,0
These compounds also have fungistat and preemergent herbicidal activity.
Polyesters made from 2,5-diketo-l,4-cyclohexane-l,4-dicarboxylic
acid, and methylene bridged derivatives of this acid have been investi-
58gated to determine the effect of carboxyl orientation on melting point.
Contrary to earlier belief, it was concluded that aromatic rings and
a carbonyl attached to the ring is not necessary for fiber formation.
The symmetry of the. polymer unit is important, however,
A series of three-dimensional polycyclic bisphenol polycarbonates
59
and polyesters has been patented by Caldwell and Jackson, The bis-
phenols disclosed in this patent were of the type:
R R
HO— V \S— X — // \\-OH
R = H, halogen, alkyl X = bicyclic group
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Bicyclic groups included the following:
Improved temperature properties and solubility in volatile solvents
was claimed for these compounds. Phosphorous was incorporated into the
compounds in order to add fire retardant properties.
Flame retardant properties have also been incorporated into the
monomers by using hexachlorocyclopentadiene to prepare the bicyclic
compound. For example, the Diels-Alder adduct of maleic anhydride and
hexachlorocyclopentadiene has been incorporated into fiberglass composi-
tions to impart flame resistance. A small amount of antimony oxide
has also been added.
Two somewhat more complicated molecules have also been incorporated
^9 ^ f^ t^
into polyesters. These are (5-15) and (5-16).
HO
OOH
LOOK
(5-15) (5-16)
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A polymer of (5-16) and styrene was sprayed on wood to form a finish
that was free from tackiness after 30 minutes and could be polished
after 15 hours.
l-Azabicyclo[2.2.1]heptane, along with several other bicyclic and
non-bicyclic heterocyclic amines, has been incorporated into polyester
64
compositions. The products were used to form films and fibers.
Bicyclo[2.2.2]octanes
Diels-Alder adducts of cyclohexadiene and maleic anhydride have
been used to make polyesters.
(5-17)
For example, compound (5-17) has been condensed with glycerol or penta-
erythritol to form polyesters which soften in the 66 to 103° range.
Alkyd resins were prepared by adding linseed oil, sunflower oil, or
coconut oil. These resins formed strong, heat and water resistant
coatings.
By using a 1,4-disubstituted diene, bridgehead substituted versions
fiQ
of (5-17) have been made.
X u
X = C O O H , COC1, COOR
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Bicyclo[2.2.2]oct-7-en-2,3,5,6-tetracarboxylic acid and the corresponding
anhydride (5-18) has also been used in polymers.
HOO
HOOC
COOH
COOH
(5-18)
Varnishes and stoving enamels have been prepared using this monomer
in various formulations. Drying oils have also been prepared from this
, 70
compound.
Perchlorocoumalin and maleic anhydride have been condensed to form
compound (5-19).
0
(5-19)
This monomer, which is obviously related to (5-18) has been used to make
fire retardant polymers.
72Taimr and Smith studied a series of polyesters made from various
combinations of the following compounds:
HOOC :OOR HOOC—r-~V'V-C
C5-20)
HOCH CH2<DH
66
,OH
(5-21)
HOOC(CH2)nCOOH
n = 4-8 HOOC COOH
HO(CH2)nOH
n = 2-6
HOH2C CH2OH
Watson had previously patented polymers made from (5-20) and (5-21).
Tables of melting point, thermal stability, and oxidation stability
were included in the papers for the various compounds studied. In general,
replacing a non-bicyclic ring structure with a bicycle[2.2.2]octane
structure had little effect on the melting point of the polymer. A
notable exception was observed with polyesters made from open chain
glycols and either terephthalic or l,4-dicarboxybicyclo[2.2.2]octane.
In this case, no effect was observed when the glycol contained an even
67
number of methylene groups, but the bicycle derivative had a significantly
lower melting point when the glycol had an odd number of methylene
groups. A similar type of behavior had been reported earlier with
polyesters obtained from p-xylylene glycol.
When the bicyclo[3.2.2]nonane ring system was used in place of
the bicyclo [2.2.2]octane ring system, the melting point was significantly
reduced. This phenomenon was attributed to the observation that the
functional groups on the bridgehead carbons are located at an angle of
about 150° in the bicyclo[3.2.2]nonane system compared to 180° in the
bicyclo[2.2.2]octane system. The bond angle should reduce symmetry in
the crystal and therefore lower the melting point. When both the alcohol
and the acid groups were bicyclic, a significant increase in melting
point was observed.
Thermal stability showed a similar pattern. With one ring present
in the polymer (bicyclic or not) the molecule was less stable than when
two rings (one bicyclic) were present. Maximum thermal stability was
observed with two bicyclic rings in the unit cell. Oxidative stability
was also greatly increased by the presence of two bicyclo[2.2.2]octane
rings in the molecule.
Batzer and Benzing used 2,5-dihydroxy-l,4-dicarboxybicyclo[2.2.2]-
octane as a monomer with hexane-1,6-diol as a model for cellulose. The
corresponding compound from 2,5-diketo-l,4-dicarboxybicyclo[2.2.2]octane
was also prepared. The influence of hydrogen bonding on solubility,
softening point, crystallization, and solution behavior was discussed.
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Oxidation resistant polymers have been reported from 2,6-dihydroxy-9-
oxabicyclo[3.3.Ijnonane and derivatives.
OH
Both polyesters and polyurethanes have been prepared from this monomer
and the appropriate diacid or diisocyanate.
Polyester resins have also been made from acetylenic diesters and
polyols. An olefinic linear polyester is obtained by addition of a
diol of the type HXYXH across the triple bond. In this case, X is
oxygen or sulfur and Y is an.alky1 or haloalkyl group containing 2-18
carbon atoms or a polyglycol containing up to 100 oxygen atoms. The
polymers were cast into films, spun into fibers, and used as coatings
and for impregnation. Compression molding produced tough, transparent
objects.
Adamantanes
The adamantane ring structure has been incorporated into polyesters
by addition of both carboxylic acid and hydroxyl groups to the ring.
Dimethyl adamantane 1,3-dicarboxylate has been used to make heat resis-
78
tant fibers and films.
l,3-Dihydroxy-5,7-dimethyladamantane has been polymerized with
CH
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79b 79b 79a
maleic anhydride, phthalic anhydride, or diethyl malonate.
These polyesters are reported to have good light, hydrolysis and thermal
stability. Films and fibers have been prepared from these compounds.
Acrylic and methacrylic esters of 3,5-dimethyl-l-adamantanol have
80been prepared. Polymers have been prepared from these monomers.
Bicyclic lactones
As with the bicyclic lactams, the bicyclic lactones have been
prepared and polymerized. The resulting polymers are not bicyclic. For
example, 2-oxabicyclo[2.1.l]hexane-3-ones have been polymerized.
R = H,CH. R = H,CH CF
A white polymer which could be pressed into clear, self-supporting
film at 100° resulted.
Polymers have also been prepared from 3-oxabicyclo[3.1.Ijheptan
QO 83a
2-one (5-22) and 3,8-dioxabicyclo[3.2.l]octan-2-one (5-23).
(5-23)
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Compound (5-23) produces thermosetting polymers that are useful as
protective coatings. 3-Oxabicyclo[2.2.2]octan-2-one derivatives have
0 17 -L
also been prepared. There is no evidence, outside of the work of
84Hall, that any attempt was made to convert them to polymers.
Miscellaneous Polyesters
Esters and polyesters have been reported from 8-hydroxytricyclo-4-
84decene. High melting resins are reported. A polymer prepared from
tricyclodecanedicarboxylic acid and glycerol was a glassy material which
Q r
hardened to a rubber-like infusible mass on heating.
Cagelike polymers have been prepared by adsorption of polymers
Of-
on cellulose. Washfastness was improved with these materials. Mixed
carboxylic acid esters of cellulose in which bicyclic acids are incor-
porated have been used as antistatic and antihalation layers and as modifiers
o y
for coupling components for color photography.
Diazabicyclooctane was used, among other acids and amines, in a
study on the inversion of maleic acid end groups on polyesters into
88fumaric acid. Diazabicyclooctane has also been treated with sulfur
89dioxide to make an additive for ethylenically unsaturated polyesters.
The adducts were also useful as catalysts for polyurethane formation..
Halogenated bicyclic aromatic hydrocarbons have been used to treat
90polyesters. Improved dyeability and dimensional stability resulted.
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Polyolefins
Polyolefins using bicyclic and cage ring systems have not been
used extensively. Polybicycloheptanes and polyadamantanes have probably
been the most thoroughly studied. Thermal and oxidative stability
generally result from the addition of bicyclic and cage groups to the
polyolefin chain.
Bicycle[2.2.1]heptanes
Cationic polymerization of norbornadiene has been reported by
91Kennedy and Hinlicky. Polymerization using aluminum chloride was
accomplished at several temperatures between 40° and -123°. Only
the material produced at -123° was completely soluble. Other tem-
peratures produced a crosslinked material. This observation is
92
consistent with an earlier patent in which poly-bicyclo[2.2.1]-2-
hept.ene was claimed and which was reported to not melt below 300°.
The repeating unit in the soluble material is apparently a 2,6-disub-
stituted nortricyclene.
3-Allylnortricyclene has also been prepared and polymerized.
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The following bicyclic monomers have all been polymerized by
94
Borne, Miller, Rose and Wood.
(5-24) (5-25) (5-26) (5-27)
Polymers of compounds (5-24), (5-25), and (5-26) are all soluble in
organic solvents. They could be molded and drawn, and showed crystallin
x-ray patterns. Compound (5-27) was insoluble in organic solvents,
and decomposed without melting.
In a study of the mechanism of polymerizations, Farmer and Martin
observed that dimerization of {3 Y -dimethylbutadiene gives methyleno-
tetramethylbicycloheptane. The exact structure of the product was
not determined, and two alternatives were proposed.
Copolymerization of ethylene with dicyclopentadiene (5-28), ethyl-
idenenorbornene (5-29), and methyl endomethylene hexahydronapthalene (5-30}
(5-28) (5-29) (5-30)
has been reported by Schnecko, Caspary and Degler using a Ziegler-
Natta catalyst. Physical properties of the polymer varied with compo-
sition.. Above 15-20% diene, the material is amorphous.
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Cross-linked copolymers of ethylene and derivatives of bicyclo-
97[2.2.l]hept-2-ene have been reported. Protective coatings, extruded
articles, and films have been made from these materials.
98Pliimer and Keller have studied copolymers of bicyclo[2.2.l]hept-
2-ene with vinyl acetate and vinyl chloride. Pledger and Butler have
99
similarly prepared a copolymer between bicyclic dienes and maleic
anhydride. Polymers such as
n
were prepared and characterized.
Polymerization of 7-oxabicyclo[2.2.1]heptane has been accomplished
using phosphorous pentafluoride in methylene chloride. The rate
of polymerization was studied, and an activation energy of 15.4 kcal/mole
was reported.
Cyclopentadiene has been polymerized and copolymerized to form
useful polymers. The products are presumably at least partially
bicyclic. Di and tricyclopentadiene, obtained by catalytically poly-
merizing cyclopentadiene, has been successfully polymerized with maleic
. . . . lOlb
anhydride.
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Bicyclo[3.1.1]heptanes
6,6,Dimethyl-2-vinyl-bicyclo[3.1.1]hept-2-ene (trivial name-
nopadiene) polymerizes slowly to a sticky yellow solid in the presence
102
of benzoyl peroxide. It also slowly copolymerized with butadiene.
Nopene forms high molecular weight polymers (MW 8000-12000) by thermo-
lysis of benzoyl peroxide. The product is similar to polystyrene
but the softening point is higher.
Bicycle[2.2.2]octanes
The Diels-Alder adduct of cyclohexadiene and maleic anhydride.
104has been converted to compound (5-31). This compound formed a
_ .CHnOH
l)H.g/Cat
2)LiAlH4
(5-31)
crystallin polymer using potassium persulfate-n-dodecylmercaptan as
a catalyst. The polymer had a Vicat softening point of 85°.
The following compound has been incorporated into polystyrene.
Polystyrene
75
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Between 0.1 and 10% are recommended.
A copolymer between 1,3-butadiene and 2-methyl-5-vinylpyridine
has also been reported.
Adamantanes
Polyadamantane has been prepared by Reinhardt. The adamantane
nuclei are connected at the 1 and 3 positions.
The polymer does not melt below 420° and is greater than 80% crystallin.
It is also insoluble in boiling acid, alkali, and common organic
solvents. Derivatives have also been made which are useful in
preparing other types of polymers. For example, monomers of the type
RAX AR have been prepared, where A is adamantane, X is a divalent
radical, and R and R are H or monovalent radicals, and m is 0 or 1.
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Polymers containing adamantane nuclei joined by short polymethylene
,. 108
chains have also been prepared',
have been used.
CH CHBrCH Br
Monomers such as the following
CH2=C
Thermally stable polymers are claimed to result.108a A similar polymer
has been made by treating 1,3-dimethyladamantane with p-di-tert-butyl-
109benzene in the presence of aluminum chloride. The resulting polymer
formed films and coatings having a high degree of thermal and oxidative
stability.
"~ CH,
Similarly, allyladamantane has been polymerized using a modified
Ziegler-Nattes catalyst system.109b
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Miscellaneous Polyolefins
Bicyclo[2.2.1]heptadiene and allene have been converted to exo-
2 53-methyltricyclo[4.2.1.0 ' Jnona-3,7-diene using palladium or nickel
as a catalyst. The material is reported to form novel polymers.
Copolymerization of ethylene, propylene, and 3-methylbicyclo-
[4.2.l]nonan-3,7-diene, or 3,4 dimethylbicyclo[4.2.l]nona-3,7-diene
has been carried out. Vulcanizable, linear, amorphous olefin copolymers
of high molecular weight resulted.
Polyvinyls
Although not many examples exist, bicyclic and cage compounds may
be incorporated into several vinyl polymer systems. For example, bicyclo-
[2.2.l]hept-2,5-diene has been copolymerized with vinyl chloride. When
a graft terpolymer was prepared with several other polymers, improved
112
shock resistance without lowered deflection temperature was observed.
The bicyclic portion of the polymer presumably had a nortricyclene
ring structure. An adduct of oc. -terpinene and maleic anhydride has
also been incorporated into a vinyl chloride polymer. The product
is colorless and has good adhesive power. The addition of camphor,
78
fenchone, <=< -isocamphenilone, apocamphor, norcamphor, or 4,4-dimethyl-
bicyclo[3.2.l]octan-2-one has also been reported to improve various
properties of vinyl chloride resins.
3-Nortricyclylacetic acid and vinyl 3-nortricyclylacetates have
been polymerized to form a clear solid.115 Camphene and 5-methylbicyclo-
CH COOH
2
CH2COOCH=CH
[2.2.l]hept-2-ene have been polymerized using a Ziegler-type catalyst,
but 5-methylbicyclo[2.2.2]oct-2-ene failed to react.
Triethylenediamine has been incorporated into a polyvinyl alcohol
117 Triethylenediamine
118
based adhesive to impart quick tack properties.
has also been incorporated into a divinyl sulfone plastic foam.
N-Acyl derivatives of 3-azabicyclo[3.2.2]nonane have been suggested
as comonomers for vinyl polymers. It was further suggested that these
0 0
NC R
R = alkyl
polymers should show good heat stability and have a good affinity for
119dyes. These compounds also have fungicidal properties.
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120Vinyladamantanes have also been reported. Their use in poly-
mers was not suggested, however.
Polyethers and epoxyresins
Bicyclic and cage compounds have not been used extensively in poly-
ether or epoxyresins. Of those that have been used, 7-oxabicyclo[2.2.1]-
heptane (1,4 epoxycyclohexane) (5-32) seems to be the most common.
Wittbecker, Hall, and Campbell have studied this system fairly
thoroughly. Lewis Acid catalysts were employed to produce the polymer,
which is not bicyclic. The polymer was found to be a high melting
SOC12
FeCl.
n
(5-32)
white solid that was insoluble in most solvents except phenols. This
122
observation is in general agreement with the observations of Wilkins.
Lower melting polymers were obtained from endo and exo-2-methyl-7-oxa-
bicyclo[2.2.1]heptane. These authors also studied the following compounds
related to (5-32).
.0
CH,
H.
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Pizzirani and Giusti have also polymerized (5-32). They
found that the polymer degraded rapidly in light to form 1,4-dichloro-
124
cyclohexane. The kinetics of the polymerization and the relative
125
rate compared to other polymers has also been studied.
Copolymers of (5-32) and other materials have been prepared by several
127
authors. Copolymers with tetrahydrofuran, ' ' trioxane,
128
and other cyclic ethers seem to be most common. Compound (5-32)
is one of several cyclic ethers that was copolymerized with p-benzoquinone
diazide.129 Some related monomers that have been studied are 7-oxa-
Oe -f
(5-32)
R = H,CH
bicyclo[2.2.l]heptan-2,3-dicarboxylic acid, its anhydride and
esters.132
COOR
COOR
Compounds (5-33) and (5-34) have also been used in polyethers, as
AcO COOCH,
=0
OOCH,
OOCHV
(5-33) (5-34)
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134 The chlorinated equiva-
135
has 2-exo-chloro-7-oxabicyclo[2.2.1]heptane.
lent of (5-32) has also been used to make polyethers.
Epoxy-polychloro-bicyclo[2.2.l]heptene has been prepared and poly-
Cl
Cl
merized by Kleiman. The resins have unusual heat and fire resistant
properties. Polyesters have also been prepared from the corresponding
glycol that have fire resistant, fungistatic, and heat resistant properties,
The compound by itself also has insecticidal and fungicidal properties.
The biological properties are enhanced by treating the compound with
mercuric chloride or other heavy metal salts.
Polymers have also been made from spirooxetanes of the type
These compounds have also been used in polyethers. The products have
high melting points, are crystallin, and are useful for molding.
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Polymerization of 2-oxabicyclo[2.2.2]octane was reported by Saegusa,
138
Hodaka, and Fujii.
SbCl,
epichlorohydrin
The products were sticky solids that were soluble in methylene chloride.
Ring opening polymerization of 4-methyl-2,6,7-trioxabicyclo[2.2.2]-
octane, 6,8-dioxabicyclo[3.2.Ijoctane, and 3,6,8-trioxabicyclo[3.2.1]-
139
octane has been achieved by Steuck with the aid of appropriate Lewis
140
acids. Okada, Sumitomo, and Hibino have also investigated the poly-
merization of 6,8-dioxabicyclo[3.2.1]octane using boron trifluoride.
etherate as the initiator.
A polymer of 2-hydroxy-9-oxabicyclo[4.2.1]octane has been prepared
from cyclooctane-l-ol-5-one. The monomer is useful in pharmaceuticals,
141
and the polymer is useful for synthetic fibers.
142Vinyladamantane
peroxide and molybdenum hexacarbonyl.
CH=CH2
[0]
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has been converted to the epoxide with t-butyl-
143
Polymers made from the epoxide are useful as wax additives, gaskets, and
rubberlike materials. A polyether has been made with adamantyl groups.144
Polythioethers have also been prepared. For example, divinyl sulfide
145has been polymerized under free radical conditions,
bicyclic structures are among the products.
The following
•CH,
84
Bicyclic resins derived from thiiranes have also been reported by
146Lautenschlager and Schnecko.
An anionic or cationic catalyst system was used so that the episulfide
group would polymerize with the olefinic group. Other monocyclic
materials were also discussed. A molding compound has been prepared
from a mixture of poly(ethylene episulfide) and N,N -di-tert-butylhexa-
147
methylenebis(carbodiimide).
Polyurethanes
Except for triethylenediamine (1,4-diazabicyclo[2.2.2]octane) and
selected derivatives, bicyclic and .cage compounds have not been used
extensively in polyurethanes. Triethylenediamine has been used primarily
as a catalyst in the formation of polyurethane foams. Part I of the
bibliography for Chapter 5 contains a listing of the papers and patents
in this area. Part II of the bibliography is a similar listing of papers
and patents where the abstracts were not specific about the bicyclic
material involved. We did not obtain copies of the original papers for
the listings in parts I or II of the bibliography.
While triethylenediamine is the most common bicyclic catalyst, .others
have been used. For example, 5,9-dimethyl-l-azabicyclo[3.3.l]nonane
and 5,9-dimethyl-l-azabicyclo[3.3,l]nonene have both been reported to
be urethane catalysts. Tertiary amines derived from 3-azabicyclo-[3.2.2J
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nonane have also been reported to catalyst for the formation of poly-
urethanes.
A few examples also exist in which the bicyclic material is part
of the polyurethane. For example, 7-oxabicyclo[2.2.1]hept-2-ene-5-
sulfonyl isocyanate and 1,2,3,4,7,7-hexachlorobicyclo[2.2.l]hept-2-ene-
5-sulfonyl isocyanate have been prepared.
N-2-Quinuclidyurethane has been polymerized with itself by
two routes, cis-1,3-Di(isocyanate)cyclohexane has been polymerized
to form a polymer with the structural units (5-35) and (5-36) in a
ratio of 65:35.
152
C — I f ^ J
o
(5-35) (5-36)
A tricyclic siloxane has been incorporated into polyurethane binders
in order to moderate ballistic properties of a propellant. The siloxane
was 1,3,5,7,9,ll-hexaphenyl-5,ll-dihydroxytricyclo[7,3,11 ' ]hexasiloxane
(Dow Corning Z-6018). The siloxane increased the burning rate of poly-
urethane propellant by 188%.
Elastomers
Bicyclic and cage compounds have been used as the main part of the
polymer chain and as accelerators in rubber compositions. In addition,
86
olefins such as norbornene and dicyclopentadiene have been mixed with
phenol-formaldehyde resins and other components to form an adhesive for
,154tire cords.
Dicyclopentadiene has been found to be a useful component in vul-
canizable olefin multipolymers. The major components are ethylene,
propylene^ or 1-butene. Tetracyclopentenyl has also been copolymerized
with ethylene and an 0( -olefin to form an elastomeric terpolymer.
Vanadium containing Ziegler catalysts have been employed to form
vulcanizable olefin copolymers containing 7-methylenebicyclo[2.2.l]hept-2-
ene, 7-isopropylidenebicyclo[2.2.l]hept-2-ene, bicyclo[2.2.2]octa-2,5,7-
triene, or 8-methylbicyclo[3.2.2]nona-2,6-diene. Ethylene and aL -olefins
are also part of these polymers. Similarly, ethylene and propylene
have been copolymerized with either 3-methylbicyclo[4.2.l]nona-3,7-diene
158
or 3,4-dimethylbicyclo[4.2.1]nona-3,7-diene.
Bicycle[2.2.l]-5-heptene-2,3-dicarboxylic acid, its anhydride;
monomethyl esters, and various salts has been used to control vulcanization
159
of a rubber compound containing sulfur and an organic accelerator.
This same acid has also been used for the vulcanization of rubber.
This was accomplished by heating a 1-10% mixture of the compound in the
rubber to 75-150°. At this temperature.,- a reverse Diels-Alder reaction
takes place forming maleic anhydride which vulcanizes the rubber.
A plasticizer for elastomers has been prepared from furfuryl acetate
and maleic anhydride. The compound is 3-acetoxymethylene-3,6-
endoxohexahydrophthalic anhydride or its butyl ester.
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Vulcanization of natural rubber has been accomplished using tri-
ethylenediaminebischloroborane.
BH2C1
Good reversion and age resistance were observed using this material.
1,1,4,7,10,10-Hexamethyltriethylenetetramine and triethylenediamine
have also been used as vulcanizing agents.
A series of amines derived from 3-azabicyclo[3.2.2]nonane have
been used as accelerators and curing agents for rubbers. Some
typical compounds are
S(C=S)n—N
RS2C
EtOOCCH S.CN
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Natural rubber tread stock and styrenebutadiene rubber have been cured
with these materials.
Poly-p-xylylenes
The di-p-xylylenes (5-37) are a somewhat different type of cage
(5-37)
compound than those in most of this report. The unique properties of
polymers prepared from these monomers,however,makes them valuable
materials for special applications.
The polymer
The actual monomer, p-xylylene, is generated quantitatively by
vacuum vapor phase pyrolysis of di-p-xylylene at 600°.
600'
2 CH
The polymer is then formed quantitatively by spontaneous polymerization
on a surface maintained below 30°. The resulting polymer is linear,
89
165high molecular weight, and soluble in chlorinated biphenyls.
In addition to the parent di-p-xylylene, monomers with a variety
of substituents have been prepared and polymerized. A polymer containing
fluorine groups in place of the hydrogen atoms on the methylene groups
is of particular interest.
This polymer exhibits "remarkable" thermal and oxidative stability at
elevated temperatures. Useful mechanical and electrical properties
are retained even after aging for 3000 hours at 250° in air.
A mass spectral study of poly-p-xylylenes has been conducted.167
Another study of charge storage on polymer foils was conducted using
1 (~\R
poly-p-xylylene along with commercial polymer films, Copolymers
were obtained by pyrolysis of mixtures of substituted p-xylylenes.
From a commercial standpoint, poly-p-xylylene is a good electrical
insulator and may be deposited in a thin film. The Union Carbide
Corporation has attempted to commercialize the polymer under the
trade name "Parylene". Both the parent p-xylylene (Parylene N) and
the monochlorinated derivative (Parylene C) have been made available.
Union Carbide claims that the polymers have good thermal stability in
the absence of air (such as hermetically sealed units and with coated
parts potted with phenolic molding compounds).
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In addition to dielectric properties, the parylenes are reported
to have superior toughness at cryogenic temperatures. Parylene C is
also an excellent barrier for the permanent gases and water vapor.
The Monomer
The di-p-xylylene used as the monomer precursor has been generated
by several procedures. For example, pyrolysis of 1,2-di-p-to.lylethane
at 800-1000° followed by quenching in an inert organic solvent at a
temperature below 300° has been reported.
H3CA /~CH2CH2
_
3
 2)Cool
Pyrolysis of p-xylene mixed with steam at 850-900° has also been reported
172to form di-p-xylylene in 8-10% yield. Direct polymerization and
copolymerization with maleic anhydride and 2-chloro-l,3-butadiene were
also obtained by pyrolysis of p-xylene at 795-920°.
An iron based alloy containing chromium and nickel has been used
to catalyze the formation of p-xylylene from oxygen and a p-xylylene
174precursor. Presumably any of the above precursors could be used.
A mixture of di-p-xylylene and terephthalic acid was obtained when
175p-xylene was pyrolyzed in a carbon dioxide atmosphere. Thus a contact
•7
time of 5.9 x 10~ sec. in a quartz tube heated to 1020° followed by
quenching at -78° in hexane was used to produce 3.56% di-p-xyylene and
2.2% terephthalic acid.
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Substituted di-p-xylylenes have also been patented. For example,
alkyl and cyano substituents have been specifically patented.
Specific Applications
The unique ability of p-xylylene to form thin films has led to
several specific applications of these polymers. One of the most sign-
178ificant applications is in thin film capacitors. These capacitors
are made by depositing a 10 nm film of poly-p-xylylene as an insulator
on one side of one of the two metal plates. A wide useful temperature
range and a high dielectric strength are possible for this technique.
The logical next step in the process of miniaturization would be to
deposit a thin film of poly-p-xylylene followed by a film of metal,
another layer of insulation, another layer of conductor, and finally a
layer of insulation.
conductors ^ k' ^* "-^Thin film insulation
Using this technique, it should be possible to make extremely small
capacitors with a. high capacitance. Apparently no attempt to do this
has been reported.
An electric insulation paper has been made by treating kraft paper
179
with p-xylylene vapors. A 2 weight per cent polymer deposition
gave an insulating paper with a 9920 V/mm breakthrough voltage and a
5.57 kg/mm tensil strength.
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Particulates have been encapsulated by exposure to p-xylylene
i 8n
vapors. A variety of materials have been encapsulated by this
technique such as lithium, lithium aluminum hydride, molecular sieves,
ammonium perchlorate, rubber stoppers, and aluminum films. As a test
of this technique, two pellets of encapsulated lithium.were placed
in water for 30 days with no noticeable hydrogen evolution.
Miscellaneous Polymers
Several bicyclic polymers have been.reported that do not fit the
general topics already discussed. For example, crosslinking of poly-
mers has been achieved with bicyclo[2.2.2]oct-5-ene-l,2,3-tricarboxylic
acid anhydride
and tricyclodecane-C5,2.1,O2'6)triol-(3,4(8-9)),182
HO
OH
OH
Cation exchange.resins have been made by treating 7-oxabicyclo-
183[2.2.1]heptan-2,3-dicarboxylic acid with formaldehyde.
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Alicyclic guanamines have also been prepared for use in resins
184by reaction with formaldehyde.
Polymer Additives
Almost all polymers need additives of one type or another to aid
in curing or to impart desireable properties to the polymer, Bicyclic
compounds have been used in several types of additives, such as curing
agents, plasticizers, stabilizers, and flame retardants.
Curing Agents
Probably the most extensively used bicyclic curing agent is 1,4-
diazabicyclo[2.2.1]octane. This compound and derivatives have been used
so extensively that they will not be discussed in detail here. Refer-
ences to the use of these compounds to cure polyesters, polyolefins,
epoxides, poly ethers, and miscellaneous other polymers is found in
part III of the bibliography for this chapter.
Several bicyclic compounds have been used as curing agents for
epoxy resins. For example, terpene hydrocarbons have been incorporated
185into one curing formulation. Maleic anhydride adducts with benzene
94
have also been used.186
R -N
0
Bicyclic curing agents have been found to be excellent for use as
char-forming insulative materials for heat shields for re-entry vehicles.
The specific compounds studied were:
187
Bicyclo[2.2.2]octa-5-ene-
2,3-dicarboxylic anhydride
(BOCA)
3,6-Endocyclopropylene-
A -tetrahydrophthalic
anhydride (CPTA)
9,10-dihydro-9,10-ethanoanthracene
-11,12-dicarboxylic anhydride
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H
H
= 0
Methylbicyclo[2.2.l]hepta-
5-ene-2,3-dicarboxylic anhy
dride (NMA)
Bicycle[2.2,1]hepta-5-ene-2,3-
dicarboxylic anhydride (NA)
7-oxo-bicyclo[2.2,1]hepta-5-
ene-2,3-dicarboxylic anhydride
(FMAA)
In addition to being good char formers, these compounds also decompose
thermally to form gaseous products that are poor heat conductors.
The retro Diels-Alder reaction, which generally precedes char formation,
does not rupture the polymer backbone, thus helping to maintain structural
96
strength. Another feature of the system is that an olefin is produced
in the skeleton during the retro Diels-Alder reaction which may serve
as a site of possible cross linking during further heating.
These same systems have also been studied using resorcinol digly-
cidyl ether.
CH2—CH CH20 OCH2 CH—C
0 "
Superior char formation is reported for these materials .also.
Two other Diels-Alder adducts that have been used to cure epoxy
resins are (5-38)189 and (5-39).19°
0
(5-39)
These compounds have also been used in polyester and polyamide form-
ulations .
Amines other than triethylenediamine have been used to cure epoxides,
For example, 1,3-diamino-adamantane has been reported as an epoxy curing
191
agent. Tricyclodecanediamine has also been reported to produce
192
epoxy resins of outstanding mechanical and chemical properties.
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Organic peroxides are commonly used as free radical polymerization
initiators, and many compounds, with a varying degree of stability,
are commercially available, Only a few bicyclic .peroxides have been
reported. Some of these materials should be useful as polymerization
initiators. For example, bicyclo[2,2.2joctane-l-formyl peroxide is
reported to be more stable than pivaloyl peroxide and less stable than
193isobutyryl peroxide, The.products of thermal decomposition corre-
sponded to a mixture of radical and ion pair or carboxy-dnversion products.
Only radical products were formed by photolysis,
193While Leffler and More were unable to prepare adamantane per-
194
oxide, Boguslavskayo, Etlis, Brovkina, and Razuvaev have used it
to initiate polymerization of methyl methacrylate. 1-Adamantylsulfonyl
195
acetyl peroxide has also been used to polymerize vinyl chloride.
Plasticizers
Most commercial polymers contain at least a limited quantity of
plasticizer to improve their properties. Some polymers such as the
flexible forms of polyvinyl chloride contain large quantities of plas-
ticizer. A wide variety of materials have been used as plasticizers.
Butyl and octyl phthalate are probably the best known.
Several bicyclic systems have also been incorporated into polymers
as plasticizers. Terpene and camphor derivatives, for example, have
been used as plasticizers for poly(trifluorochloroethylene). Difenchyl
oxydiacetate, bis(3,3-diethylbicyclo[2,2.2]octan-2-yl)oxydiacetate, and
bis(1,3,3-triethylbicyclo[2.2,2]octan-2-yl)tetramethylenedioxydiacetate
98
have similarly been proposed as plasticizers for polyvinyl chloride,
197
cellulose ethers, and cellulose esters. Selected terpene or
sesquiterpene alcohols and their esters have been suggested as plasti-
198
cizers for vinyl resins, nitrocellulose, and ethylcellulose. For
example, nopinenylmethanol acetate was suggested for polyvinyl chloride.
The reaction of terpenes with unsaturated dicarboxylic acids followed
by esterification of the acid groups produced compounds such as 1-methyl-
4-propylbicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic acid which are reported
199to be plasticizers for plastics and lacquers,
Bicyclo[2.2.l]hept-5-ene-2,3-dicarboxylic acid esters have been
used as plasticizers for polyvinyl chloride. Specifically, the dibutyl
ester of ethylene glycol bis(bicyclo[2.2.l]hept-5-ene-2,3-dicarboxylic
acid) has been reported, as has di-2,5-endomethylene- A -tetrahydro-
benzyl sebacate. The Diels-Alder adduct of furfuryl alcohol and
maleic acid has been esterified with 2-ethylhexyl alcohol to form a
i ^- • ^ i • i ui • j 200cplasticizer for polyvinyl chloride.
Chlorinated derivatives of these materials have also been prepared.
For example, 1,4,5,6-tetrachloro-7,7-dialkyloxybicyclo[2.2.1]-5-heptene-
2,3-dicarboxylic acids have been reported by McBee and Newcomer.
Compound (5-40) has been suggested as a plasticizer for PVC, and alkyd
X
X
.^^i
X
H2CH2CHCH3
COOR'
(5-40)
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resins as well as pesticides, Halogenated bicyclic keto acid esters
have also been used to plasticize vinyl resins. Specifically, 1,2,3,4,
7,7-hexachloro-2-norbornene-5-ylmethyl levilenate, among other compounds,
0
II
.CH2OC(CH2)2COCH3
orioi.
has been utilized, Hexachlorocyclopentadiene adducts of unsaturated
amides have been suggested as plasticizers for a vinyl chloride-vinyl
203
acetate copolymer. Specifically, N.N,-dibutyl-8-Cl,4,5,6,7-hexachloro-
3-octylbicyclo[2,2.1]-5-heptene-2-yl)octanamide has been suggested.
Halogenated cyclopentadiene-hexahalocyclopentadiene adducts have also
204been suggested as plasticizers, tackifiers, and insecticides.
The Diels-Alder adduct between cyclooctatetraene and maleic anhy-
205dride has been esterified to form softeners for synthetic resins.
0
0
2 ^Esters of tricyclo[4,2,2.0 ' ]-dec-7-ene-3,4,9,10-tetracarboxylic acid
dianhydride have also been used as plasticizers for polyvinyl chloride
*
and other polymers.
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Bicyclic ester lactones such as (5-41) have been used as plasti-
207
cizers for polyvinyl halides.
•R
R
(5-41)
N-acyl imines derived from 3-azabicyclo[3,2,2]nonane have.been
onQ
used as plasticizers, The N-decanoyl derivative has received special
attention. *
ll-0xabicyclo[4,4.Ijhendecanes have been suggested as intermediates
in the-synthesis of solvents, plasticizers, and glycols.209
101
Adamantane derivatives that have been used as plasticizers are
210 211dihydroxyalkyladamantanes and 1-adamantyl acetate. The latter
compound is also proposed for use in perfumes.
Stabilizers
Most polymers are subject to slow degradation caused by sunlight.
The addition of compounds to the polymer that can absorb ultraviolet
radiation has been found to slow the rate of deterioration. Bicyclic
and cage compounds have been used for this purpose and to increase the
oxidative stability of polymers.
A mixture of p -pinene and 1,10-dithiodecane has been used to
212
stabilized polyvinyl chloride, A 2 to 15% solution of these materials
in the polymer was recommended.
Alkyd resins are reported to have improved stability when (5-42)
AA A 213is added.
F F
F- -F
•F
F
0
(5-42)
Similarly, the dipropyl, di-iso-butyl and dinonyl esters of 7-oxabicyclo-
[2.2.l]-5-heptene-2,3-dicarboxylic acid have been used as light and
214heat stabilizers for vinyl and vinylidine polymers and copolymers.
102
(5-43).
Another class of general purpose ultraviolet stabilizers is
215
R
X = H, 0, OH
n = 1 or 2
(5-43)
Triethylenediamine and derivatives have been used as an inhibitor
for polymers of various types. Thus, triethylenediamine has been used
as an ultraviolet and heat stabilizer for polyacrolein butyl acetol.
2-Methyltriethylenediamine and 2-ethyltriethylenediamine have been
used as oxidation inhibitors for poly(oxyalkylene).217 The mono or di
oxide of ethylenediamine has also been used as a polymerization in-
91 8hibitor for the stabilization of organic compounds.
Metal bicyclononanes such as (5-44) have been used as resin inhibitors
COOXOe
H COOC
J
X = CH3 or
Pentaerythritol
M = Fe3+ Zn2+
Co
Nr
Cd
2+
2+
J
2+
Mn2+, A13+
Sn3+>
(5-44)
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for ultraviolet radiation.. Good results were obtained from phenol,
219
vinyl and urethane resins. Compounds (5-45) and (5-46) have also
220been used as ultraviolet light absorbers.
0
(5-45)
Preparation methods have been reported for the antioxidants 3-TK
and TK-4 which are reported to give high stability to polyethylene-
terephthalate and to rubbers. Neither the structure or the name of
the additives was included in the abstract, but they are presumably
221bicyclic.
Flame Retardants
Flame retardance is usually imparted to polymers by the addition
of materials containing phosphorous, halogens, or metal salts. The
effectiveness, and general utility of these materials varies widely,
and there is a continued search for new materials as polymers are
incorporated into more and more products. All of the bicyclic flame
retardants reported so far have been of the halogenated type. These
have usually been derivatives of perhalogenated cyclopentadiene. The
preparation, properties, and reactions of this class of compounds was
studied extensively by E. T. McBee in the late 1940's and early 1950's,
104
Compounds of this type also generally show fungicidal and insecticidal
activity, and many of the compounds discussed in the pesticide chapter
(Chapter 7) could also be used as flame retardants. These compounds
have not generally been crossreferenced in this report.
Sultones derived from hexachlorobicyclo[2.2.l]heptadiene have been
222
suggested as flame retardants, fungicides, and insecticides.
The exact structure of the compounds is not known, but in one case the
structure is believed to be:
Halobicycloalkanyl aryl ethers of the general formula (5-47)
have been proposed as useful in resins, plastics, pharmaceuticals
(5-47) Z = halogen
Y = Z,H,NH ,OH,CN,N09,SO.
x = o or r
insecticides and other products.223 Hexa-halobicyclo[2.2.1]hept-5-
105
ene-2,3-bis ureas have been treated with formaldehyde to form flame
0
II
NHCN(H) (R)
.NHCN(H)n(R)2_n
0
Y =• F,Cl,Br
R = C,-C?n alkyl, cyclohexyl, phenyl, chlorophenyl,benzyl
n = 0,1
224
retardant urea-formaldehyde resins. They have also been used as
additives to impart flame retardancy to polyurethanes.
Two other types of compounds that have been proposed as flame
225
retardancy additives are (5-48) and (5-49).
X
(5-48) (5-49)
X = Cl,Br, H (at least 2 X's = Br or Cl)
Y,Y* = carboxy or carboxyalkyl
m = 1 or 2
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9 ^(\
Another compound is l,3,3,4,5,6-hexachloro-2-keto-7-acetoxy[2.2.2]
bicyclooctane 5.
Cl
Cl
Monomers
Several bicyclic and cage compounds have been prepared that might
find utility as monomers. A few of these are collected in this section
to serve as a stimulation for new products. Obvious monomers that have
been discussed in earlier parts of this chapter have generally not been
included. No attempt has been made to be exhaustive in this section.
Bicycle[2.2.1]heptanes
Aminobicycloheptene carboxylates and aminotricycloheptane carboxy-
lates might be used in polyamides.227 Similarly, 2,3,4,5-tetraphenyl-
COOY
NR1R2 R1R2 OOY
RJ = hydrocarbon (C^ -Cg)
R2 = H, R
Y = alkyl with 1 to 5 carbons
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l-(2-phenylvinyl)-8-ketobicyclo[2.2.1]-3-heptene might be useful in
h=CHPh
Ph
Ph
OO O
the formation of polyolefins.
A possible monomer for use in epoxyresins is 5,6-epoxybicyclo[2.2.1]
heptan-2-ylmethyl-5,6-epoxybicyclo[2.2. l].heptan-2-ylcarboxylate.
0
II
H - 0 -C
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This and similar compounds have been reported by Medved and Christie.
Non bicyclic polymers might be made from 7-oxabicyclo[2.2.1]heptane
230
which was synthesized by Wittenberg.
Zero valent nickel has been used to make dimers and trimers of
231bicycloheptadiene. These materials might be incorporated into
108
polyolefins. Tetrahydrotricyclopentadienyldiamines and the corresponding
isocyanates have also been prepared, and may be useful as monomers.232
X = -NH , -NCHO
Bicyclo[2.2.2]octanes
233Malta and Stock have studied the preparation and thermodynamic
dissociation constants of 4-substituted bicyclo[2.2.2]octane-1-carboxy-
lic acids.
~-r\x3-COOH
X = eg. COOH, OH, HN^ CONH2
234
Kauer, Benson and Parshall have prepared compounds of this type by
condensing ethylene with cyclohexa-l,3-diene-l,4-dicarboxylic acid.
235Similarly, Chapman, Sotheeswaran, and Toyne have dicarboxylated
compounds containing 2,3-dicarboxylic acids leaving 1,4 disubstituted
products.
OOR OOR
COOH
-2COo
'
COOH
OOR COOR
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Some of these compounds should make useful monomers for the formation
of polyesters, polyamides, and other polymers.
4-Alkoxybicyclo[2.2,2]octan-2-one has been prepared and suggested
o*z £
as a starting material for polymers and drugs.
The corresponding 1-substituted compounds have also been reported.237
Benzoquinone and other adducts with cyclooctatetrene also might
i j 238make good monomers.
0 OH
)H
With these basic starting materials, a variety of possible monomers
might be prepared.
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Other Bicyclic Ring Systems
l,4-Diphenylbicyclo[3,2.l]oct-3-ene has been prepared as an inter-
mediate in the manufacture of polymers.
,r __, 240is (5-50).
239 Another potential monomer
CH2OH
CH2OH
(5-50)
This compound might aid in crosslinking polyester or other polymers.
A series of polycyclic decanes has been prepared which are reported
to have utility in polyurethanes, elastomers, synthetic fibers, alkyld
resins, antifreeze, solvents and plasticizers.241 Some examples are;
Sulfur containing monomers based on 1,5,9-cyclodecatriene has also been
«- A 242reported.
Ill
Adamantanes
Adamantane-2-carboxylic acid and (2 adamantyl) acetic acid have
243both been synthesized. Esters of both of these compounds might
be useful polymer additives. Similarly, adamantyl ketones have been
prepared which might serve as intermediates for monomer or polymer
244
additives. Vinyl adamantanes which are reported to be useful
intermediates in the preparation of epoxyethyladamantane have been
245
made from "^ -methyl-1-adamantanemethanol.
HO-CHCH, CH=CH,
Several new 1,4-disubstituted adamantanes have been prepared by
Geluk and Schlatmann.245 An example is 4-amino-l-hydroxyadamantane.
5,7-Dimethyl-l,3-diaminoadamantane. has also been reported.247
Miscellaneous Polymer Additives
A creaseproofing material for cellulose textiles has been formulated
248
using bicyclopentadiene as one component of a graft terpolymer.
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Alkyl-N-(0-bicyclohexylcarbonates) have been found useful as modifiers
249
and extenders for various synthetic resins. These compounds have
also been found useful as fungicides, insecticides, and bactericides.
The ammonium salt of N-dodecyl or N-octadecyl monamide of bicycle[2.2.1]-
5-heptene-2,3-decarboxylic acid has been used as an emulsifier for
250
water thinned paints. Chlorinated camphor enolacetate and related
bicyclic compounds have been used as plasticizers for nitro and aceto-
251
cellulose. 9-Amino-9-azabicyclo[3.3.l]nonane has been proposed as
252
an antioxidant.
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Critique
Most of the obvious bicyclic and cage compounds that might be
expected to form polymers have been prepared and polymerized. In general,
these materials have been reported to produce polymers with improved
thermal and oxidative stability.
Unfortunately, no uniform method of evaluating the improved properties
has been used. Furthermore, in many of the patents covering these
materials, the use of the compounds in polymers is only one of several
uses suggested. In these cases, there is no experimentally based
reason to believe that the compounds would necessarily make superior
polymers.
There is reason to suspect, however, that at least a partial
effort has been made to evaluate the area of bicyclic monomers for
commercial value. This suspicion is based on the observation that
a large number of patents and papers were issued during the early
1960's. DuPont in particular seems to have tried hard to make useful
polymers with these compounds. In spite of this effort, it is not
obvious that any bicyclic or cage polymer (except the p-xylylenes)
has ever been commercialized.
If the improved thermal and oxidative stability that has generally
been claimed for these compounds is significant, then some commercial
effort would seem to have been appropriate unless some other necessary
properties of the polymers are inferior. Since there is no evidence
in the literature to indicate a technical problem, the lack of commercial-
ization may be economic in origin.
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An economic problem is easy to rationalize. The market for
thermally and oxidatively superior polymers is probably not large since
existing polymers are of good quality for most purposes. Thus, a
large scale plant producing large quantities of the polymer could not
be justified, and the polymer would probably have to command a premium
price. The higher the price, the more the market would be restricted.
With a small market, the cost of additional research and development work
probably could not be justified by a large corporation.
A small company might be able to successfully manufacture some
of the polymers described here if a market could be guaranteed and if
it did not have to invest in extensive research to determine which products
to make and how to make them.
If this reasoning is correct, and an organization such as NASA has
a need for small, but significant quantities of thermally and oxidatively
stable polymers, it will probably have to support the development work
itself. To do this, it will have to prepare the polymers and evaluate
them against a uniform test procedure that is relevant to its needs.
If a formulation having sufficiently enhanced properties can be developed,
then a monomer process development project will be needed to produce
a commercially viable route to the product.
At this point, a small chemical company could probably be persuaded
to manufacture the product to predetermined specifications if an initial
market could be assured. The company could then support further
process improvement as the market developed.
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While bicyclic polymers have been fairly extensively studied,
bicyclic polymer additives have not been studied as thoroughly. The
use of bicyclic compounds as polymer additives seems to have been
randomly explored, with no thorough attempt to organize the field.
The phosphorous based flame retardants in particular have been completely
ignored.
As an example, triphenyl phosphine oxide has been advertized as
a heat stable phosphorous flame retardant. Replacing the benzene rings
with bicyclo[2.2.l]heptane or bicyclo[2.2.2]octane rings should not
significantly affect'the size or shape of the molecule, but should
increase the temperature stability and melting point of the product.
While the phosphine oxide might be difficult to synthesize with the
phosphorous at the bridgehead, the corresponding phosphite should
be easy to make, and might be a useful additive. Other bicyclic compounds
where the phosphorous is incorporated into the ring might also be
useful.
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Chapter 6 - Medicinal Applications
Bicyclic, tricyclic and higher cyclic compounds are used exten-
sively in the field of medicine. The most common applications are as
antivirals and antidepressants.
The 1-aminoadamantanes (symmetrel, amantadine) and their various
derivatives represent the basic nucleus used to fight viral infections.
}
The bicyclo[2.2.2]octanes and various compounds derived from this
nucleus possess the ability to alleviate depression brought on by
various conditions. The miscellaneous applications can be found in
almost any therapeutic area of medicine.
The use of bicyclic and cage compounds in medicine appears to be
gl-owing. This is probably due to their superior properties. For
example, some compounds have been reported to be highly active yet have
low toxicity. Others have prolonged activity because they are only
slowly expelled from the body. .
Analgesics
One of the greatest objectives in medicine has been to alleviate
the suffering caused by pain. Analgesics are drugs with this pain
relieving action and are classified as either narcotic or non-narcotic.
This classification is one of legal considerations,and from a medical
standpoint it would be more precise to classify the analgesics as
either strong or mild. Most of the narcotic analgesics are strong,and
most of the non-narcotic analgesics are mild.
The analgesic action of the opiates has been known throughout
history. Over the years the structure of these compounds have been
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determined and a multitude of derivatives have been prepared. Many of
these derivatives show analgesic action without the euphoriant and
addictive effects that are normally observed with the narcotic
analgesics .
Recently, an opiate receptor has been described. This receptor
is said to be in nervous tissue and its proposed existance is based on
structure-reactivity similarities of active opioid drugs, stereospeci-
ficity, and activity of the opiate antagonists, Tritiated naloxone
is a specific example and has been found to bind in the nervous tissue
of the brain.
In contrast to the narcotic analgesics the non-narcotic analgesics
usually possess antipyretic, and in some cases, antiinflammatory
properties. Members of this family are the salicylates, pyrazolones,
and analine derivatives with the newest members indomethacin and
mefanamic acid. All members are analgesic, antipyretic, and only the
anoline family does. not possess antiinflammatory and antirheumatic
properties. These analgesics are classified as mild due to their inabil-
ity to reduce severe pain,
The bicyclic analgesic compounds fall into various . categories .
The first are the azabicyclo[2, 2. Ijheptane and bieyclo [2. 2,1] heptane
systems. The initial compounds in this series are the endo- and exo-
2-methyl-5-phenyl-5-carbethoxy-2-azabicyclo[2. 2. 2jheptanes C6-1) , C6-2) .
(6-1)
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Physiochemical studies show that the endo-phenyl epimer (6-2) is six
times more potent than the exo-isomer and two times more potent than
4
meperidine (Demerol). The difference in geometry between the exo-
and endo-isomers suggests different modes of interaction with an anal-
getic receptor. 2-Hydroxymethyl-2-phenyl-3-pyrrolidinylmethyl-5-
norbornene was synthesized as a possible analgesic member of this class,
but after pharmacological screening, it was found not to possess
analgesic activity.
Ph RI = Hydroxymethyl
R1 R = Pyrrolidinomethyl
The next highest homolog in the analgesic series is the general
class of cyclic dicarboxycyclic imides of the blcyclo[2.2.:l]-hept-5-
ene and bicyclo[2.2.2]oct-5-ene series. A number of compounds of this
type possessing analgesic and antispasmodic properties have been syn-
thesized by Nakanishi, et-al.
In the bicyclo[3.2.1] category are the 3-(monocarboxycyclic aryl)-
3-carboxy tropanes and their various ester derivatives which are useful
as analgesic compounds. Intermediates related to these compounds are
•
C02R1
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the anticholinergeric and ganglionic blocking agents.
The 3-methyl-8-propinyl-3,8-diazabicyclo[3.2.Ijoctane system is
Q
reported to have the property of high analgesic activity.
However, various differences "in chemical and biological behavior
are found between the 8-substituted-3-methyldiazabicyclooctanes and
the corresponding isomeric 3-substituted-8-methyldiazabicyclooctanes.
Another diazabicyclooctane analgesic compound in which R or R may be
an alkyl or acyl group, having properties other than analgesia, has
9
been reported by S. Lepetit. These therapeutic activities include
diuretic, central and peripheral nervous system depressant effects.
A synthetic method has been devised and derivatives prepared for
the camphane series of analgesics. In this series, the most impor-
tant derivatives showing marked analgesic effects are: N,N-dimethyl-2-
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[(9-hydroxy-3-camphoryl)amino]acetamide, N,N-dimethyl-2-[(9-hydroxy-
3-camphoryl(methylamino)acetamide, 3-methylamino-lO-hydroxycamphor,
and N,N-dimethyl-2-[N-(10-hydroxy-3-camphoryl)methylamino]acetamide.
2-Aminoquinazoline compounds and addition salts of the general
formula (6-3) where R is various groups including 3-azabicyclo[3.2.2]
non-3-yl have been prepared and are useful for their analgesic and
antiallergenic properties.
R = cyclohexyl, aryl
Similar to the aminoquinazoline compounds (6-3) elaborated above
are the 3-substituted-4-trifluoromethylindoles which have analgesic
activity themselves and also serve as intermediates for other biologi-
12
cally active indoles. The bicyclic moiety, 3-azabicyclo[3.2.2]nonan-
3-yl, is positioned at R..
A substituted cyclobutanone has been prepared by Eastman Kodak
Co. and serves as an intermediate in the preparation of analgesics
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and dyeable polymers. The derivatives prepared include 2,2,4,4-
tetramethyl-3-(3-azabicyclo[3.2.2]nonan-3-yl)cyclobutanone.
The last of the bicyclic analgesics are of the bicyclo[3.3.1]-
nonane family. Iwai and Kurabayashi have described the synthesis of
the l-methyl-3-azabicyclo[3.3.1]nonane derivatives useful as
14 15
analgesics. '. These derivatives include l-methyl-3-phenethyl-9-
hydroxy-3-phenyl-3-azabicyclo[3,3,l]nonane (6-4), 1-methyl-3-phenethyl-
9-oxo-3-azabicyclo[3.3.1]nonane-5-carboxylate (6-5) and l-methyl-3-
phenyethyl-9-oxo-3-azabicyclo[3.3.1]nonane (6-6),
ph(CH) Ph ph(CH
OH
ph(CH_)9-
(6-4) (6-5) (6-6)
Similar to the above systems, (6-4), (6-5), (6-6), are the anal-
gesic 3-methyl-9-hydroxy-9-phenyl-3-azabicyclo[3.3.1]nonanes, These
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compounds and their acid addition salts have exceptionally high storage
stability.16
Ph
High analgesic activity and low toxicity are the features of a similar
17
series of compounds reported by Iwai, et.al. The last in this series
Ph
R = CH2CH2ph
RI = MeOREt
"I O
is the 9-oxo system reported to have an added antipyretic action.
Although the 1-aminoadamantanes have been recognized for their
antiviral activity,- it has been reported that derivatives of these
compounds have been prepared and tested for their analgesic, anti-
19inflammatory, and antipyretic properties. The adamantane-1-
carboxylate analog of salicylic and anthranilic acid has also been
prepared. The synthesis of adamantyl analogues of narcotic analgesics
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21has been reported by Voldeng, et.al. Preliminary studies with mice
indicate that the ester hydrochloride salt is more potent and longer
lasting than meperidine hydrochloride.
Antiarrhythmic Drugs
Disorders of cardiac rhythm are believed to arise as a consequence
of electrophysiologic changes in the heart. Antiarrhythmic drugs act
by normalizing or altering these disturbances, Heart impulses are
22generated by one of the two proposed mechanisms, the first of these
being spontaneous discharge of a pacemaker cell at a particular site,
and second, the re-entry mechanism. There is evidence to indicate that
the various nerve fibers are actuated above normal by epinephrine,
digitalis and low potassium ion concentration, and deactivated by the
prototype antiarrhythmic drug, quinidine, or high potassium ion concen-
tration.
Other antiarrhythmic drugs include procainamide, lidocane, a local
anesthetic used to treat ventricular-arrhythmias, diphenylhydantion,
an anticonvulsant, propraolol, and potassium salts.
A new antiarrhythmic drug, BL-3677A (d-5-endo-benzoyloxy-N(di-
methylaminopropyl)-bicyclo[2,2.1]heptane-2,3-endo dicarboximide hydro-
chloride) , has been evaluated on experimental cardiac arrhythmias in
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23the dog. BL-3677A reversed ouabain-induced ventricular tachycardia
and markedly increased the amount of ouabain required for cardiac
N-CCHJ N(CH ) -HC1
/ ^ O O £.
0
toxification. Additional properties of BL-3677A include prolonged
conduction in the His-Purkinje system and ventricular muscle, and some
local anesthetic activity.
The 1,5-diphenylbispidine derivatives, most notably 1,5-diphenyl-
3,7-bis(B-diethylaminoethyl)bispidine-9-ol, have been compared to
quinidine, a known antiarrhythmic drug, and were found to be more active
24in vivo and less active in vitro.
Boehme and Nichols have synthesized a new series of bicyclo[2:2.1]-
heptane compounds which possess antifibrillatory activity besides anti-
or o/^
arrhythmic properties. ' Included in the class of antiarrhythmic
drugs are the antispasmodics. These drugs also effect the heart
rhythm.27a'b'c'd
Antibiotics and Antibacterials
Systemic bacterial infections could not be treated with drugs
prior to 1935. Antiseptics: and disinfectants were used topically to
eradicate infections, but their unfavorable therapeutic index prevented
their use as systemic agents. Topical uses included effective treat-
ment of.malaria, amebiasis, and spirochetal infections.
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In 1935, prontosil, a dye, was reported to protect mice against a
systemic streptococcal infection, and patients suffering from such an
28infection were also cured, Prontosil itself was ineffective against
the bacteria in the test tube, but the eradication of the systemic
infections in living systems proved to be a milestone in the history
of chemotherapy.
Later, it was discovered that prontosil is broken down in the body
to give p-aminobenzenesulfonamide, later described as sulfanilamide,
Sulfanilamide, in turn, was demonstrated to be the active breakdown
product. In time, numerous derivatives of sulfanilamide were prepared,
S02NH2
Prontosil Sulfanilamide
and a host of systemic infections succumbed to the actions of these
new drugs. The treatment of these infections lead to.new discoveries
about bacterial metabolism. Biologic antagonism, carbonic anhydrase
inhibitors, and antithyroid drugs are examples of the various areas
revealed to scientists by the study of the sulfonamides«
The success in treatment brought on by the sulfonamides revived
interest in the antibiotics, or those compounds produced by micro-
organisms used to inhibit the growth of other microorganisms. One of
the most remarkable observations of antibiosis was Fleming's discovery
that Penicillium mold and the culture filtrates of this mold prevented
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29the multiplication of staphylococci. A team at Oxford, led by Florey,
succeeded in separating a concentrate of this antibacterial factor
and its pronounced activity and lack of toxicity were demonstrated. '
0 H
II I
0CH2-C-N.
J
^J^-SF7^ Me
procainJ " Na'K'lI N k
CO.H2
Penicillin G
The potency and lack of toxicity of penicillin turned investigators
to search for more sources of antibiotics. In a short time, numerous
antibiotics were prepared. Some were too toxic for clinical applica-
tions, but from this research came welcome additions to therapeutics,
such as streptomycin, the tetracyclines, chloramphenicol, and neomycin.
Compounds having the bicyclic structure have been used in various
antibacterial compositions. The l,4-diazabicyclo[2.2.2]octane(triethyl-
enediamine) system has been used to prepare dimerized propiolate esters
which show bacteriostatic action against Bacillus subtilis and Saccha-
32
romyces cerevisiae. A series of dithiocarbonic acid esters have been
prepared which show activity against bacteria,. fungi, and coccidia.
These derivatives are prepared from the formaldehyde adduct of an amine
with carbon disulfide or from the substituted thiocarbonate with the
formaldehyde adduct of the amine. The 2-(2-azabicyclo[2,2,2]octyl)
moiety serves as an amine. The 1,4-bis-cyclic and -arylaminobicyclo-
[2.2.2]octane derivatives have been prepared and are useful antibac-
34terials against both gram-positive and gram-negative bacteria.
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These compounds serve also to lower cholesterol levels in the blood.
Among the compounds prepared are l,4-bis(aminomethyl)bicyclo[2.2.2]octane
(6-7) and N,N -dicyclohexyl-N,N'-methylbicyclo[2.2.2]octane-l,4-dicar-
boxamide (6-8). Useful antibacterials of the same general structure of
CH-NHi <-
CH2NH2 CON
Me
(6-7) (6-8)
(6-7) and (6-8) are the bicyclo[2.2.2]octane derivatives shown below.
These derivatives also possess the ability to reduce the levels of
35
RHNCH
cholesterol in the blood.
Antibacterial bicyclo[3,2.2jnonane derivatives have been reported.
The first of these derivatives are the arylalkylamine compounds with
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the 3-aza-3-bicyclo[3.2.2]nonyl group attached. Another antibacterial
compound that also has trichomonicidal properties has been reported by
37Gutsche, et al. Among 16 compounds prepared was the 3-azabicyclo-
[3.2.2]nonan-3-yl derivative.
If \ N
// \\_/ X_ Q_CH2CH2
A broad-spectrum antimicrobial .using the general class of 3-acyl-
38
alkyl-3-azabicyclo[3.2.2]nonane nucleus has been prepared. The
antimicrobial activity exhibited is used against Staphylococcus aureus,
Escherichia coli and others. Mannich bases with antimicrobial activity
have also been reported and inhibit the growth of such microbial species
as Saccharomyces cerevisiae, E:scherichia coli, and Staphylococcus
39
aureus.
The antibacterial bis(biperidyl) alkanes exhibit general pharma-
40
cological, antibacterial and antiparasitic properties.
N(CH2)3NMe2
(6-9)
The adamantylcarbonyl derivative of (6-9) has been prepared. This patent
also includes the method of preparation of the tablet forms and thin-
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layer chromatography data. Sarbach, et,al have reported the use of the
adamantanecarbonyl group in their antibacterial and fungicidal 3-(5-
41
nitro-2-£uryl)-2-bromopropenal acylhydrazones.
r\ H=CBrCH-N-NHR R = Adamantanecarbonyl
The well-known antibiotic tetracycline has been prepared as an
adamantoate salt. This tetracycline adamantoate salt has been demon-
strated to be effective against gram-positive, gram-negative, and
42
rickettsiae organisms. Also there are pharmacological, spectral,
OH o OH 0
CONH,
NMe,
and antiviral data given. The antimicrobial adamantyl-s-triazine
»
43
synthesis has been reported by Narayanan, and various derivatives
(CH2)NNH
have been prepared. These compounds also have hypoglycemic properties.
The last in this series is the 4-[[(3-adamantylamino)-propyl]amino]-7-
chloro-2-(p-nitrostyryl)quinoline derivatives where R=l-adamantyl,
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44These compounds have antibacterial and antiviral properties.
CH=CH
The last of the antibiotics and antibacterials are the penicillins
and sulfanilamides . Concerning the penicillins, the general synthesis
45
of 6-aminopenicillanic acid derivatives has', been reported. The most
important compound prepared is theNa^6- (1-adamantylcarbonylamino)-
penicillinate. Also used were the 3-substituted-adamantane-l-carbox-
cyclic acids(R=F,Cl,MeO,HO)C02H,Br,IJPh) . Also, various bicyclo[2 .2.1]-
heptanes, bicyclo[2.2. 2]octanes, and tricyclo[4.3. l]undecanes were used.
These penicillins were active against strains of Staphylococci. Another
general synthetic route has been devised and the <X- (adamant- 1-ylthio)-
46
akylpenicillins have been prepared. No special properties have been
reported for these systems .
Hermann and Snyder have reported the synthesis of o<-amino-l-
adamantylmethylpenicillins. These penicillins exhibit excellent
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acid sensitivity and resistance to penicillinase, an important step in
the treatment of bacteria that produce penicillinase.
R = H, Me
(NH2)RCONH—| r^ N^^ Me x = H+anion
0
A similar penicillin derivative that is also resistant to penicill-
inase has been prepared by Loevens Kemiske Fabrik Produktionsaktieselskab.
These 3-amino-l-adamantylpenicillins are broad spectrum antibiotics
used against Staphylococcus aureus, Escherichia coli, P-roteus mirabilis
and a host of others. Serum levels as compared in rat and man (to
methicillin and penicillin-G-Na) are also reported, The 1-amino-
adamantane benzylpenicillin salt prepared by Galardo has been observed
49to have slow release activity. This is highly important because
penicillins can be broken down by gastric juices and the absorption of
this antibiotic is poor in the gastrointestinal tract. Related to
this is the antibiotic action and better absorption in organisms of
ex. -arainobenzylpenicillanic acid esters. These penicillin compounds
include the 1-adamantylcarboxymethyl derivative. The last of the
52
penicillin derivatives, prepared by J. R. Giegy A.-G. have been reported
to be used when bacterial strains resistant to penicillin-G are found.
The spectacular results observed in-the penicillin family by pre-
paring various derivatives have not been observed in the sulfanilamide
family. Narayanan has prepared new antimicrobial N'-(1-adamantylalkl)-
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sulfonamides. Among the derivatives prepared was N-(l-adamantyl)-p-
nitrobenzenesulfonamide and N -(1-adamantyl)sulfonamide. A new series
54
of sulfonamides has been prepared by Daeniker. These new compounds
include l,4-endomethylene-3-phenyl-cyclohexane-2-sulfonamide, and 1,4-
endoethylene-5,6-oxido-cyclohexane-2-sulfonamide.
The last of the sulfonamides in this series are the sulfonamides
containing the adamantyl radical, These compounds were prepared to
determine the effect on microbial activity by the large adamantyl
group. However, none of these compounds showed any antibacterial
activity.
Anticancer Drugs
Although the antineoplastic agents, or anticancer drugs, have not
had the dramatic impact on medicine of the antibacterial drugs, they
are becoming increasingly important. Leukemia, malignant lymphoma,
multiple myeloma, and carcinomas have been treated successfully with
these drugs, and some cures have been reported.
The drugs currently used in anticancer chemotherapy are generally
highly toxic and not very selective. Consequently, their therapeutic
index is quite low. The most recent emphasis in cancer chemotherapy
is the application of synergistic combinations of the various chemo-
therapeutic agents coupled with a knowledge of the cell cycle on which
these agents act. Using this technique, the life expectancy of children
with acute leukemias has been increased, and disseminated choriocarcinoma
in young women has been cured.
The various anticancer drugs fall into the following categories:
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1. Alkylating agents
2. Antimetabolites
3. Hormonal agents
4. Radioactive isotopes
5. Antibiotics and miscellaneous
The bicyclic and cage compounds found in anticancer drugs are
generally antimetabolites, but some compounds in other categories
such as the alkylating agents are also found. The bicyclic and cage
compound used in cancer chemotherapy include the classes of bicyclo-
[2.2.l]heptanes, adamantanes, and miscellaneous polycyclics.
R
-R
Bicyclo[2.2.1]heptanes
CO
Pettit, et al have prepared l,4-bis-(2-chloroethyl)-l,4-diazonia-
bicyclo[2.2.l]heptane dichloride, a novel quaternary ammonium salt.
Information concerning the chemical and physical aspects of this new
ring system has. been summarized in this report. H nuclear magnetic
resonance data are also available.
Thirteen potential anticancer bicyclic nitriles and related com-
59pounds have been formulated by Scheiner and Vaughn. These new
compounds were made available by Diels-Alder cycloaddition reactions
involving fumaronitrile, maleonitrile, acrylonitrile, and tetracyano-
ethylene as dienophiles and cyclopentadiene, cyclohexadiene, cyclo-
heptadiene, and cyclooctatetraene as dienes.
Grogan and Rice have produced a series of 7-oxabicyclo[2.2.1]-
heptane-2,3-dicarboximides (6-10) and studied their pharmacological
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activities. Some of the compounds also demonstrated pharmacological
properties other than anticancer activity.
0
Similar to (6-10) is cantharidin. This homeopathic anticancer
agent has been described by Baranger and is especially active against
lymphoma in chickens.
Bicyclo[3.2.2]nonanes
The preparation of halogenated aminobisphenols as possible carcino-
static agents has been reported by Shaner and Meadow. Among these
compounds is the 3-azabicyclo[3.2.2]nonane derivative.
Adamantanes
The various anticancer agents containing the adamantane functional
group include the classes of antitumor, antileukemic, and anticarcino-
matic agents.
D-Arabinofuranosylcytosine is known to control the growth of certain
tumors. Wiley and Neil have prepared 1- 6 -D-arabinofuranosylcyto-
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sine-5 -(1-adamantane carboxylate) and 5 -0-adamantoyl-D-arabinofuran-
oxylcytosine. These two compounds are reported to be highly potent and
are absorbed at a uniform rate. Consequently, these derivatives are
64
more suitable as depot agents. Niel, et al have also described the
use of various treatment schedules for the 1- Q -D-arabinofuranosyl-
cytosine derivative.
1-Adamantanamine hydrochloride and six derivatives prepared by
Kolymkova have been tested for their inhibitory and antiblastic actions
on human normal and tumor cells, Angiosarcoma As, pancreatic carcinoma
CaPa, and others were subject to sensitivity tests. Angiosarcoma line
As and pancreatic carcinoma CaPa were most sensitive to l-(acetylamino)-
adamantane and l-(methylamino)adamantane. 1-Adamantamine produced
sensitivity in cells from lines 709 and CaVe. l-CDimethylamino)adaman-
tane and 1,5-bis-(N-methyladamantamino)pentane dimethobromide were not
seen to selectively act on tumor cells. The least toxic compound
reported was 1-Cdiethylamino)adamantane hydrochloride.
The 5 -0-derivatives of aracytidine have been synthesized by Kelly,
et^al and are effective drugs against leukemia, Among the 30 compounds
prepared is the adamantane-carbonyl derivative.
NH,
=
 adamantanecarbonyl
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Amantadine, an immunosuppresive agent, was given to patients during
active immunotherapy for acute lymphoblastic leukemia and was found
to inhibit the effects of this treatment.
The synthesis of 5-(l-adamantyl)-pyrimidines has been reported
s O
by Jonak, et.al.
OH
R = H, Me
These compounds moderately inhibited mouse sarcoma 180.cells, and
mouse mammary and andenocarcinoma, The authors also prepared S-p.-
adamantyl)-2,4-diaminopyrimidine (6-11) and 5-(l-adamantyl)-2,4-diamino-
6-methylpyrimidine (6-12) analogues.
NH,
R = H (6-11), Me ;(6-12)
(6-11) = H (6-12) = Me
Both (6-11) and (6-12) showed exceptionally high activity toward mouse
mammary adenocarcinoma cells (TA3) in culture. 5-(l-Adamantyl)-2,4-
diamino-6-methylpyrimidine inhibited cell growth as effectively as
methotrexate, a folic acid antagonist.
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Miscellaneous polycyclics
Peterson,et al have synthesized about 300 derivatives of 2-amino-
1,4-naphthoquinone and related compounds. These compounds were investi-
gated for their carcinostatic activity. Relationships between structure
and reactivity were considered. The carcinostatic quinones were
particulary effective against Ehrlich carcinoma and Crocker carcinoma
180 of the mouse. Among the compounds tested were the tricyclo-
9 f\ ^ S 9 f~\[2.2.1.0 'Jheptane and tetracyclo[2,2,1.2 ' .0 ' Jnonane derivatives.
—NH—CH2
Anticholinergics
Smooth muscle spasm and the action of hydrochloric acid contribute
to pain>in peptic ulcer and possibly to its perpetuation. The anti-
cholinergics reduce smooth muscle spasm and may also reduce the secretion
of hydrochloric acid. Basically, these drugs are tertiary or quaternary
amines related to atropine.
The advantages of the quaternary anticholinergics are claimed to
be reduced central nervous system side effects and possible ganglionic
blocking action. The ability to block the vagus through peripheral
anticholinergic effects is also claimed. Although large doses can block
gastrointestinal motility and hydrochloric acid production, there are
some side effects. These include blurred vision, dryness of the mouth,
and micturition difficulties.
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The bicyclic and cage compounds shown to have central or peripheral
anticholinergic activity fall into the classes of the bicyclo[2.2.1]-
heptanes, bicyclo[3,3,Ijnonanes (granatanes), bicyclo[3,3,2]decanes,
and the tricyclic[3.3.1,1 ' Jdecane (adamantane) compounds.
Bicyclo[2.2.1]heptanes
Hass and Klavehn have synthesized 3-piperidino-l-phenyl-l-
(bicyclo[2.2.l]hept-5-en-2-yl)-l-propanol (Akineton). Akineton tests
on isolated guinea pig intestine and blood pressure in the cat showed
that this compound is an effective anticholinergic drug. However,
Akineton is most efficatious in suppressing convulsions produced by
nicotine in mice and rabbits.
Bicyclo[3.3,1]nonanes
The granatane derivatives, homologues of tropane, are .reported to
have potent anticholinergic activity.
tropane granatane
However, these compounds have not been used extensively due to the
•7 9
strong side effects. Yoneda, et-'al' have synthesized and.tested the
6,6- and 7,7-gemdialkyl-9-azabicyclo[3,3,l]nonane derivatives. These
compounds were prepared in an attempt to improve the pharmacological
activities of the 9-azabicyclo[3,3.l]nonane system. The authors
indicate that various glycolate derivatives had strong central anti-
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cholinergic activity, and that high central specificity was imparted
when gem-dialkyl groups were introduced onto the 9-azabicyclo[3.3.1]-
nonane skeleton.
Ribbentrop and Schaumann have conducted a study of granatane
compounds. In a comparison to known anticholinergics, atropine, scopol-
amine, biperidine and benactyzine, the most active compounds, were demon-
strated to be the granatanol-3-esters. Ester derivatives of N-( ft -
hydroxyethyl)-norgranatane have been prepared from benzilic, and substi-
tuted benzilic acid, methyl esters, acid chlorides, and chloro acid
chlorides. These compounds show central and peripheral anticholinergic
activity. Stach, Dold, and Schaumann ' ' ' have published a series
of patents dealing with the synthesis of granatoline and 3 fo -granatol
derivatives of ethers and esters. C.F. Boehringer and Soehne have also
prepared the nortropane, N-(hydroxyalkyl)-norgranatane and 3 ^  -norgran-
atanol ester derivatives in this series. ' ' Martell and Soine
have synthesized 3-hydroxy-l-azabicyclo[3.3.1]nonane and have investi-
gated certain of the ester derivatives as potential anticholinergics.
Results of this investigation have not been further reported.
Bicyclo[3.2.2]nonanes
Anticholinergics can antagonize or reverse motor incoordination.
Tremorine or oxotremorine induced muscular rigidity and akinesia in
mice, which renders them unable to remain on a rotating rod, has been
shown to be reversed by a new potent, centrally acting and anticholiner-
gic drug. This drug, SC-13639 (2,3-diphenyl-4-(3-azabicyclo[3.2.2]non-
3-yl)butyramide hydrochloride), was discovered to be more potent, longer
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lasting, and possess twice the separation of anticholinergic and loco-
78
motor stimulant actions.
Adamantane derivatives
The 1-adaraantanecarboxcyclic acid ester of scopolamine has been
79
reported to be a powerful anticholinergic. It is prepared by allowing
1-adamantanecarbonyl chloride to react with scopolamine hydrobromide
and then treating the solution with hydrochloric acid,
Antidepressants
Prior to the 1950's, there existed no pharmaceutical agents that
could counteract depression. Consequently, psychotherapy and electro-
convulsive therapy were the main forms of treatment for this condition.
Toward the late 1950's, the first pharmaceutical agents were
developed and most were classified as monoamine oxidase (MAO) inhibitors.
This classification is used due to the ability of these compounds to
inhibit metabolic oxidative deamination of amines such as dopamine and
tyramine. Dibenzazepine derivatives were discovered later to be useful
in treatment of depressive syndromes,
Imipramine (Tofranil), a tricyclic antidepressant, was discovered
by accident while clinical tests for antipsychotic activity were being
80
conducted. This drug was followed by others such as amitriptyline
and protriptyline and their demethylated metabolites such as desimi-
pramine and nortriptyline.
The mechanism by which these drugs act is attributed to the cate-
81
cholamine hypothesis. The various antidepressants are said to
increase the effective catecholamine.levels in the central nervous system,
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and the tricyclic antidepressants such as imipramine interfere with
the uptake of catecholamine after its release from the nerve endings.
As a class of antidepressant compounds, bicyclic and cage compounds
have been shown to effectively antagonize tetrabenzene-induced sedation
in mice, and potentiate the norepinephrine and phenethylamine pressor
effect in ganglion-blocked anesthetized dogs.
The bicyclic antidepressants have the general formula
R
in which R, R,, X and Y are the various constituents, and the dashed
line represents a possible double bond, The phenyl group at the 4-
position may be substituted with pyridyl or cyclohexane, and either of
these groups may themselves be substituted, generally at the 4-position.
Bicycle[2.2.2]octane derivatives
The first of these compounds are the 5-aryloxatricyclo[3.2.2.0 ' ]-
81
nonan-1-yl urethanes of the general formula (6-13):
Ar
NHR
(6-13)
Ar =
R = H, Me, or
0
-C-O- 1
= Alkyl (1 to 8 carbons), N,N-dimethyl-
2-aminoethyl, ethylpyrrolidinyl, 2-
methoxyethyl, benzyl
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These compounds may be synthesized by converting the appropriate
4-arylbicyclo[2.2,2]oct-2-ene-l-carboxycyclic acid to the corresponding
azide followed by a modified Curtis Reaction to, form the isocyanate.
The isocyanate is then treated with an alcohol to form the corresponding
urethane.
The compounds of formula (6-13) that are most preferred are those
in which Ar is an unsaturated phenyl or pyridyl, R is -CO_R,, and
R, is an alkyl group of 1 through 4 carbon atoms. These compounds
show the best antidepressant activity in warm-blooded animals,
Similar compounds having the same antidepressant activities are the
4-arylbicyclo[2,2.2]oct-l-yl urethanes that are used as pharmaceutically
83
active agents. Generally, these compounds have the following basic
structures:
NHCOOR NHCOOR
R = Alkyl 1 to 8 carbons, Et,
pyrrolidinyl, 0-CH -
R.^ 2 = H, Me, Et, Cl, Br, F,
N02, amino, dialkylamino
The non-toxic anion salts of these compounds are also included in the
context of these patents. Also substituted at the Ar group is a
84pyridine ring with various substituents. These compounds have the
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general formula:
NHC02R
A similar series of compounds have also been shown to produce anti-
85depressant effects in warm-blooded animals. These compounds also have
the bicyclo[2.2.2]octane nucleus C6-14),
R R ,R = H, alkyl (1 to 4 carbons),
allyl
X,Y = H, Me, Et, Cn, Cl
(6-14)
The aromatic ring at position 4 may also occur as a cyclohexyl structure
having similar antidepressant actions, The substituents are the same
QfL
as (6-14), and a dosage method is also available for the administra-
tion of this antidepressant, a> The sulfuric, tartaric, maleic,
88
succinic, and mandelic, or lactic acid salts can also be prepared.
A variation of structure (6-14) having a pyridine ring substituted at
the 4-position has also been shown to possess antidepressant properties.89
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Also included in the scope of this patent are the salts of the free
amine derivatives, ' An orally ingestible capsule and tablet form
91
may also be prepared,
4-Trifluoromethylbicyclo[2,2,2]octane-l-amines and oct-2-ene-l-
amines showing antidepressant activity have been prepared by Gregory and
92Whitney. .These compounds have the general formula (6-15)
-CF,
(6-15)
where R is hydrogen, methyl, or ethyl, and X is -CH2CH - or -CH=CH-,
Also prepared were the salts of (6-15)
H
H-N-R
r
CF,
A CT•
,e .
where R and X are the same as in (.6-15) and A is a nontoxic anion.
Various laboratory studies involving the prediction of antidepres-
sant activity, metabolism, and physiology of bicyclic and cage compounds
have been carried out,
93In a study conducted by Sanghvi, et.al it was concluded that some
agents shown to have antidepressant qualities in the reversal of seda-
tion or rodent hypothermia, demonstrated no apparent clinical
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antidepressant activity. Among these antidepressants is Exp-561
(4-phenylbicyclo[2.2.2]octan-l-amine hydrochloride monohydrate).
Tetracyclic compounds
A tetracyclic compound, Maprotiline, has been reported to possess
94
antidepressant properties. This antidepressant has the general
ability to antagonize tetrabenzene-induced sedation, has similar
effects to imiprimine (inhibition of hypothermia), and contains the
capacity to provoke depletion of cerebral catecholamines. This tetra-
cyclic compound is reported to be the first of its kind, and may have a
substantially different mode of action on the metabolism of serotonin
than the typical tricyclics.
Another tetracyclic antidepressant, Toly.on, is reported to have
similar effects to that of Maprotiline even under acute and chronic
administration, Following acute administration, the concentration of
brain monoamines was reduced in the brain for several hours. Chronic
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administration increased the concentration of brain normetanephrine.
The pharmacological actions of Tolvon suggests that it acts on trypt-
aminergic receptors in the brain and acts on the central nervous system
97in a manner similar to minor tranquilizers,
Tricyclic compounds
A tricyclic compound 3-(diethylaminoethylthio)-nortricyclene
S-CH2CH2-N(Me)2
R = H, alkyl, alkoxy, halo,
haloalkyl
98has been reported by Gray and Heitmeier to have antidepressant action.
This compound and its derivatives also have utility as bronchiodilators.
The effects of tri- and tetracyclic antidepressants on the heart
99
and circulation has been studied. It has been determined that when
administered in recommended dosages for three weeks some tetracyclic
antidepressants: had no decisive influence on blood pressure or heart
rate.
Adamantane derivatives
Commercial pharmaceutical preparations of various adamantane com-
pounds have been reported by Squibb § Sons. Among the numerous derivatives
are the adamantylbenzoth'iozepinones,
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the spiro-[adamantane-2,2'-(3'H)-l ] ,5-benzothiazepine compounds,
X = S
Y = 0
the 2,3-dihydro~5-[2-(N-methyl-l-adamantylamino)ethyl]-2-phenyl-l,5-
benzoxazepin-4(5H)ones,
Me
(CH2)2-N-(CH2)2—N
a
the adamantylamino phenyl-l,5-benzothiazepine derivatives, '
and the 2-(l-adamantyl)-5-Caminoalkyl)-lJ5-benzothiazepines, lOOf
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Antifibrinolytic Agents
The role of fibrinolysis in the maintenance of blood fluidity has
been known since the turn of the century. The groundwork for under-
standing the chemistry and biochemistry of the process was first
developed during the early 1930's. The development of agents that could
dissolve intravenous thrombi followed. These compounds are called anti-
fibrinolytic agents.
Naturally occuring circulating fibrinolytic inhibitors regulate
hyperfibrinolysis in the human, Synthetic inhibitors, provided by
recent advances, neutralize excessive fibrinolysis and permit clinical
management of bleeding that may be induced by the .excessive pathological
fibrinolysis.
In the complement mechanism, the conversion of the first component
i ,
of complement C1 to C, esterase (the active proteolytic enzyme) is
closely tied to the fibrinolytic system, Antifibrinolytic compounds are
active inhibitors of this comple.ment system.
Bicyclo[2.2,2]octanes
A new potent fibrinolytic inhibitor was discovered in 1969 by
scientists at Merck, Sharp and Dohme Laboratories, and has been recently
reviewed in a book edited by Schor. This compound, 4-aminomethyl-
H
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bicyclo[2.2.2]octane-l-carboxcyclic acid, was prepared on the assumption
that a synthetic amino acid system with a definite rigid central
nucleus would give maximum antifibrinolytic activity, The synthesis
of this rigid bicyclic system was undertaken, and this approach led
102to the synthesis and consequent high order of activity. This com-
pound was compared to known antifibrinolytic agents and was shown to be
approximately sixty times more potent than €. -aminocaproic acid.
Baumgarten,
procedures.
 et.al have evaluated this compound by in-vitro assay
Loeffler, et.al have reported the synthetic details, biological
activities, and structure-activity relationships of various bicyclo-
[2.2.Ijheptane, bicyclo[2,2.2]octane, bicyclo[3,2,2jnonanes and cubane
derivatives as potential antifibrinolytic agents. An extensive table
listing the relative activities of these fibrinolytic inhibitors is also
available. Loeffler has also patented 4-(<X. -aminoethyl)bicyclo[2,2.2]-
octane-1-carboxcyclic acid, 4-(aminomethyl)bicyclo[2.2.2]octane-l-
acetic acid, 4-(aminomethyl)bicyclo[2,2,l]heptane-l-carboxcyclic
acid, and various aminomethylbicycloalkane-1-carboxcyclic acid
108derivatives. 4-Aminomethyl-l-cubane carboxcyclic acid recently has
109been shown to have antifibrinolytic activities.
WMe
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Anti-inflammatory Agents
The process of inflammation involves changes in tissue in response
to injury. This injury may be brought about by bacteria, trauma,
chemicals, heat or other phenomena. The substance histamine and other
humoral compounds are released by the damaged tissue into the surround-
ing fluids, resulting in the increased permeability of the capillaries.
This action allows large quantities of fluid-and protein, including
fibrinogen, to leak into the tissues. Local extracellular edema results.
The anti-inflammatory drugs act to reduce extracellular edema.
The anti-inflammatory action of these drugs is useful in treatment of
rheumatic complications and acts to decrease temperature in.fever.
A number of new anti-inflammatory drugs have surfaced in recent
years as a result of screening using laboratory animals. These new
drugs include indomethacin and flufenamic acid. In addition to the
above mentioned new drugs, and the old standard used in the past, many
bicyclic and cage compounds have been tested for their anti-inflammatory
capacity,
Bicyclo[2.2,2]octanes
The first bicyclic system to be considered has .been prepared by
109Maier. Pharmacological investigations on a variety of known or novel
quinuclidine compounds have been carried out. Compounds consisting of
the following formula have shown that they possess a high level of
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CH_0
CH0CH_OH2 2 M
H-CH(OH)-Y'/X]
HS02-R
R = lower alkyl, phenyl, lower alkylphenyl
anti-inflammatory activity. Although these quinuclidine derivatives
are more toxic than the known anti-inflammatory compounds, chloroquine
diphosphate, the former compounds are remarkably more effective.
Bicyclo[3.2,1]octanes
Camphidine derivatives have been prepared that show anti-inflammatory
activity, Camphidine is treated with chloroacetonitrile and sodium
carbonate to give N-(cyanomethyl)camphidine,
C1CH2CN NCH2CN
Thirteen other derivatives have also been prepared. These compounds
also show antithrombic activities.
Schiatti, et.al have prepared 3-methyl-8^(2^nitrobenzoyl)-3,8-
diazabicyclo[3,2.1]octane which is useful in the treatment of painful
inflammation of the joints and arthritic conditions.
-co:<X NMe
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Bicyclo[3,2.2]nonanes
Complex nitriles containing the azabicycloalkane structure have
112been prepared by Cusic and Yonan, The title compounds were prepared
by treating an azabicycloalkanone with the appropriate derivatizing
agent.
N(CH2)nCPh(CN)—(f
These compounds are useful as anti-inflammatory and antiulcer agents,
They also inhibit the growth of bacteria and algae. Derivatives of
benzophenone and benzhydrol have been shown to possess anti-inflammatory
effects. A patent by Houlihan discloses the synthesis of various
benzophenone and benzhydrol compounds, Among these numerous derivatives
are the 3-(3-azabicyclo[3,2.2]non-3-ylmethyl)benzophenone and 4-(3-
azabicyclo[3,2,2,]non-3-ylmethyl)benzophenone hydrochloride salts.
These compounds also have antidiabetic pharmacological properties.
114Schutt describes the synthesis of novel aminopyran derivatives
which upon heating undergo rearrangement to form bicyclo alkanone
derivatives.
R! = H, aryl
R2 = H, alkyl
R, = H, halogen, haloalkyl
X = polycarbon alkylene
185
these compounds are used as anti-inflammatory and analgesic agents.
The disclosures of this patent are a continuation of U, S. Patent
3,309,370 by the same author.
A series of 2-amino-bicycloheptanes, octanes, nonanes, and decanes
have been prepared and are shown to.be useful, as anti-inflammatory
agents. The compounds may be administered in the quaternary ammon-
ium state in an admixture of pharmaceutically acceptable organic or
inorganic solid or liquid carriers, given orally or parenterally.
Adamantane compounds
A number of adamantane derivatives have been prepared and used
in anti-inflammatory preparations, The first of these compounds are
the dialkylaminoalkyl and related esters of adamantanecarboxcyclic
acids which are reported to have antibacterial, antiprotozoal, anti-
fungal, and antialgal properties. The compounds are prepared by
the reaction of an adamantanecarboxcyclic acid with the appropriate
dialkylaminoalkyl halide. Other adamantanecarboxcyclic acid derivatives
119have been formulated by the G. D. Searle Co, and are disclosed in
a French patent,
The anti-inflammatory trichloropregnadienes and esters have been
118prepared by Shapiro and Hershberg, Among the various 21-substituted
120
acetates and valerates is the 21-adamantoate, Bell has synthesized
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the 1- (carboxyalkyl)indoles which are anti- inflammatory agents. The
adamantanecarbonyl group is located at R,
Last in this series are the anti-inflammatory 0- (Uadamantane-
121
carboxamido)-phenylacetic acid derivatives,
CHR2C02H R = H, Me, MeO,
R, = H, F, MeO
CONh
 v -/—«M1
 R2 = H, Me, Bu
R
These compounds were prepared from 1-adamantanecarbonyl chloride,
Antiviral Agents
In the past, chemotherapy of viral diseases such as measles,
poliomylitis, and influenza did not exist, The larger viruses that
caused trachoma and lymphogranuloma venereum responded well to anti-
biotics.
Recently, new developments in antiviral therapy have been realized.
Idoxuridine has been used successfully in the treatment of.herpetic
keratitis via topical application.
The bicyclic and cage compounds that exhibit antiviral activity
include.- the bicyclic, adamantane and miscellaneous systems, The
bicyclic systems consist of the bicyclo[2,2.2]octanes and octenes,
the bicyclo [3.2.1]octanes, and the bicyclo[3,2,2]nonanes,
The adamantane types and derivatives include the most common
member of this class, 1-aminoadamantane (mydantane, symmetrel, aman-
tadine).
187
The miscellaneous compounds include such unusual systems as the
pentacyclo[5.4.0.0 ' .Q ' .0 ' ]undecanes, the 11-azatricyclo
I f- 7 Q
[4.4.1.0 ' ]undecanes, and the tricyclo[4.4.0.0 ' jdecanes.
Bicycle [2.2.2] octanes
The smallest bicyclic systems to meet the requirements of having
antiviral activity are the l-aminobicyclooc't-2-enes and the bicyclo-
oct-2-enes-l-methylamines. ' ' These compounds show excellent
ability to prevent the occurrence and growth of harmful viruses. The
saturated analogue of this system has also been prepared. '
125Chow has prepared the bicycle [2. 2,2] octane- 2-methylamine system.
These compounds or their addition salts cured or prevented viral
infections, especially of the A._ strain, in warm-blooded animals.
Pig influenza has been found to be susceptible to the bicycle-
•I O/l
[2. 2. 2] octane system. In a patent by duPont, the following systems
R,R_NOZt
were found to have antiviral activity attended with therapeutic and
prophylactic activities.
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,127Whitney, et al have synthesized various cage amines and have
studied their usefulness as antiviral agents. The novel synthesis of
numerous bicyclo[2.2.2]octan-l-amines and bicyclo[2.2.2]octane methyl-
amines is described. It was found that the unsaturated systems were
similar to their saturated counterparts, and that with the bicyclo-
[2,2.2]octan-l-amines optimal activity was achieved when R = methyl.
Bicyclo[3.2.1]octanes
A series of amino, aminomethyl, and «^ -aminoethyl bicyclo[3.2.1]-
octanes that show antiviral activity have been prepared by Chow.
A XA
A
128a,b
CH_
I 3
One A = -CH-NH,
All others = H
One B = CH2NH
All others = H
When A or B is at the 2-position, a 40-95% increase in the survival rate
of Asian flu-infected mice were observed. At the 3-position there was
observed a 30-50% increase, and the 8-substituted compound showed a
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12945-55% increase. Varraa and Nobles have prepared substituted N-
aminomethylisatins.
R = Br or H
2 = 3-azabicyclo[3.2.1]oct-3-
yl or 3-azabicyclo[3.2.2]non-
3-yl
These substances show a. high order of activity against poliomyelitis
type II, herpes simplex, measles, and parainfluenza 3 (HA-1),
Adamantane Types and Derivatives
Generally, most of the adamantane antivirals are derivatives of
1- or 2-aminoadamantanes, It appears that.the most active species is
1-aminoadamantane and its various derivatives, The 2-aminoadaroantane
compounds have comparable activity.
The adamantanes act by various routes, The first of these is
the inhibition to penetration of the host cell by the virus. This
action comes about by the coating ability of the aminoadamantanes.
These compounds coat the cell surface and interfere with the viral pene-
tration thus inhibiting reproduction of the virus, This affords
protection of the host cell. Other routes of inhibition include
interference of multicyclic replication and inhibition of RNA synthesis.
This mode of action is not virucidal, and some viruses are still able to
attach; themselves to the host cell wall,
The various adamantane compounds act on numerous viruses. The
most common are the influenza A, A , C and 0 strains. Well-known
diseases such as polio, hepatitis. Rubella, measles, and herpes simplex
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infections are controlled or irradicated by the adamantane compounds.
Other not-commonly-known diseases caused by viruses such as pseudo-
rabies, and parainfluenza also succumb to the aminoadamantane drugs.
Viruses such as semiliki forest virus, tobacco mosaic, hepatic and
rhino viruses are also susceptible to this antiviral action.
The literature concerning the activity, mode of action, and viral
^.susceptibility of the adamantane antivirals is extensive. Part I of
the bibliography for this chapter lists the references to antiviral
compounds derived from adamantane,
Unusual Systems
Other cage systems have been used in antiviral chemotherapy as
a consequence of the widespread success of the adamantane compounds,
3 8The first of these compounds is the tricyclo[4,4,0.0 ' ]decan-l-ylamine
system.
H2N
The antiviral actions and the intermediates used to acquire this compound
are described in a patent by Deslongchamps. Berthold has
7 Q
described the preparation.of tricyclo[4.3.1,0 ' Jdecane and tricyclo-
3 8[4.3,0.0 ' ]nonane systems substituted at the 3-position with amino,
aminomethyl, or <X.-aminoethyl groups. These compounds are prepared in
a sequence of reactions from 2,6-dioxobicyclo[3,3.l]heptane-3,7-dicar-
boxylate, Dupont has reported the preparation of 3-aminobicyclo-
3 8[4.3.1,1 ' Jundecane derivatives useful as antiviral agents.
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133J. R. Giegy has also prepared this system by another synthetic method.
3 8Derivatives of the 3-aminotricyclo[4,3.1.1 ' ]undecanes have.been
134formulated by Cairns, A typical compound is 3-N,N-dimethylamino-
•Z Q
tricyclo[4.3,1.1 ' ]undecane and its hydrochloride salt.
Grunewaldj e.t.al have investigated the medicinal chemistry of
[10] annulenes and related compounds. Among the compounds reported
are the ll-azatricyclo[4.4.1.0 ' ]undecane and ll-azatricyclo[4,4,1.0 ' ]-
undeca-3,8-diene systems. The compounds were not as effective as
NH
N
1-aminoadamantane hydrochloride.
The most unusual system investigated was the trimethylpentacyclo-
[5.4.0.02'6.03'°,05'9]undecan-8,ll-dione derivatives.136 The prepara-
tion of amino derivatives of this system were studied for antiviral
1.
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activity. Compound 5 and 6 showed no activity in vitro against influenza
A (WSN), parainfluenza 1 (Sendai), and influenza A (Ann Arbor).
192
Compounds 1 and 3 showed some activity against influenza A(WSN). Com-
t
pound 5 showed superficial activity against pheumonitis.
Blood Pressure Depressants and Stimulants
The treatment of hypertension in the last few years has been
revolutionized by the introduction of drugs that can lower blood
pressure without intolerable side effects. These drugs act by various
mechanisms, such as direct vasodilation, receptor blockage, inhibition
of monoamine oxidase, ganglionic blockade, myocardial depression and
increased sodium ion excretion, In most cases, therapy is directed
at promoting sodium excretion. The classification of antihypertensive
drugs is carried out according to their mode of action. Some of the
drugs used in antihypertensive therapy are Hydralazine, Dizaoxide,
Phenoxybenzamine, Ismelin, and Paragyline.
Bicyclic and tricyclic compounds are used in treatment of hyper-
tensive states. The various classes that may be found are the bicyclo-
[2.2.1]heptanes,• ..bicyclo [2.2, 2]octanes, bicyclo[3.2,1]octanes, bicyclo-
[3,2.2]nonanes and higher classifications of polycyclic compounds such
as tricyclo[3.2.2.0 ' ]nonanes.
Bicyclo[2.2.2]octanes and Bicyclo[2,2,1]heptanes
Shionogui and Co. have reported the synthesis of the quaternary
ammonium salts of bicyclo[2.2,2joct-7-ene derivatives, These compounds
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are reported to have excellent blood pressure lowering activity.
Some of the compounds prepared are acid imide derivatives such as 1 -
(co -dimethylaminopropy1)-5,7-dioxobieyelo[2.2.2]octano[2,3;3',4']-
i ' 1382 ,5 -dioxopyrrolidine, various methyl iodide quaternary salts of
139 '
this compound, and 1 -( oo -dimethylaminopropyl)-5,7-dihydrooxybicyclo-
[2.2.2]octano[2,3;3',4']pyrrolidine, °' This company has also
manufactured 2-substituted-4,7-ethano-3a,4,7,7a-tetrahydroisoindoline-
*1 A O
1,3-diones which also have the added ability to act as antispasmodics.
A preparatory synthesis starting from the bicyclo[2,2.2]octane nucleus
for many of the above compounds has been published by Takeda,etal ' a>
The 7-oxobicyclo[2.2.l]heptane-2,3-dicarboximides prepared by
lithium aluminum hydride or electrolytic reduction of 3,6-endooxy-
145perhydroph'thialimides have been reported. These compounds, whose
parent structure is Endothal(discussed in Chapter 8) have.been reported
to be synthesized in 80-90% yields and are converted to the acid salt
or quaternary or bisquaternary salts. The isoindolines obtained in
this manner are very effective in treating hypertension. Among the
derivatives reported to have low toxicity is the N-dimethylaminoethyl-
4,7-dimethyl-4,7-endoxyhexahydroisoindoline- derivative, A patent
Me
has been prepared for the general synthesis of these compounds 147
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Endomethylene .derivatives of 1,2-dimethylhexahydropyridazaines
showing hypotensive and ganglionic blocking activity have been prepared
•I Q^
by Snyder, 2,3-Dimethyl-2,3-diazabicyclo[2,2,l]heptane is a typical
product.
Me
149Stern has investigated the pharmacological action of quinuc-
lidine and related compounds, Thioquinuclidinebromide (bicyclo[2,2,2]-
1-thamiumoctane bromide), bicyclo[2,2.1j-l-thianiumheptane chloride,
l-azabicyclo[2,2,Ijheptane-hydrochloride and quinuclidine hydrochloride
have been reported to lower blood pressure in cats and rabbits. Bicyclo-
[2,2,l]-l-thianiumheptane chloride is reported to be as active as
acetylcholine in lowering blood pressure.
Other bicyclo[2,2.IJheptane and bicyclo[2.2.2]octane compounds
showing hypotensive properties are norbornyl derivatives of piperidyl
carbamates, camphidine compounds, oc -phellandrine derivatives,
and various basic esters of 2-norcamphanecarboxylic and bicyclo-
[2.2.2]octane-2-carboxycyclic acids; .
Bicyclo[3.2.1]octanes
Grogan and Rice have prepared a series of N-dialkylamino-3-
azabicyclo[3.2.l]octane-2,4-diones, Monohydrochlorides and monometh-
iodides-were prepared, and the quaternary salts were screened for hypo-
tensive activity in dogs. The bisquaternary salts showed good hypoten-
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sive action and a favorable therapeutic index. Other derivatives
prepared demonstrating hypotensive action are the mono- and bisquat-
ernary salts of N-dialkylamino-3-azabicyclo[3.2.1]octanes.
Systems that may also be included in the bicyclo[3,2,1]octane -.
category that show hypotensive activity are the tropane derivatives,
the indolyl lower-alkyl tertiary amines, and the various azabicyclo-
1 ro
[3.2,1]octanes.
Bicyclo[3.2.2]nonanes
159Laake Oy has presented the synthesis of 3-azabicyclo[3,2,2] -
nonane derivatives prepared by condensing 3-azabicyclo[3,2,2]nonane with
haloamines in butanol. The quaternary salts have important blood pressure
lowering abilities. The most important feature, however, is the long
lasting effects, Typical representatives of these bicyclic systems
are the N,N-dimethylaminoethyl-3-azabicyclo[3,2.2]nonane derivatives.
Piperidinecarbbximides and some corresponding derivatives have been
prepared by Kirchner. Among the derivatives prepared are the 1-
carbamoyl-2-[2-(3-azabicyclo[3.2.2]nonyl)ethyl]piperidine, and
3-[2-(2-piperidyl)ethyl]-3-azabicyclo[3.2,2]nonane derivatives. These
compounds were tested for hypotensive activity in the unanesthetized
hypertensive rat.
Bicyclo[3,3.1]nonanes
1 fV?Tucker and Lundemann have prepared 9-amino-9-azabicyclo[3.3.1]-
nonane by treating 9=nitroso-9-azabicyclo[3.3,1]nonane with lithium
aluminum hydride in diethyl ether. This compound demonstrates antihyper-
196
tensive and monamine oxidase inhibitory activity. Various benzamide
derivatives employing 9-azabicyclo[3,3,l]nonane have also been prepared.
Pharmacological tests of hypotensive activity on rats have been inves-
tigated and formulas for pellets have been given,
Rossi, Valvo and Butta have reported the synthesis of 3-azabicyclo-
[3,3.l]nonane derivatives with powerful hypotensive and ganglioplegic
164properties. The compounds were prepared by replacing the amino
hydrogen at position 3~ by a linear chain of 2-5 carbon atoms carrying
at the end of this chain an amino group disubstituted with methyl or
., , . .. 165,166
ethyl moieties, '
The synthesis and pharmacological properties of 9-alkylamino-
alkyl-substituted 3-benzyl-3,9-diazabicyclo[3.3,l]nonanes have been
investigated by Nikitskaya and Gerchikova. 3-Benzyl-9 a -diethylamino-
ethyl-3,9-diazabicyclo[3.3.1]nonane and various derivatives all reduced
the arterial pressure in anesthetized cats by 20-50 mm for 5-10 minutes,
Most derivatives also had weak central cholinolytic action and one
derivative demonstrated prevention of arecoline tremors,
(Azabicycloalkyl)alkylguanidines prepared by treatment of the
appropriate bicyclic amine with 5-methylisothiourea sulfate in the proper
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solvent have been prepared by Mull. Representative members of this
class showing antihypertensive actions are 2-(3-aza-3-bicyclo[3.3.1]-
197
nonyl).ethylguanidine and 2-(3,7-diaza-7-methyl-3-bicyclo[3.3.Ijnonyl-
ethylguanidine.
Tricyclic systems
The araidoxime 0-carbamates have been demonstrated to be useful as
antihypertensive agents by Henderson. Among the derivatives prepared
*7 /*
are tricyclo[3. 2.2.0 ' ]non-6-yl compounds.
Blood pressure stimulants
Archer has prepared bicyclic compounds of the tropane and
granatanine series. Some of the derivatives were useful as blood pres-
sure elevators and as stimulants to the central nervous system. Doses
of 3 A -phenyltropane in dogs of 0.3 to 0.6 rag/kg raised blood pressure
40-60 mm. The methiodide salt worked equally well but the therapeutic
index was lower. The 3-phenyl-2-granatenes have been shown to exert
their influence on blood pressure via the central nervous system.
C. F. Boehringer and Soehne have reported on the synthesis and activity
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of these compounds.
Central Nervous System Depressants and Stimulants
The central nervous system may be acted upon by various classes of
drugs. Among these are the general classes of hypnotic drugs, stimu-
lants of the convulsant type, antiepileptic drugs, narcotic analgesics,
and non-narcotic analgesics.
Drugs that can produce a state of depression of the central nervous
system are referred to as hypnotics. When used in small doses these
drugs are active as sedatives. Hypnotics find many important uses in
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medicine, such as sleeping pills, in combination with analgesics for
painful states, as antidotes for stimulant or convulsant disorders. The
most important members of this class are the barbituates, used as early
as 1903.
A number of drugs have stimulant action on the central nervous
system and when taken in sufficient doses produce convulsive states.
These drugs generally stimulate respiration and combat the depressant
action of barbituates. Because these stimulants have an awakening
effect they are often referred to as analeptics. A majority of the
analeptics act on the brain stem and some exert their action on the
cerebrum. The use of central nervous system stimulants is decreasing
in medical applications. The only application presently seems to be
as respiratory stimulators and even this indication is somewhat debat-
able.
The antiepileptics are drugs that combat manifestations of paro-
xysmal cerebral dysrhythmia. These drugs are central nervous system
depressants with a selectivity of action such that they can prevent
epileptic seizures in doses that do not cause drowsiness. The anti-
epileptics have some undesirable side effects, but even under these
conditions, a measure of protection can be afforded to approximately
80% of the epileptics. This is an outstanding achievement in the
pharmacologic approach to the treatment of the disease.
The narcotic and non-narcotic analgesics have been discussed in
this report under the consolidated title of Analgesics.
The various classes of bicyclic and cage compounds comprising the
members of depressants and stimulants are the bicycloheptanes, octanes,
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nonanes, decanes, and adamantanes. Bicycloheptanes, octanes, nonanes,
and decanes are found in both classes of stimulants and depressants,
but the adamantane compounds are found only in the depressants.
Daeniker has prepared bicyclo[2.2.l]heptane-2-sulfonamide
derivatives. These compounds are reported to have a stimulatory effect
on the central nervous system when administered inter alia. Their
stimulating or awakening effect allows them to be used as analeptics.
These analeptics have the general formula:
SO NH
N = 1,2
R =.H, Me
A synthesis is described,
3-Arylquinuclidines and selected derivatives have been reported
174to have a stimulatory effect on the central nervous system. They
alsoIhaVe an excitory effect on respiration. The 3-arylquinuclidines
are prepared by treating 3-quinuclidone with an arylmetallic compound,
dehydrated, and then hydrogenated to give the product.
Other bicyclo[2.2.2]octanes shown to have central nervous system
stimulant properties are the 2-(3,4-disubstituted phenyl)-3-amino-
bicyclo[2.2.2]octan-2-ols, and the N-cycloalkyl and N-(cycloalken-
1-yl)azabicyclooctanes.
Some of the commonly used central nervous system stimulants are
known to have caffeine-like activities. Others may exhibit allevia-
tion of mental depression and may have veterinary uses. ' The
N-cycloalkylazabicyclo[3.2.2.]nonane derivatives have been shown to have
200
inhibitory pseudocholinesterase, urinary secretion and anti-inflammatory
... ... 180
activities.
181
Houlihan has synthesized diazabicyclononanes of the general
formula which have central nervous system stimulant properties. Also
prepared were the 2-phenyl and 2-(2-chlorophenyl) derivative.
Central nervous system depressants
The N-aralkyl camphidines have been investigated for their central
182
nervous system depressant activity by Hermanson. He found that
two N-aralkyl-5-substituted camphidine salts had a sedative effect on
the central nervous system. The toxicology and other effects were also
investigated. The chemical structure and sedative effect were studied
in order to determine structure-activity correlations. When the cam-
phidine ring was substituted with other heterocyclic structures, no
sedative activity was observed. A chlorine atom substituted at the 5-
position of the camphidine ring lowered the effectiveness of the drug,
while chlorine, nitrite, methyl, and methoxy substitution on the
benzyl ring enhanced the effect. Other camphidines have demonstrated
183depressor activities on the central nervous system.
l-Azabicyclo[2.2.2]octanes have been shown to possess central
nervous system depressor activities. Compounds of this type are 2,3-
201
184heterocyclic fused quinuclidines and various bicyclo[2.2,2]oct-5-
185
ene-bis (2,3-dicarboximide) compounds.
3-Azabicyclo[3.2.2]nonanes have demonstrated central nervous system
186
properties. These compounds have the general structure:
COCH
'
R
'
Formulation for oral doses may also be encountered in this patent.
The last of the bicyclic compounds to show central nervous system
activity are the bicyclic glutarimides, bicyclic barbituric acid, and
187bicyclic oxazolidinediones. The synthesis of these compounds was
conducted in order to study thevpossibility of the existance of a
unified anticonvulsant receptor site.
1 88
Szinai and Lunn have prepared adamantane derivatives that .show
central nervous system depressant action. Some of the derivatives
prepared were the'1-acetyladamantane and l,2-dimethyladamantane[2,l-b]-
pyrrolidine. About 30 derivatives have been prepared. A series of
adamantane compounds having central nervous system and antihistaminic
189
activity have been prepared by Bernstein. These compounds are useful
in the treatment of allergies and Parkinsonism. 1-Substituted amino-
adamantanes have also demonstrated central nervous system depressant
activity.190
Contraceptives
In 1959, the first report of successful inhibition of ovulation by
orally administered norethylnodrel-mestranol compounds appeared. By
202
1966, more than seven million women were taking oral contraceptives
although the use of such contraceptives had some unpredictable side-
effects. However, the results indicate that these drugs are the most
effective means of preventing pregnancy.
There are three types of contraceptive formulations:
(1) Progestogen-estrogen combinations; (2) Sequential estrogen-
progestogen; and (3) Low-dosage progestogens,
Most of the bicyclic and cage compounds incorporated into contra-
ceptives are bicyclo[2.2.2]octane and adamantane derivatives, The
bicyclo[2.2.2]octanes are either androstane steroidal esters of estro-
genic steroids. The adamantane compounds in themselves have pronounced
antifertility and therefore contraceptive activities.
Bicycle[2.2.2]octanes
191Cross and Fried have prepared the bicyclo[2.2.2]octane-l-
carboxylate and bicycle[2.2.2]octane-1-methylenecarbonate esters of
androstane and 19-norandrostane steroids. These esters have long-acting
antifertility progestational activities, and have the general formula
0
II
CH -0-C—0—
I
The dotted line represents a possible double bond. The steroid nucleus
to which these bicyclooctanes are attached have the general formula
203
CsCR,
and the bicyclic moieties are attached at either R or R The
bicyclo[2.2.2]octane-1-carboxylate and bicyclo[2.2.2]octane-1-methylene-
carbonate may also be attached to an estrogenic steroid via the ester
192linkage.
193aAldrich and Herrmann have prepared a series of 4-phenylbicyclo-
193b[2.2.2]octane derivatives that show contraceptive actions,
compounds have the general formula
These
and it was found that when applied in amounts of 0.01 to 5 mg/kg could
193cprevent pregnancies in rats. Another similar system with the
general formula seen below and prepared by Gregory and Lee represents
194 195
compounds that may be useful as contraceptives. Karmas has
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= R3 = X = H
R2 = Ac
R = Et
reported that the 2-methyl-3-ethyl-4-(substituted-phenyl)cyclohexane
carboxcyclic acid derivatives possess useful anti-littering properties
in animals. These compounds have the following formula:
Selected 2-formyl- and 2 oc -(cyanoamidino)-A-nor-S oC-androstane
derivatives have demonstrated antifertility properties. The 2--
formyl-A-nor-5 <X -androst-l-en-17 oC. -olbicyclo[2.2.2]-octane-1-carboxy-
late derivatives has been prepared. This compound has the formula
205
and is prepared with bicyclo[2.2.2]octane-l-carboxycyclic acid chloride
and 2-formyl-A-nor-5 o£ -androst-l-en-17 e> -ol.
Adamantane derivatives
Adaniantane derivatives of androstane and estrogenic steroids have
191been prepared. Cross and Fried in preparation of their androstane
and 19-norandrostane steroidal esters prepared the tricyclo[3.3.1.1 ' ]-
decane-l-methylenecarbonate(adamantane-l-methylene carbonate)derivative.
This compound is prepared from adamantane-1-carboxcyclic acid and the
corresponding androstane alcohol. The synthetic preparation of the
adamantane derivative in the estrogenic steroid series is very
similar. Schribner describes the preparation and properties
of the 2-formyl-A-nor-5 <X -androst-l-en-17 0 -ol adamantane-1 -carboxy-
late. This compound is prepared from adamantane-1-carboxcilic acid
chloride and 2-formyl-A-nor-5 <X-androst-l-en-17 ft -61 and demonstrates
antifertility properties.
Other adamantane-compounds that show antifertility or antizygotic
activity have been prepared. These compounds are adamantane(substituted
197 198phenyl), 2,3-dialkyl-4-arylcyclohexenemethanols, and esters of
1992-methyl-3-ethyl-4-phenylcyclohexanecarboxcyclic acids.
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Ganglionic Blocking Drugs
The development of ganglionic blocking agents began with the
discovery that nicotine could block ganglionic transmission. Langley
made extensive use of nicotine as a local application for charting
sympathetic ganglia in the cat. Tetraethylammonium salts were also
known for years to block the effect of ganglionic stimulants, and in
1946, the mode of action on mammalian circulation was thoroughly
investigated. From the results of this investigation it was
suggested that ganglionic transmission may be blocked in a selective
manner. Interest in hypertensive diseases and vasospastic disorders
initiated the expansion of the investigations of ganglionic blocking
activity. From this a variety of ganglionic blocking agents were devel-
oped. Some of the most common compounds are hexamethonium, pentolinium
chlorisondamine, and trimethaphan camphor sulfonate. The newest members
of this class are mecamylanune and pempidine. Trimethaphan camphor
sulfonate and mecamylamine are bicyclic compound derivatives.
CH S0_
0
Trimethaphan camphor
sulfonate
CH-6
CH- . HC1
\J
H3
NHCHT
Mecamylamine
hydrochloride
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The majority of gang!ionic blocking drugs are quaternary ammonium
compounds and are used principally for decreasing the action of the
sympathetic division of the autonomic nervous system on circulation.
Numerous side effects may be noticed due to hinderance of parasympath-
etic ganglionic transmission.
The bicyclic and cage compounds employed in ganglionic blocking
agents are bicyclo[2.2.l]heptanes, bicyclo[3.2.1]octanes, bicyclo[3.3.1]-
nonanes, and the bicyclo[4.2.1]nonane derivatives. Some of these com-
pounds are congeners of mecamylamine and pempidine, and most are quat-
ernary ammonium compounds, all possessing the ganglionic blocking
ability via depolarization inhibition of acetylcholine.
The ganglionic blocking activity of aminobicyclo[2.2.1]heptanes
201have been investigated by Corne, Lee, and Wratt. The structure-
activity relationships for ganglionic blocking action in lower homo-
logues of mecamylamine are discussed. Activities in larger rings were
found to be similar and successive introduction of C-Me surrounding the
nitrogen atom resulted in an increase in ganglionic blockade and
duration of action. When compared to hexamethonium, these compounds
were found to be comparable in action. Acute oral and intravenous tox-
icities and requirements for strong ganglionic blocking action are also
,. , 202discussed.
New bisquaternary compounds have been derived from 3,5-ethylene-
piperidine and its derivatives, most notably camphidine, by quaterini-
203
zation with alkyl or aralkyl salts of inorganic or organic acids.
Numerous quaternary compounds of l-(3-dimethylamino propyl)-3,4,4-
208
trimethyl-3,5-ethylenepiperidine have been prepared. N-substituted
chlorinated camphidine derivatives containing NH groups in the side
chain have been shown to have strong ganglionic blocking properties. a
Pharmacologic properties have also been reported.
Tertiary-amino substituted compounds of the tropane and granatane
series demonstrating ganglionic blocking actions have been investiga-
205ted. Pharmacologic investigation via response in dogs and nictitating
membranes in cats has demonstrated that these compounds have ganglionic
blocking effects. The quaternary ammonium salts of these compounds
are highly effective.
The pharmacological properties of 3-azabicyclo[3.3.1]nonane have
been investigated by Tommasini and Passerini. The compounds spec-
ifically investigated were the derivatives of 3-isogranatanine. The
methyl derivative was found to be active due to its ganglionic blocking
activity. A derivative of 9-methyl-3,9-diazabicyclo[3.3.1]nonane has
been investigated for its pharmacologic properties by Nikitskaya,
207Usovskaya and Rubtsor. 3-(3-Dimethylaminopropinyl)-9-methyl-3,9-
diazabicyclo[3.3.l]nonane and similar tetramethylene derivatives had
strong curare activity similar to that of decamethoniam. Curare-like
actions on impulse conduction in cats are found in a similar derivative,
OHS
nobutane(1,4-bis(9-methyl-3,9-diazabicyclo[3.3,1]nonano-3)butane).
Thepentamethylene and hexamethylene derivatives had similar activity
but were weaker.
209
4,9-Diazabicyclo[4.2.1]nonane derivatives have been shown to have
209ganglionic blocking actions and. demonstrate serotonin antagonism.
Representative members of these compounds are 4-benzhydryl-9-methyl-
4,9-diazabicyclo[4.2.1]nonane and 4-(9-fluorenyl}-9-methyl-4,9-diaza-
bicyclo[4.2.1]nonane.
210
Hypoglycemic Agents
The introduction of hypoglycemic sulfonylurea compounds greatly
210 211
enhanced the management of diabetes. In 1942, Laubatieres '
observed that certain sulfonamides produced symptoms of hypoglycemia.
Subsequent investigations in other laboratories established that certain
sulfonylureas can produce hypoglycemia in certain animals. The most
commonly used sulfonylureas used today are tolbutamide, chlorpropramide,
acetohexamide, and tolazamide.
Most of the bicyclic and cage compounds are sulfonyl or sulfonyl
i
semicarbazide derivatives. They are composed of the classes of bicyclo-
heptane, bicyclooctane, and bicyclononane compounds, and the adamantane
T Q
and tricyclo[4,3,l.1 ' Jundecane derivatives.
Bicyclo[2.2,1]heptanes and Bicyclo[2.2.2]octanes
Bicyclo[2.2.1]heptane compounds possessing antidiabetic actions
212have been prepared by Winter, et.al. Among the sulfonylureas prepared
was the bicyclo[2,2,l]hept-2-yl.derivative. Nortricyclyamine phenyl-
sulfonyl urea compounds, considered as a class of bicyclo[2.2.l]heptanes,
213have also demonstrated blood sugar level reduction ability. Nontoxic
benzenesulfonylureas have demonstrated hypoglycemic properties. '
215Other compounds have been prepared by Dietrich • and J, R. Giegy,
O 1 fi
A.-G, The quinuclidine derivatives have also shown antidiabetic
and hypoglycemic properties, '
211
Bicycle[3,2,1]octanes and Bicyclo[3,2,2]nonanes
Hypoglycemic (benzenesulfonamidocarbonyl) camphidines with the
general formula
CONHS02—^ y-X X = Cl.NH ,F,Br, or Me
219have been prepared by Carron, et al, The chlorine .derivative.decreased
rat glycemia after an oral dose of .125 to 250 rag/kg. These compounds
also had peripheral spasmolytic and blood pressure effects,
A new synthesis of nortropane (8-azabicyclo[3,2,1]octane) and the
220
acid addition salts of these compounds has been reported. The
products are intermediates in the preparation of orally active anti-
diabetics and diuretics. These compounds are prepared from azabicyclo-
octanes in which the nitrogen atom is substituted with a methyl group
which is then substituted with a hydrogen atom.
The preparation of 3-azabicyclo[3,2,2]nonane phenylsufonylurea
221derivatives has been described. These compounds and their addition
salts are useful as blood sugar-reducing agents, A number of derivatives
with the general formula
\V-SO NHCON I I R = H,halogen, alkyl,
x \ J alkoxy, alkylthio,
or acyl .
212
have been formulated, A very similar derivative has been shown
S02NHCONHN |
222 'to have pronounced hypoglycemic effects and low toxicity. These
compounds find use in the management of diabetes mellitus 223
Bicycle [3. 3. IJnonanes
Sandoz, Ltd, has prepared antidiabetic compounds useful in treating
224diabetes mellitus via reducing the effects of this condition.
These compounds are derivatives of 9-azabicyclo [3, 3. IJnonanes and" have
99 C
prolonged effects. ' Other compounds found useful in the treat-
ment of diabetes are phenylsulfonylsemicarbazides of the N-amino-
997 99Rgranatane (9-azabicyclo [3, 3. l]nonane) and 3-azabicyclo[3.3.1]nonane
class .
Adamantane Derivatives
Pharmacological isoquinoline derivatives having the formula
R = H,Br,Cl
R, = 1-adamantyl
229have demonstrated blood sugar lowering activities. These compounds
are prepared by the condensation of sulfonamides with the appropriate
213
adamantyl isocyanate. Dietrich has prepared various N-adamantyl-N -
arylsulfonylureas having antidiabetical properties, '.' These
compounds have the general structures
R-,
R.
S02NHCONHAd
•SO NHCONHAd
R = halogen, CF , alkyl,
alkoxy, alkylthio
R = halogen, CF , alkyl,
alkoxy, satd alkyl group
R = CF_, low alkenyl, alkanoyl,
Ar
S02NHCONHAd
RI = halogen, H, alkyl, alkoxy,
alkylthio
Ad = adamantane
and may be prepared by the .reaction of l^aminoadamantane, -the correspond-
ing arylsulfonyl isocyanate, or an arylsulfonyl urethane or urea.
When R=CF3, acyl, akenyl, or aryl, these compounds show high hypogly-
231 232
cemic activity and low toxicity in warm-blooded animals. '
233Gerzon has also prepared a series of N-(substituted)-phenylsulfonyl-
N -1-adamantylureas.
3 8
Tricyclo[4,3,1,1 ' ]undecanes and Miscellaneous systems.
It has been observed that N'-tricyclo[4,3.1.1 ' ]undec-3-yl-N-
p-aminobenzene-sulfonylureas of the formula
—NH—CO-NH
215
possess strong hypoglycemic action when given orally or parenterally
234
even in low dosages. These compounds have hypoglycemic action much
greater than the known pharmaceutically accepted antidiabetical com-
pounds containing alkyl substituents of 3 to 4 carbon atoms at the
phenyl nucleus. Consequently, the therapeutic index is much more favor-
able than the existing oral antidiabetics. The derivatives described
3 8
here are prepared by reacting tricyclo[4,3,1.1 ' ]undecane-3-amine with
an arylsulfonyl isocyanate, A Netherlands patent covers other N-aryl-
sulfonyl-Nl;itricyclo[4,3.1.1 ' ]-3-undecylurea derivatives as anti-
235diabetical compounds.
Miscellaneous hypoglycemic compounds of bicyclo{3,1,1]heptane,
bicyclo[3,2.1joctane, and bicyclo[3.3,l]nonanes have been prepared
07 fi
by Tucker, et al. These compounds show hypoglycemic activity in
237
rats, and also demonstrate low oral toxicity. Weber, et.al have also
prepared bicyclo[2,2.2]octane and bicyclo[3.2.1]octane hypoglycemic
Cphenylsulfonyl)ureas,
Local Anesthetics
Local anesthetics produce transient and reversable loss of sensa-
tion in a circumscribed area of the body by interfering with nervous
conduction. In 1884 the drug cocaine was introduced by Kol-ler. This
drug was used as a topical anesthetic in ophthalmology.
In 1904 procaine was introduced by Einhorn. Procaine could be
injected and was the first local anesthetic in which this could be
safely done. Procaine was used exclusively and widely until lidocaine
came to be known. Lidocaine is now considered the drug of choice for
local anesthesia, Other important local anesthetics are tetracaine,
216
mepivacaine, prilocaine, and bupivacaine. All of the local.anesthetics
are either esters or amides, and are different in their toxicity,
metabolism, onset, and duration of action,
Electrophysiologic studies.demonstrate that the local anesthetics
interfere with the depolarization phase of the action potential. As
a consequence, when a nerve.cell is excited, the cell does not depolar-
ize sufficiently and thus a propagated action potential is blocked.
Represented in the class of local anesthetics are the bicyclo-
[3.2.1]octanes, bicyclo[3.3,ljnonanes, bicyclo[4.3.Ijdecanes and adaman-
tane derivatives.
i
N -[N-(monocarboxcyclic aryl)carbanoyl]-lower alkyl amines have
O -Z Q
been reported to have local anesthetic properties. In particular
the nortropane (8-azabicyclo[3,2,1]octane).derivatives are prepared by
adding N-(2,6-dimethylphenyl)carbamoylmethyl chloride to nortropane,
Other bicyclo[3.2,1]octane derivatives showing intravenous local
239
anesthetic action are (bicyclo-octenyl)-alkyl maleic acid derivatives.
These compounds also exhibit soporific actions,
Ohri, et.al have prepared twenty 3-azabicyclo[3.3.1]nonane
derivatives and have examined them for analgesic activity. In their
findings they report that the 3-methyl-9 -benzoyloxy-3-azabicyclo-
[3.3.l]nonane derivative
MeN
217
exhibited local anesthetic activity comparable to that of procaine-
hydrochloride.
242Houlihan has demonstrated that diazacycloalkanes of the
general formula ,
r ^ i i
R = H,Cl,alkoxy
have local anesthetic activity by actions via the central nervous
system.
Adamantane derivatives that have local anesthetic activity and
that block adrenergic response are reported to be prepared in good
243yield. These l-(adamantylmethoxy)-2-hydroxy-3-propylamines have
the general formula
CH2OCH2CH(OH)CH2X
X = C ^
R = H, sec butyl
Parkinsonism Drugs
With the discovery of'L-dopa, the pharmacology of Parkinson's
Disease has been greatly revolutionized. In the past, the treatment of
this disabling condition has been carried out with (1) the belladona
alkaloids and congeners, (2) antihistamines, (3) anticholinergic and
antihistiminic combinations, and (4) dextroamphetamine for the treatment
218
of some conditions of postencephalic parkinsonism,
Parkinson's Disease is characterized by tremor, rigidity, and
akinesia and other paralysis syndromes and postencephalic conditions.
This disease may also be caused by drugs. The treatment of Parkinson's
Disease was described more than a hundred years ago by the administration
of belladonna alkaloids.
Some of the drugs used to treat Parkinson's Disease are trihexyl-
phenidyl hydrochloride, diphenhydramine hydrochlorides, benztropine
mesitylate, and orphenadrine hydrochloride.
Bicyclo[3.3. l]nonane and adamantane derivatives have found use in
the treatment of Parkinson's Disease, These compounds act in a similar
manner to the previously described drugs.
The pharmacological properties of 6,6,9-trimethyl-l-azabicyclo-
[3.3. 1] non-3- P -yl<=< ,aa,-di(-2-thienyl)glycolate hydrochloride mono-
244hydrate, a new anti-Parkinsonian agent, has been studied by Nose,et al .
This compound may be useful in the treatment of Parkinson's Disease
and shows no major undesirable side effects. When studied, this drug
has pronounced anti-acetylcholine, anti-tremorine- induced tremor, anti-
physostigmine-induced death, anti-halopiperodel-induced Parkinsonism
and anti-EEG arousal activities. A study has also been conducted on
245
the metabolic fate of this drug. 2-(3-Azabicyclo[3.3.1]nonyl)ethyl
esters of c>\ -phenyl-o< -isopropylglycolic acid have demonstrated activ-
246ity in treating Parkinson's Disease.
Intravenous doses of amantadine hydrochloride as small as
8.0 x 10 milligrams/kilogram may release dopamine and other cate-
247
cholamines from neuronal sites in dogs. Selective anticholinergic
219
effects could not be demonstrated in animal tests. Amantadine was
concluded to be 1/209,000 as potent as atropine in antagonizing con-
tractions of guinea pig ileum treated with acetylcholine. Amantadine
has also demonstrated antagonization of chlorperqazine and harm-
249
aline induced dreams.
Adamantane derivatives that demonstrated dopamine on catecol amine
250 251
release have been reported by Shromberg and Scaffon.
Pharmaceutical Applications
Pharmaceutical bicyclic and cage compounds found in the literature
may be divided into many classes, such as pharmaceutically acceptable
salts, intermediates in the preparation of compounds useful in pharmacy
and agriculture, and in the production of drugs. These compounds are
mentioned in the individual reports, but no specific medicinal action
is listed. For this reason, compounds with "pharmaceutical" activity
are listed in Part II of the bibliography for this chapter.
Sedatives
Hypnotics, when used in small doses, are referred to as sedatives.
Hypnotics produce a state of depression of the central nervous system
resembling normal sleep. The sedatives produce a state of drowsiness.
When used in large doses, sedative-hypnotics can produce anesthesia,
coma, and death.
The most important sedative-hypnotics are the barbiturates. When
used properly these drugs are safe and highly effective. Although
they are habit-forming and may lead to addiction, these compounds are
not necessarily inferior to the new sedative-hypnotics. The newer
drugs are piperidinediones such as glutethimide and methyprylon. Besides
220
the barbiturates and piperidinediones are the carbamates, bromides,
alcohols, and parldehyde.
The bicyclic and cage compounds finding use as sedatives are the
bicyclo[3.2.1]octane, bicyclo[3.3.Ijnonane and adamantane systems.
Many of these compounds are similar to barbituric acid or piperidine-
dione.
252Takahashi, Fujimura, and Hamajima have formulated 1,8,8-dimethyl-
3-azabicyclo[3.2.l]nona-2,4,-dione derivatives that show sedative action.
These compounds have the general formula
.0
r tNCHMeCOA A = NME2,NEt2,NH2
and are prepared from l,8,8-trimethyl-3-azabicyclo[3.2.l]octane (cam-
phorimide), o< -bromopropinyldimethylamine and sodium hydroxide.
253
Derivatives have also been prepared with N,N-dimethylchloracetamide.
3-Azabicyclo[3,3.l]nonane compounds of the general formula
/R-T* R, = Bz
N ' -1
/ xR.f ' R,, = R,=
'2 1X3
R,N Y"°V-R. R4 = Me
_Qif R = H
\ O
R5 RA = Bzo
254a bhave been prepared by Nakanishi, Arimura, and Muro. ' These com-
pounds demonstrate useful sedative and analgesic action. A number
of derivatives all varying at R, to R, have been synthesized. A
similarly structured compound' has been prepared from 3-phenethyl-9-
221
oxo-3-azabicyclo[3.3.Ijnonane via the Greignard reaction with bromo-
benzene.
Ph(CH2-).
OR
.Rh R = H,
propinyl
2)propionic
anhydride
255
The products are sedatives. 2-(4-Arylpiperazine)bicyclo[3.3.l]nona-
2569-ol derivatives have been reported to have sedative action,
compounds have the formula
R = H
These
= Ph,Me
and the free amine and hydrochlorides have long-term sedative effects.
Administration of the drug to mice caused a decrease of spontaneous
motor activity and loss of coordinated motor activity.
The adamantane group in sedative preparation has been reported by
257Gerzon, et al. SjSjy-Trimethyladamantane-l-carboxamide was prepared
in 90-95% yield. The sedative activity in mice has also been investi-
gated, and structure-activity relationships are contrasted with previ-
ously described adamantane containing agents.
222
Spasmolytics
The spasmolytics or antispasmodics are drugs that abolish spasms
that occur in the involuntary muscles inervated by the central nervous
system. The abolition of muscarinic effects prevents spasm of involun-
tary muscle and the drugs causing this are called neurotropic anti-
spasmodics. Atropine is an example of this type of drug. Further-
more, some antispasmodics act directly on the muscle cells regardless
of inervation and these drugs are called muscalotropic antispasmodics.
Papaverine is an example.
The bicyclic compounds found in use as spasmolytics are bicyclo-
[2.2.1]heptanes, bicyclo[2,2.2]octanes, and bicyclo[3.2.1]octanes.
Many of the spasmolytics are esters of quinuclidines and bicyclic
alcohols. Some are amine derivatives.
2S8
Klavehn has prepared basic acid esters of bicyclo[2.2.1]heptane
compounds useful as spasmolytics. Among the compounds prepared are
[2-hydroxybicyclo[2.2.2]heptyl]-2-phenylacetic acid and various
hydrochloride and methosulfate salts.
223
Spasmolytic 5- or 6-phenylacetoxy-2-methyl-2-azabicyclo[2.2,2]-
259
octanes have been prepared by Bernard! et al. These compounds with
/
the following structure
are reported to have high antispastic activities at low toxicity and
are prepared by esterification in the presence of an amine, A similar
type of compound
J-Me
I I
Cl—C—PhC02-
H
prepared by the same.researchers exhibited improved in-vitro and in-vivo
antispastic activity. The compounds prepared were the hydrochloride
Jf\(\
and methyl iodide salts,
Basic bicyclic esters prepared by Sternbach have been demonstrated
to have antispastic actions, ' Ester derivatives of the 1-azabi-
cyclo[2,2,2]octan-3-ol series are useful as spasmolytics. Esters of
bicyclic amino alcohols have been tested for spasmolytic actions with
7f\^t
isolated intestine. These esters demonstrated activity similar to
atropine while others were considerably weaker.
Spasmolytic 3,8-disubstituted-3,8-diazabicyclo[3,2,1]octanes with
264
spasmolytic action have been prepared by Kirchner. A large number
224
of derivatives have been prepared and some show local anesthetic
activity also,
Steroid Compounds
The various steroid compounds investigated in this.report are of
four kinds: (1) testosterone derivatives, C.2) pregnane derivatives,
(3) estrane derivatives and C4) androstane derivatives,
Testosterone is an androgen and is the principal testicular hormone.
The esterification of testosterone gives compounds with certain advan-
tages such as superior oral or anal absorption and longer lasting
effects.
Testosterone is the hormone responsible for the .development and
maintenance of male secondary sex characteristics. Testosterone has a
protein anabolic effect; it can.produce a positive nitrogen, potassium,
phosphorus, and sodium balance. This compound also demonstrates
myotropic and androgenic effects.
The bicyclic and cage compounds that have found use as functional
groups of a steroid nucleus are the bicyclo[2,2,2]octane and adamantane
compounds,. These derivatized steroid compounds show myotropic, andro-
genic, corticoid, and hormonal and antihormonal activities
Bicyclo[2,2,2]octanes
Boswell has introduced the bicyclo[2.2,2]octane-l -methyl and
4 -methylbicyclo[2,2,2]octane-l'-methyl carbonates of variously substi-
tuted testosterones and 19-nortestosterones, as represented by the
following formula:
225
0
II
0-C-O-CH
R1=R2=R3=R4=R5=H °r CH3
a,b, or c = single or double
bonds
These compounds may be prepared by reaction of the steroidal chloro- or
jf.f.
fluoroformate with the bicyclooctylmethyl alcohol, or by reaction of
the steroidal alcohol with the bicyclooctylmethyl chloro formate.
Cross and Fried have prepared a bicyclo[2.2. 2]octane-l-carboxy-
4
late and bicyclo[2,2. 2]octane-l-methylenecarbonate esters of A
pregnane corticoid steroids. These compounds demonstrate long acting
corticoid and ant i inflammatory activity.
Adamantane compounds
O£ Q
Rapala has prepared esters of cortico steroids. The esterifica-
tion of cortico steroids with' ladamantoic acid anhydride, the mixed
anhydride of 1-adamantoic acid and trif luoroacetic acid, or 1-adamantoic
acid chloride was carried out. Among the compounds prepared are fluoro-
andrenolone 21-(l-adamantoate) and prednisolone 21-(l-adamantoate) .
Rapala has also prepared new esters of 3-methoxyestradiol with 1-
269a b c
adamantanecarboxylate, ' ' showing antiandrogenic effects, testerone
esters having very high myotropic-androgenic ratios with antiestro-
271
genie activity, and 19-nortestosterone-17 ft -adamantoate esters
possessing a profound and unique anabolic potency with high myotropic
activity.
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Various steroidal esters have been shown to demonstrate anabolic,
androgenic, or hormonal and antihormonal activities. Those compounds
that are anabolic-androgenics are 17-acyloxy-2-oxaestra-4,9-dien-3-ones
272
and adamantane derivatives of the general formula
273The 1-adamantyl and l^adamantylmethyl carbonates of testosterone
274
and 7o<-difluoromethylandrosten-3-ones show these effects also.
Compounds that show activities besides anabolic actions are the
275l-halomethyl-5o<-androstanes and androst-1-enes and various adamantoate
esters of 13^ -alkylgon-4-en-3-ols.
A number of syntheses involving the use of adamantane derivatives
277
.have been reported, Among these are corticosteroid 21- (1-adamantoates),
278
esters of 17<K-ethynyl-13 p> -ethylgonene-3, 17p -diols, 14 p -estr-
279 2804-enes, and 6-halo-9 ft ,10c< -androstadienes and trienes.
Tranquil izers
Antipsychotic and antianxiety drugs are substituted newer terms for
the major and minor tranquil izers, respectively, The antipsychotic
drugs produce an improvement in the mood and behavior of psychotic
patients without sedation and addiction. The antipsychotic drugs are
represented by the phenothiazines, thioxanthenes, and butyrophenones .
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The antianxiety drugs are not basically different from.sedative-
hypnotics. This is due to the reduced tolerance and.physical depen-
dence and higher safety margin of these compounds. The antianxiety
drugs are represented by the benzodiaz'epines, meprobamate, and .related
drugs.
Tranquilizers that employ bicyclic.and cage compounds as a part of
the active molecule use such compounds as bicyclo[3,2.l]octane, bicyclo-
[3,2.2]nonane, bicyclo[3,3,l]nonane, and adamantane derived compounds.
Some of the bicyclic derived compounds, such as the 3,8-diazabicyclo-
octane phenothiazine and 2-C4-aryl-l-piperazinyl)bicyclo[3,3,l]nonan-
9-ones derivatives act as antipsychotic tranquilizer agents,
Derivatives of phenothiazine, an antipsychotic drug, have been
prepared. These compounds are active tranquilizers with low toxicity,
long duration of effect, and few side effects. ' These compounds
have the general formula
R = H,Cl,MeO, or CF
RI = Me or HOCH2CH2-
and are prepared from 2-trifluorroethyl-10-(3-chloropropyl)phenothiazine
and 3-hydroxyethyl-3,8-diazabicyclo[3,2,1]octane.
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CIBA, Ltd. has prepared 3-[4-(4-fluorophenyl)-4-oxo-l-butyl]-
2823-azabicyclo[3.2,2]nonane as a tranquilizer.
CO(CH.)_—N
£ o
This compound is obtained by heating 3-azabicyclo[3,2,2jnonane and
p-FC,H.CO(CH9) Cl in the presence of a base or by the reaction of 3-
OH" £* O
(3-cyanopropyl)-3-azabicyclo[3,2,2jnonane with p-FC.H.MgBr,
Grogan has reported the preparation of numerous azabicycloalkanes
283
that have potentially tranquilizing ability. These compounds and
their nontoxic addition and quaternary salts are prepared and physical
constants given,
284Ward has prepared 6,7-benzo-2-(4-phenyl-l-piperazinyl)bicyclo-
[3.3,l]nonan-9-one derivatives. The isomeric axial and equatorial
compounds are reported .to be novel compounds with tranquilizing
OQ r
activity. A series of these compounds was synthesized and some were
converted to the 9-phenyl-9-hydroxy derivatives. An activity similar
to chlordiazepoxide was demonstrated by 2-(4-phenyl-l-piperazinyl)-9-
phenylbicyclo[3.3.1]nonan-9-ol.286
Adamantane carboxyclic acid esters of phenothiazine have found
287
applications as tranquilizers. These adamantane carboxcyclic acid
ester compounds are useful as long acting tranquilizing agents and
229
are prepared by treating a phenothiazine.derivative with an adamantyl
N = 1 or 2
acyl chloride,
Miscellaneous Medicinal Compounds
There are numerous bicyclic and cage compounds that show differen-
tial medicinal uses. This section of Chapter 6 is devoted to compounds
that have more than three individual medicinal applications. The
compounds are arranged according to activity (or function, use) and
may be found in Table I-listed in alphabetical order according to the
specification. The actual compounds listed in column two and other
specific uses may be found in column three.
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Chapter 7 - Biochemical Systems Applications
Bicyclic and cage compounds find many applications in studies of a
biochemical nature, Such diversified uses as stimulantion of insulin
release, lipid metabolism effects, sensitation of bacteria, and blocking
group preparations are to be found. In this chapter are listed those
compounds that have been determined to be biochemically active or
useful as a biochemical preparatory compound. The systems that find
use as biochemically active compounds include bicyclo[2.2,1]heptanes,
bicyclo[2.2,2]octanes, bicyclo[3,3,ljnonanes, and the adamantane
derivatives.
Joost, et al have prepared 5- and 6-methyl-2-aminobicyclo[2.2,1]-
heptane-2-carboxcyclic acids that have been shown to stimulate insulin
release as efficiently as leucine and leucine analogues. This study
was carried out using the perfused rat pancreas and pancreatic islets.
The interperitoneal administration of exo-2-aminobicyclo[2.2,1]-
heptane-2-carboxcyclic acid and similar derivatives has been shown to
perturb the levels of neutral amino acids in the cerebral cortex while
the levels of valine and isleucine were observed to rise.
The bicyclic derivative, cantharidin, noted as the principal
irritant in Spanish Fly, has been tested, for its effect on incorpora-
tion of 35S-labeled sulfate,3 It was found that the uptake of ^ SO^ '
was noticeably decreased in di-sodium-cantharidin treated epidermis as
compared to trypsin- and untreated tissue.
SC-26096 (2-methyl-3-oxo-2-azabicyclo[2.2,2]octan-6-exo-yl-
5(-4-biphenylyl)-3-methyl valerate) has been tested on respiration and
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oxidative phosphorylation of rat liver mitochondria, In intact and
sonicated mitochondria, NAD-involved respiration was inhibited and
succinate-linked respiration was also inhibited but at higher doses,
The results of these tests indicates that SC^ 26096 is bound to mito-
chondria in vitro,
A rodenticide has been prepared that has an LDrn of 1,8x10" mg/kg
body.weight, This compound, 4-isopropyl-r216,7-trioxa-l-phosphabicyclo-
[2,2,2]octane-l-oxide, given interperitoneally to mice produced con-
vulsive seizures and death within minutes. The toxicity of this compound
is attributed to the inhibition of acetylcholinesterase in the nervous
system,
Agents affecting lipid metabolism have been formulated, 1,4-
disubstituted bicyclo[2,2,2]octane derivatives prepared are studied and
spectral properties of these compounds are described,
Bicyclononanes have found pharmacological use in the study of the
stereochemistry of microbiological hydroxylation, Hydroxylation of
3-benzoyl-3-azabicyclo[3,3,l]nonane by Rhizopus arrhizue gives 3-benzoyl-
endo-3-azabicyclo[3.3.1]nonan-6-ol and (1R,5R)-3-benzoyl-3-azabicyclo-
[3.3.ljnonan-l-ol. Chromic, acid oxidation studies show that oxidation
of 3-benzoyl-3-azabicyclo[3.3,l]nonane gives 3-benzoyl-3-azabicyclo[3.3.1]-
nonan-3-one, and N-benzoyl-cis-3-aminomethylcyclohexanecarboxcyclic acid.
This demonstrates stereoselective microbiological hydroxylation by this
bacteria, Other steric phenomenon have been observed with 9-azabicyclo-
o
[3,3.IJnonanes,
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Mitotic activity of cell cultures has been shown to be decreased by
aminpadamantane chloride. This mitotic activity reduction was observed
in chick embryo fibroblasts and transplanted HeLa cell cultures,
Aminoadamantane is theorized to inhibit the entrance into mitosis by
g
the cell, because direct effect on mitosis once begun was not observed.
An in-vivo technique for assessing the formation of a hemostatic
platelet plug has been developed,:. This technique depends on the
formation of a hemostatic platelet plug following puncture in a small
vein of the mouse mesentary. Six compounds, among them 5 -adamantyl
adenosine were given orally, intravenously, or in the diet and obser-
vations on hemostasis observed,
Adamantoyl esters of pyridoxol demonstrating potential usefulness
as probes for hydrophobic regions at receptor site of pyridoxal have
been formulated, These compounds have been prepared in order to
investigate the chemical and biological usefulness of adamantyl compounds
in vitamin B chemistry and pharmacology,
Adamantane hydrochloride has been reported to inhibit the mitogenic
12a
response of human lymphocytes stimulated with phytohemagglutinin.
Concentrations of adamantane used to inhibit the response were similar
to the concentrations required to inhibit viral replication. The data
suggests that adamantane, phytohemagglutinin andlipid containing RNA
viruses participate in cell-membrane interactions. This response has
also been studied in horses.
Adamantanamines and their derivatives have.been prepared as
sensitizing agents for 5-hydroxytryptamine-induced muscular contraction.
Adamantanes sensitized mucosa-free isolated rat fundus strip with maximal
274
-3
sensitization observed at approximately 10 M, Other adamantane .deriv-
atives showed less activity and it was concluded that adamantane com-
pounds react with storage sites of 5-hydroxytryptamine or influence the
drug-receptor metabolism,
The biological fate of adamantane compounds has been studied. In
14a
a report by Geuens and Stephens the influence of pH of the urine
on the rate of excretion of 1-aminoadamantane was examined, A dose of
150 mg. initially followed by 50 mg/day thereafter at pH 5,0, showed 5
to 7%/hour of the body content excreted. At pH 8,0, this rate was
less than 1%. The distribution and excretion of 1-aminoadamantane
hydrochloride has been observed by Uchiyama and Shibuya, Mice were
given orally 1-aminoadamantane hydrochloride and sacrificed 0,25 to
100 hours later. The greatest amount in all organs tested was found
in the liver, followed by the kidney, lung, spleen, and heart. Micro-
biological hydroxylation and demethylation studies in vito have also
been carried out. The bacteria Sporotrichum sulfurescens hydroxylated
to N-benzoyl-4 &,-N-dimethyl-l-adamantylamine to N-benzoyl-4 0> ,-N-
14cdimethyl-l-adamantylamine-4,7-diol. In rats, the in vivo and in
vitro N-demethylation of N,N-dimethyl-3,5,7-trimethyladamantane-l-
carboximide, was observed. The main route of metabolism was observed
to be oxidative demethylation which was enhanced by phenobarbitol and
inhibited by 2,4-dichloro-6-phenylphenoxyethylamine.
The rat brain has been shown to.be a fertile organ of investigation
for studies on bioelectric activity and uptake of dopamine and noradren-
aline. 1-Aminoadamantane hydrochloride and the sulfate salt analogue
activated the bioelectric activity of the cerebral cortex, produced
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variations in the rhythm of.the hippocampus, and induced a transient
15abradycardia, 1-Aminoadamantane hydrochloride inhibited the uptake
of noradrenaline by nerve endings and also inhibited dopamine uptake
•7 "I r"L
by 69% at 10" g/ml concentrations,
1-Aminoadamantane has been shown to potentiate the response to
L-dopa in mice, These effects include piloer^ection, salivation,
increased motor activity and hyperactivity, Aminoadamantane has also
been shown to inhibit DNA synthesis by 24% and.decrease the number of
cells producing DNA to 30-50%, The average generation time was also
increased.
Much of the knowledge of protein structure comes from studies of
synthetically produced peptides, In the last few years, the synthesis
of large peptide chains showing biological activity has afforded precise
correlations between structure and reactivity.
In order to synthesize a peptide it is necessary to protect those
groups that are susceptible to reaction but which are required to be
free in the final product. This protection is accomplished by blocking
groups, and are selected so that they may later be easily removed. A
table of suitable blocking groups generally used may be found in the
Foundations of Modern Biochemistry series, "Organic Chemistry of
I Q
Biological Compounds" by Bunker. This table lists the blocking groups
that are used for thiol, amine, alcohol, and carboxylate functional
groups found in the-amino acid structures.
The methods employed for forming peptide bonds involve activation
of the carboxyl or amine groups to be joined by.reagents that do not
276
disturb the blocking groups. Earlier methods utilized the acid chloride
or azide but newer derivatizing agents are now used.
The cage compounds used in peptide synthesis as blocking groups
are virtually all adamantyloxycarbonyl or adamantyl groups. These
groups have been used in arginine, cysteine, histidine, tryptophan,
and neucleosides, and have found used in the synthesis of penicillins
and cephalosporins.
19Jaeger and Geiger have reported that the arginine functional
groups can be protected by the adamantyloxycarbonyl group. Few dis-
advantages in peptide synthesis is the feature of this method. Approx-
imately 30 peptides are reported to have been synthesized, with good
protection of the guanidino function and improved solubility in organic
20
solvents. The authors also report use of the adamantyloxycarbonyl
blocking group in cysteine peptide synthesis, useful as intermediates
21in cysteine-containing peptides.
The adamantyloxycarbonyl blocking group is prepared from 1-
adamantol and dichlorocarbonate. The resulting chloroformate is allowed
22to react with amino acids to.give the 1-adamantyloxycarbonyl derivatives.
Some of these derivatives have been obtained in the crystaline state,
whereas the corresponding tertbutyloxycarbonyl derivatives have not
been reported or are amorphous solids. The adamantyloxycarbonyl groups
are removed by acid-catalyzed solvolysis with trifluoroacetic acid to
give the free amino acids.
Other derivatives that have been prepared are the 1-(adamantyloxy-
23
carbonyl)-N-(benzyloxycarbonyl)-histidine and - tryptophan compounds
277
and those that are useful in the synthesis of penicillins and cephalo-
24 25
sporin and nucleosides.
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Chapter 8 - Pesticides
For the purpose of this chapter, pesticides will be defined as
chemicals that are used to kill insects, fungi, weeds and other pests.
Thus, the term pesticide includes insecticides, fungicidals, herbicides
and similar materials. Insect repellents are also included in this
chapter because they constitute a significant group of compounds, but
not a large enough group to justify a separate chapter.
Bicyclic and cage compounds have been used extensively as pesti-
cides, and several compounds have received extensive commercial
production. Aldrin and Dieldrin are'particularly well known insecticides.
The highly chlorinated compounds such as these have proven to be espec-
ially effective. Unfortunately, the long lifetime and other long range
physiological effects of these materials that are just now becoming
apparent are leading to increased regulations against their use.
This trend can be expected to continue, and non-chlorinated alterna-
tives may need to be found,
A difficulty encountered with the literature search in this area
is that.many of the papers discuss field testing of various materials,
and only trade names or codes are given. In those cases, it was
difficult to determine what, if any, bicyclic or cage compounds were
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involved. Whenever possible, tradenames were matched to compound
structures. Nevertheless, there can be no assurance that the entire
literature has been covered in this area,
Fungicides
Chlorinated hydrocarbons dominate the bicyclic fungicides.
Bicycle[2.2.1]heptanes
l,2,3,4,6,7,7-Heptachloro-5-phenylbicyclo[2.2.1]-2-heptene has
been prepared as a fungicidal material. A similar compound is 1,2,3,
2
4,7,7-hexachloro-5-(aminophenyl)bicyclo[2.2.1J-2-heptene.
Cl
Chlorinated mercury compounds have also been prepared. In particular,
N-[alkyl mercuric]-1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-
dicarboximides and related cycloalkyl, alkenyl, aryl, and aralkyl
compounds have been used.
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Compound (8-1) has been found to be effective as a fungicide
1
6 ci
(8-1)
. 4
against Alternario solani. It also has bacteriostatic (against
Staphylococcus aureus), herbicidal, miticidal, insecticidal, and plant
growth regulatory activity.
The Propargyl ester of bicyclo[2.2.1]hept-5-ene-2-carboxylic acid
and its saturated equivalent has been reported to be useful as a bac-
tericide or fungicide.
Two sulfur compounds have also been reported, Compound (8-2)
0
SCHRCC1,
^^
0
(8-2)
is the only bicyclic compound among several related compounds that was
tested against a variety of fungi. Specific test results are reported.
Similarly, 3-(p-tolysulfonyl)5-chloronortricyclene is reported to be
a pesticide and an intermediate for the production of O< , |3 -unsaturated
sulfones which are useful as fungicides, bactericides, monomers, and
dyestuff intermediates.
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Bicyclo[2.2.2]octane
Q
Sims has prepared several bieyclooctanes similar to (8-3) .
X = H or Cl
R = H, CH3
R1 =
X
(8-3)
The compounds are fungicides and have been tested against Stemphylium
sarcinaeforme and Monilinia fructicola.
Compound (8-4) has been found to be both an effective fungicide
(CH3)3C-N-C
(8-4)
Cl
g
and a useful insecticide. Derivatives of bicyclo[2.2.l]oct-5-ene
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are active against fungi in cereal crops, tobacco, tomato, pumpkin
and apple plants. Some of these compounds have shown activity as
herbicides and against mites.
Tributyl tin salts of two bicyclic carboxylic acids (8-5) and
(8-6) were tested as fungicides in paints. The bicyclic compounds
showed generally lower activity than other tin compounds tested. On
the other hand, compound (8-7) has been reported to be an effective
COOSnBu, OOSnBu
OOSnlu,
(8-5)
(8-6)
SnBu,
fungicide for paints.12
Other ring systems
1,5-Diazabicyclo[3.2.Ijoctanes are useful as fly repellants
R = C^-Cg alkyl, C6-C,2 aryl
preemergence herbicides, and soil fumigants. When R is H, the soil
fungus Rhizoctonia solani was inhibited to the extent of 80% by an
application of 75 pounds per acre; Bactericidal and fungicidal activity
was also observed with 2,3,4,4-tetrahalobicyclo[3.2.1]octa-2,6-dienes
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and 2,3,4)4-tetrahalo-8-oxabicyclo[3.2,l]octa-2,6-dienes.14
Metal chelates of bicyclononadiene have been used as algicides,
fungicides, and bactericides. The specific compound is (8-8).
COOX
COOX
2M
X = C1-C4 alkyl
(8-8)
M = , , , , , , ,
C12+, Zn2+, Br3+, Pb2+, Sn2+, Co2+, Hg2+, Zn02+
Another bicyclo[3.3.1]nonane system that has been used as a fungicide
is (8-9).16
0,
(8-9)
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Two 3-azabicyclo[3.2.2]nonane systems have been proposed as
fungicides, disinfectants, pigments, dyes, bactericides, central
nervous system stimulants, enzyme inhibitors, sedatives and diuretics.
17 18Both N-substituted benzoyl derivatives, and carbamoyl derivatives
have been prepared.
CO-Ar
\
COX
Compound (8-10) has been used for agricultural fungicides. 19
RR C=N02CNH-
(8-10)
When R,R was (CH ) , compound (8-9) was formulated into a seed dis-
infectant .
Three adamantane systems that have been suggested as fungicides
?fi 21 77
are (8-11), C8-12) , and (8-13),
N-N.
SCH COOEt
(8-11) (8-12)
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RNHCO CNHR
(8-13)
Compound (8-12) was also proposed as a pharmaceutical, Compound (8-13)
was particularly useful against Fusarium solani, a soil fungicide that
causes root system damage,
Herbicides
The most extensively used bicyclic herbicide is 7-oxabicyclo[2.2.] •
heptane-2,3-dicarboxylic acid (8-14)
COOH
COOH
(8-14)
Endothal
and its sodium salts. This compound has been used extensively. It has
also been used as both a preemergence and postemergence weed killer
for farm crops. It has also been used as a defclient for potatoes and
other crops and to control aquatic plants. It has been commercialized
under the name Endothal. -The disodium salt is called Aquathal. A
suspension of (8-14) and isopropyl-N-phenylcarbamate is known as
Murbetal. There are literally hundreds of papers in which (8-14)
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under one or more of its trade names has been compared to other herb-
icides for various crops. Physiological effects and toxicity studies
are also common. No attempt has been made to collect the literature
in this area.
Bicyclic groups have been used with tributyl tin compounds to
23produce both pre- and postemergence herbicidal activity. Specifically,
the bicyclo[2.2,l]hept-2-yl and 3-nortricyclenyl groups have been used,
Preemergence herbicides have also been reported from nortricyclylureas.29
NR''CONRR'
Herbicides derived from hexachlorocyclopentadiene include (8-15),
(8-16), and (8-17).
X = Cl, Br
Y = H, Cl, Br, OCH
o
R1 = H, lower alky
it in
R or R = acyl, carboxyl,
carbalkoxy,
carbonre.tal l.oxy,
cyano, carbamyl
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Compound (8-15) afforded complete control of the grass weed Sitaria
25italica. Compound (8-16) showed almost complete herbicidal effects
Oy-
when R = SnBu,. It was also effective against a variety of insects,
o
Compound (8-17) was suggested as a plant defolient for peaches, cotton,
27
ramie, vine berries, and other field crops. It was also suggested
for use in regulating the setting of fruit, as a phytotoxic or herb-
icidal agent, and in the compounding of lubricating oils and rubbers.
Compounds of the . type (8-18) have been prepared and extensively
28
tested for herbicidal activity.
(8-18)
N-substituted azabicyclooctanes with herbicidal activity have been
29prepared by Sturm and Vogel, Twenty-seven compounds of this type were
proposed.
Several N-substituted-3-azabicyclo[3.2.2]nonanes have been reported
to be herbicides. For example, N-halomethylcarbonyl-3-azabicyclo[3.2.2]-
nonanes have been found to be harmless to cotton and corn while completely
30inhibiting foxtail grass, barnyard grass, and wild grass. Pythium
ultimum and Rhizoctonia solani were completely inhibited at a concen-
tration of 30 ppm. Compounds of the type (8-19) have been screened
290
NCOCHRZ
(8-19)
R = H, lower alkyl
Z = halogen, trihaloace-
toxy, SCN, or methyl
sulfonyloxy
for pre- and postemergence herbicidal activity, Crabgrass, water-
grass, red oats, mustard, and curled dock were controlled by some of
these compounds.
Azabicyclononanecarbothiolates (8-20) have been prepared.32
-OCSR
(8-20)
When R was isopropyl, the compound controlled barnyard grass at two
pounds per acre. The allyl compound controlled Johnson grass at 0.5
pounds per acre. Other derivatives showed similar behavior.
Derivatives of (8-21) were tested as preemergence herbicides
COCH2SP(S)(OR)2
(8-21)
and found to be effective against the seeds of crab grass, annual
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33bluegrass, watergrass, red oats, pigweed, and mustard, A variety
of weeds and grasses are also killed by 2-mercaptobenzthiazole and 2-
mercaptothyozol derivatives of 3-azabicyclononane.
CH_
1—S-
o r
N-Tricyclo[5.2,1.0 ' Jdecylamide derivatives have been used in
the form of solutions, suspensions, and powders as herbicides.
Insecticides
Bicyclic and cage compounds have been used extensively in insect-
icides. Chlorinated compounds have been used most commonly, and their
chemistry has been thoroughly studied. The subject of chlorinated
insecticides was reviewed in 1974, and will not be covered in detail
here. Some of the more common chlorinated bicyclic insecticides are
shown.
Cl
292
isodrin
J^- ,-.-,
'^YTU fa.
Cl
Endrin
_keto-endrin
photo
293
cr
photoheptachlor
Mirex
CK
Kepone
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In recent years, discoveries concerning long term toxic effects,
lack of biodegradability, and other problems associated with the use
of chlorinated insecticides have led to increasing restrictions on
their use. This situation can be expected to continue. Consequently,
the use of chlorinated insecticides will probably decrease as alternate
materials are found. In the discussion that follows, the highly chlor-
inated insecticides have generally been omitted.
In addition to insecticidal properties of their own, several
bicyclic compounds have been used as synergists with other materials,
primarly pyrethrins. For example, N-(2-ethylhexyl)-bicyclo[2.2.l]hept-
5-ene-2,3-dicarboximide has been found to be especially useful with
37 38pyrethrins. N-Octylbicycloheptane dicarboximide and 1,2-methylene-
39dioxy-4[2-octylsulfonyl propyl]benzene have also proven to be effec-
tive. Piperonyl fencholate and » -allylpiperonyl fencholate have been
40found to have a synergistic effect with allethrin.
N-(2-ethylhexyl)bicyclo[2.2.l]hept-5-ene-2,3-dicarboximide has
41been found to be an effective insecticide, The N-butyl and N-amyl
42
derivatives have also been shown to have insecticidal activity.
Koch has prepared Diels-Alder adducts of cyclopentadiene and
cyclohexadiene with fumaric acid. The products are useful as insect-
icides, insect repellents, and plasticizers. Dimethyl bicyclo[2.2.1]-
hept-5-ene-2,3-dicarboxylate has also been tested and found to be an
effective insecticide that works synergistically with other insecticides
44
and insect repellents. The methyl ester has also been utilized,
45b
as has the 2-ethylhexyl esters. The following related compounds
46have also been studied:
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CN
CN
A similar furan derivative is:
which is useful as a vermicide, and for control of mites, insects,
47bacteria, fungi, and protozoa.
The addition of functional groups to norbornene has also led to
48 4Q 4Qinsecticidal materials. For example, (8-22), (8-23), (8-24),
(8-25),5° (8-26),51 (8-27),51 {8-28),52 (g-29),53 and (8-30)54 are
either insecticides or insecticide precursors. Some of these compounds
also have possible application as plastics and lubricant additives.
CNS
(8-22)
CH2NC
(8-23) (8-24)
(8-25)
CH2OR
(8-26)
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CH2OH
(8-28) (8-29)
0
CH2OCCH2SCN
(8-30)
Of a series of terpene oxides that were tested against flies and
mealy bugs, menthofuran worked best, The effect was markedly reduced
with bark-beetles.
Neutral 5-bicyclo[2,2,l]-2,3-diazaheptyl esters such as 030-
dimethyl-5-(N,N-dicarbethoxybicyclo[2.2.1]-2,3-diazahept-5-yl)dithio-
phosphate have been found useful as insecticides, fungicides, plasti-
cizers, flotation agents, and oil additives,
Carboxylic acid and imide derivatives of bicyclo[2,2.2]octanes have
been found useful as insecticides. Thus, N-(octylthiopropyl)-l-isopro-
pyl-4-methylbicyclo[2.2.2]oct-5-ene-2,3-dicarboximide and similar
compounds have been reported by Nakanishi, Mukai and Saheki.
iPr
. 57
Compounds of the type (8-31) have been suggested as insecticidal
58
compositions.
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Z = alky1' aryl> aralkyl,
alkaryl, cycloalkyl;
Z — C — CH2 — 0 — As alkoxy, aryloxy, acyloxy,
./ acyloxymethyl, benzoxy-
H2 — 0*^ ^ methyl, chrysanthemumoxy-
methyl
(8-31)
Aminoadamantane was found to be not highly effective as a chemo-
sterilant against house flies, screw worm flies, and boll weevils.
Reduced egg hatch was observed, however, when (8-32) was fed to screw
59
worm flies.
X = CON3, NHCON(CA3)2
(8-32)
A variety of 9-thiobicyclononane derivatives have been reported to
be useful as insecticides, herbicides, fungicides, bactericides, and
nematocides.
Insect Repellents and Attractants
While insect repellents and attractants are not necessarily
pesticides in themselves, they are sometimes incorporated into insect-
icide compositions. Some of the compounds that have been tested for
insect repellent activity have also been used in insecticide studies.
For these reasons, insect repellents have been included after the
insecticide section of this report.
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.In the 1950's, a series of insect repellent studies were conducted
on a wide variety of materials, some of which were bicyclic.
In these and other studies, several thousand materials were screened
as potential mosquito repellents. In one paper alone, 4300 compounds
were screened. e As part of the studies conducted during this time,
dimethyl bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate was found to be
effective against mixed populations of several species of Aedes mosqui-
toes.62
/--z
More recently, Johnson, et al evaluated a series of alicyclic,
bicyclic, and unsaturated acetals, aminoacetals, and carboxamide
acetals. They concluded that compounds with a boiling point of 100-1500/
0.5 mm had the optimum degree of volatility. The compounds tested,
which included several compounds containing bicyclo[2.2.1]heptane groups,
did not appear to have properties as good as N,N-diethyl-m-toluamide.
64This same compound has also been tested against ticks and mites and
against fleas.
Bicyclo[2.2.1]heptane-2,3-dicarboxylic acid esters prepared from
glycols have been used as insect repellents. Another compound that
showed promise was 2-amino-3-isobornyloxy-2-methyl-l-propanol.
Physical properties and toxicological properties of a variety
of insect repellents have been reported. The effect of insect repellents
on plastics and paints has also been investigated, as has their
incorporation, into cosmetics.
Pine bark beetles have been found to be strongly attracted to the
72
pheronome l,5-dimethyl-6,8-dioxabicyclo[3.2,l]octane. Many studies
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have been carried out on this pheronome and minor variations.
Miscellaneous Pesticides
In addition to the pesticide compounds already discussed, there
are many areas where there were not enough literature citations to
justify a separate heading. There are also many examples where the
compounds are claimed to be pesticides, but no further details are
available. These are all collected in this section.
Substituted azabicyclooctanes and nonanes have been suggested
73for a variety of purposes. Fluorosilicates are said to be useful
in mothproofing agents. Penicillin salts are useful as aids in puri-
fication of penicillins. & -Methyl-o^,o< -diphenyl-V-azabicyclooctyl-
propanols are useful as acid acceptors in reactions such as dehydrogen-
ation. The thiocyanates, when condensed with formaldehyde, form resinous
materials that are useful as pickling inhibitors.
Nematocides have been made from 5-(substituted amino) benzimid-
74
azoles. Among the substituents tested was the 1-adamantyl group.
O f-
Another nematocide is 1,2,4,7,7-pentachlorotricyclo[2.2.1.0 ' ]heptane-
3-one-5-sulfonyl chloride.
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The bis(N,N-dimethylalkylamine) salt of 7-oxabicyclo[2.2.1]heptane-
2,3-dicarboxy.lic acid has been used as a synergist with mercury compounds
for the treatment of algae in swimming pools. The zinc and silver
salts have also been used,
Plants treated with disodium-3,6-endohexahydrophthalate are toxic
to rodents. A dye is added to make the plant distinguishable from
non-poisonous plants.
Compounds (8-32),78 (8-33),79 (8-34),80 (8-35),81 and (8-36)82
are all reported to be useful as pesticides, toxicants, and poisons.
(8-34)
(8-36)
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Compounds of the type (8-32) are also reported to be useful as inter-
mediates for pharmaceuticals, plastics, and as fat and oil additives.
Bicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic acid has been proposed
Q 7
as an intermediate for pesticides by Reicheneder and Nebel.
84
Bluestone has also found that bicyclo[2.2,2]oct-7-ene tetracarboxylic
diimides of the type (8-37) also may be used as pesticides.
N-Rr
0 0
Compound (8-38) has been suggested as an intermediate in the formation
(8-38)
85
of pesticides and pharmaceuticals. Compound (8-39) has also been
(8-39)
suggested as an intermediate for the formation of agricultural and
8f>pharmaceutical preparations.
302
A number of studies have been conducted to determine the toxico-
logical effect of pesticides on man and warm-blooded animals. Many
87
of these studies have included bicyclic pesticides. Toxic effects
of pesticides on fish have also been studied.
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Chapter 9 - Miscellaneous Applications
In addition to the applications of bicyclic and cage compounds
discussed in the preceding chapter, there are several less extensive
areas where these compounds have been used. These areas include plant
growth regulators, fuels and fuel additives, lubricants and corrosion
inhibitors, and perfumes. Each of these areas could probably benefit
from an organized attempt to expand it.
Plant Growth Regulators
The best known plant growth regulators are natural products.
The Gibberelins in particular have been well studied over the years,
OH
Gibberelic Acid
COOH
and are known to significantly accelerate plant growth. Another plant
growth regulator that has received considerable attention in recent
years is helminthosporol and its derivatives.
CHO
H-ol
CH90H
coo: N COOH
H-acid
/
H -H-Acid
\
helminthosporol
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This material was first isolated from the fungus Helminthosporium
sativum in 1963 by Tamura, et al.
No attempt was made to locate all of the references to naturally
occurring growth regulators, and the Gibberelins were specifically
eliminated from the search. Some of the key references to the helmin-
thosporol work may be found in the bibliography for this chapter.
The major topic of this chapter is synthetic, bicyclic plant growth
regulators. In addition to the compounds discussed here, several of
the compounds mentioned in the pesticide chapter, particularly the
herbicide section, are also claimed to have plant growth regulatory
properties.
Derivatives of Endothal (7-oxabicyclo[2.2.l]hept-5-ene-2,3-dicar-
boxylic acid) have been found to have plant growth regulatory properties
in addition to herbicidal properties. For example, they have been
used to increase the yield of seeds from seed beet plantings and to
4
increase the yield of sugar from sugar cane. Phthalamic acid deriva-
tives of endothal have been used to dwarf or otherwise affect the growth
of plants. The non-oxygen bridged compound (N-aminobicyclo[2.2.1]hept-
5 6a5-ene-2,3-dicarboximide) has also been used. ' Some of the specific
derivatives that have been studied are:
X = N,N-dimethyldodecylamine
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-N(CH3)2
The mechanism of the plant regulatory action is not clear at this time.
One possibility is that the derivatives have little or no effect on
the plant, but the active ingredient is slowly released by hydrolysis
at such a rate that toxic concentrations are not reached. The result
of these studies is that a known herbicide and defolient has been
modified chemically to produce a series of less active materials. This
concept might be worth pursuing further with other pesticidal composi-
tions. In this manner, it might be possible to develop materials that
would affect maturing rate, yield, and other characteristics of
agricultural crops with a high degree of specificity.
Soloway, Morales, and Overbeek have found that compounds of
the type (9-1) have plant regulatory activity.
(9-1)
Compound (9-2) is also a plant growth regulator.
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8
(9-2)
S02NH2
Compound (9-3) has been found to completely inhibit germination and
(9-3)
growth of linseed, mustard, ryegrass, and oats when applied pre- and
Q
postemergently. 1,4-Bis (3-hydroxy-2--hexyl) -1,4-diazabicyclo [2.2.2]-
octane dihydroxide inhibited the growth of certain microorganisms and
plant life. The actions of certain enzymes are also inhibited. The
compound was also useful as a polymerization promoter for polyurethane
foam.
Fuels and Fuel Additives
Hydrocarbon fuels usually consist of a mixture of hydrocarbons of
optimum boiling range for the particular application. Studies have been
conducted with pure hydrocarbons, however, and several bicyclic materials
have been found to be useful fuels as a consequence of these studies.
315
Mixed isomers of pentacyclo[8.2.1.1 ' .0 ' .0 ' ]tetradeca-5,ll-
diene (9-4) have been prepared and tested as energy-rich fuels.
(9-4)
They have a heat of combustion of about 11 kcal/ml. A similar high
energy fuel component is hexacyclo[7.2.1,13'7,15'13.02'8.04>6]tetradec-
10-ene (9-5).12
(9-5)
Both of these materials arermade by dimerizing bicycloheptadiene.
Thirty-eight compounds, several of which were bicyclic, were tested
by Gollis, et al. Data reported includes decomposition temperature,
heat capacity, thermal conductivity, heat of combustion (based on weight
and volume), luminometer number, viscosity, freezing point, melting
point and hydrogen to carbon ratio., Among the bicyclic compounds
tested were pinane and tricyclo[7,1,1.0.0 ' ]decane.
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The synthesis of sixty-two hydrocarbons in the motor fuel and
14lubricating oil range has been reported by Weisser and Trdlicka.
Homologs of tricyclo{3.3.1.l]decane were included.
Oxidation of tetracyclo[3.3,1,0 ' ,0 ' jnonane (9-6) in a reaction
chamber has been suggested as a means of obtaining high thrust.
Oxidation of tricyclo[7.1.0.0 ' jdecane (9-7) has also been claimed as
a source of high thrust.
(9-6) (9-7)
Methyl adamantane and dimethyladamantane have been claimed as jet
fuels, or components of jet fuel blends. They are also said to be
useful in the preparation of diester type lubricants.
Fuel oils have been stabilized with a polyvalent metal salt of the
18
monoamide of bicyclo[2.2,2]oct-2,3-dicarboxylic acid, Terpenes have
been condensed with maleic, fumaric, citraconic, mesaconic, aconitic,
and itaconic acids, their anhydrides and esters, to form hydrocarbon
stabilizers that are said to prevent sludge formation in fuel oils,
19
cutting oils, and other types of oils.
1-Azabicycloalkanes have been found useful in gasoline, fuels
20
and lubricants to stabilize against sludge formation.
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O /")!•.
The compounds are also useful as agricultural chemicals. Compound (9-8)
CH2OH
(9-8)
was one of a variety of 2-dialkylaminocyclobutane-l-methanols that were
21
said to be useful as fuel oil stabilizers,
Triethylenediamine and trimethylenediamine have been treated with
((CH_)_N),B at 140-200° to form additives for motor fuels.22 The
o o o
compounds are also said to have anticorrosive properties when incorporated
into lubricating oils.
Lubricants and Corrosion Inhibitors
Bicyclic compounds have been incorporated into lubricants as both
the main constituent of the oil and as additives. Adamantane groups
in particular have been used in some of the diester types of synthetic
lubricating oils. Some of the fuel additives discussed in the previous
section are also useful as lubricant additives,
Terpenes have been incorporated into lubricant compositions by
23
Brennan and Raybould. They found that a sulfurized phosphorized
terpene alcohol would impart antiwear characteristics to a mineral oil.
Thompson has reported that terpenes may be treated with alpha, beta
unsaturated polycarboxylic acids and appropriate N-alkyl-ethanolamines
to form a corrosion inhibitor.
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25Soloway has suggested that compound (9-9) might be useful as a
lubricating oil additive.
R
CH=C
The condensation products of hexachlorocyclopentadiene with 1,4-dehydro-
benzoic acid are also useful as components of lubricants or as insect-
26
Cl Cl
icides.'
Cl
Cl COOH Cl
' (9-10)
Esters such as (9-10) are said to be excellently suited as softeners
X = -COOCH2R, -CH2OOCR
R = hydrocarbon up to 170 atoms
27
and as high grade lubricating oils. The related compound (9-11) has
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X = H,Y=CH2OOCR
X = Y = CH2OOCR
(9-11)
> also been used as a lubricating oil, a softener, and in the lacquer and
28plastic industry. Hydraulic oils and electrotechnical insulation have
29
also been suggested as uses for these compounds. Other derivatives
of dicyclopentadiene containing chlorine, mercaptane, sulfide, or poly-
30
sulfide groups are suggested for high pressure lubricant additives.
A 4% concentration of the additive increased the extreme pressure index
of a basic aircraft oil from 10 to 104.
Bis(trifluormethyl)substituted bicyclo-octatrienes have been
suggested as heat transfer and pressure fluids.
Lubricating oils have been improved by adding small amounts of the
polyvalent metal salt of the monoamide of a dicarboxylic acid. Alkyl-
substituted bicycylo[2. 2. l.]hept-5-ene-2,3-dicarboxylic acid was one of
32 32 33the acids specified. Both detergent and antirust properties
were mentioned for these compounds.
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Compounds of the types (9-12) and (9-13) are useful as heat transfer
fCH2VCF3
Z = -(CH2)nCF3
n = 0 to 3
(9-12)
34fluids and working fluids in Rankine Cycle engines.
Ester lubricants, antifreeze, and components of alkyd resins have
been been made from l-hydroxymethyl-6,8-dioxabicyclo[3,2.1]octane.
Another heterocyclic system is 9-chloro-3-oxabicyclo[3,3,l]nonane which
is used as a cutting oil to make threads in stainless steel pipe.36
A high or low temperature liquid lubricant or hydraulic fluid is
made from compound (9-14) and organopolysiloxanes.
R
I
Ph2
(
1
0
1
3i SiPh2
0
1
D ' ni 1ol t
R
j
SiPh2
D (9-14)
Compound (9-14) can also be ring opened by heating with 0,001-0.1% of an
alkaline material to form insulators and heat resistant coatings.
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A crystal of adamantane was used in a surface slip test by fastening
38
crystals to a disk base plate. It was determined from this study that
the average molecule moved about one millimeter before being desorbed.
Methyl and dimethyladamantanes prepared by isomerization of C,,_1?
tricyclic napthalenes have been found useful in diester type lubricants,
39
as jet fuels, and as components of jet fuel blends. Ethyl substituted
adamantanes are reported to have high thermal stability and are useful
40
as cooling agents and lubricants.
Esters of 1-carboxyadamantane had good thermal stability and good
stability against radicals but poor oxidation stability in the presence
of metals. Poor load carrying capacity was also observed, but this
41
could be improved with a small quantity of oleic acid. Adamantane
42diesters have also been prepared as lubricants.
°2CR2
Poly(3,5-dimethyl-l-adamantyl acrylate) has been suggested as a
43
viscosity index improver. 1,3-Diaminoadamantane dinitrite has been
44
reported to be a corrosion inhibitor.
Perfumes
Many constituents of perfumes are naturally occurring materials.
Terpenese and esters are common. Many of these materials are bicyclic.
As a consequence, it is not unreasonable to expect that some synthetic
bicyclic compounds also might find use in perfumes.
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45 iKretschmar and Erman have prepared 2-methylene-3-exo(trans-4 -
, t
methyl-5 -hydroxypent-3 -enyl)bicyclo[2.2.Ijheptane and related com-
pounds for use as perfumes. Bicyclo[2,2.2]octenes of the type(9-15) have
46
also been prepared as perfume intermediates. Bicycle[2.2,2]octane-
COOR'
(9-15)
2-carboxaldehyde has been condensed with.methyl ethyl ketone to produce
47
a perfume material.
Ethers of 4,8,8-trimethyl-9-7methylene(3.3. lJbicyclo-4-nonanol
have been reported to have a strong woody amber^like scent that decreases
48in intensity with increasing atomic weight,
A grassy-weedy camphoraceous order is obtained from compounds related
49to (9-16). They have been incorporated into perfume, flavor, and
323
detergent compositions, Bicyclo[3,3,Ijnonanes have been irradiated
to form bicyclo[5.1.1]non-2-en-9-one,
The corresponding bicyclo[4,1 ,Ijoctane-S^one has also been reported.
These compounds have a fougere odor and have been formulated into
detergents.
8-oxatricyclodecane is reported to be useful as a solvent and as
a component of perfumes. Perfume compositions have also been made
52from adamantane derivatives. For example, 1-adamantyl :methyl ketone,
ethyl 1-adamantylcarboxylate, and 1-adamantylnitrile have been used.
Detergents
Schmerling has prepared compounds of the type (9-17) which have
r-(0=(ZO) H)
^ ^
 Jn m
(OH)
A.
(9-17)
surface active properties, An alkyl bicycloheptylarylsulfonate
containing at least three carbon atoms in the alkyl group has also
54been claimed as a surface-active agent, Mono- or dialkylsubstituted
324
bicycloalkane sulfates, sulfonates, and hydroxy polyoxyalkylenes in
which the alkyl substituent contains up to 18 carbon atoms are useful
as biodegradable detergents. Polycyclic decarboximides made from
compound (9-18) were found to be stable to ultraviolet light and are
(9-18)
useful as optical brighteners and as light protectors.
Dyes and Dye Intermediates
Fire retardant pigments are reported to be derived from hexachloro-
57 S8
cyclopentadiene. Compounds (9-19) and (9-20) are phthalein dyes.
(9-19) (9-20)
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3-Azabicyclo[3.2.2]nonane sulfonamides are purple pigments that are
59
suitable for aqueous dispersion.
The incorporation of bicyclo[2,2.1]hept-5-ene-2,3-dicarboxylic acid
into an acrylonitrile-methyl acrylate copolymer gave a polymer that
would absorb Blue K and Red 2S cation dyes better than materials that
did not contain the bicyclic group, 3-(p-01ylsulfonyl)-5-chloro-
nortricyclene was one of several compounds which .are reported to be
useful as dyestuff intermediates, pesticides and monomers,
Liquid Crystals
67
Dewar has studied the effect of replacing benzene rings in liquid
crystals with bicyclo[2,2,2]octane groups.
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The object of the study was to prepare a liquid crystal material that
could be used as a solvent for spectroscopy, Replacement of the central
ring by a bicyclooctyl group lowered the transition temperature 28°.
Replacement of a terminal group lowered the transition temperature by
76°. No mesophase was observed when both terminal phenyl groups were
replaced, but the value was estimated to be 167° from a phase diagram.
Thus, the two effects appear to be additive. No liquid crystal behavior
could be observed when all three phenyl groups were replaced.
The authors concluded that a linear geometry is the prime factor
in generating liquid crystal behavior, The aromatic character of the
benzene ring was also found to be important by providing polarity for
the ends of the molecule. It was suggested that terminal groups will
327
be necessary to make an ultraviolet transparent liquid crystal, A
suggestion was made that the liquid crystals described here might be
suitable as the liquid phase in gas chromatography for the separation
of position isomers,
Miscellaneous Applications
A cigarette filter paper impregnated with bicyclo[3.3.1]nonan-3-
on-9-oxyl is said to remove 45 to 55% of the nitrosyl radicals from
the smoke passing through the filter. Tobacco additives have been
made from non-volatile, flavor containing Diels-Alter adducts.
Light sensitive photographic.recording materials have been made
7 f-\
using 4,8-bis(tricyclo[2,2.1,0 ' ]heptan-3-ylcarboamoyl)-l,5-napthalene-
dicarboxylic acid as one component. Poly-p-Xylylenes have been used
as a photomasking system with improved resolution and reproductibility.
Natural and synthetic resins containing bicyclic groups have been
tested for paper sizes. Pine resin has been converted to a drying
/- 0
oil for paints and varnishes by fractionation and thermal isomerization.
A study has also been made on foaming properties of pine oil for mineral
flotation,. 69
Fire resistant bituminous preparations for roof coverings have been
prepared by mixing the bituminous material with perchloropentacyclo-
[5.2.1.0 ' .0 ' .0 ' ]decane and other polyhalogenated compounds.
A recipe containing these materials with a small amount of antimony oxide
and asbestos does not burn.
328
Degreasing agents for metals and spotting agents for textiles
71have been made from compounds like (9-21).
R
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Chapter 10 - Suggestions for Further Work
Suggestions for further work have been made in appropriate places
throughout this report. It is the purpose of this final chapter to
collect these suggestions together, adding additional-suggestions
where they might be useful.
Polymers
The use of bicyclic and cage compounds in polymers was discussed
in Chapter 5. A few individuals, especially at du Pont, seem to have
undertaken a reasonably thorough study of bicyclic monomers. As a con-
sequence of their work, bicyclic equivalents of many of the common
bicyclic compounds have been prepared and incorporated into polymers.
In general, the resulting polymers have been reported to have improved
thermal properties. Unfortunately, no uniform method of testing seems
to have been used, and it is difficult to determine which, if any, of
the reported materials might have useful commercial properties.
If this area is ever to be developed for commercial purposes, it
will be necessary to evaluate each of the polymers using a uniform,
standard procedure. Special criteria might be established for special
applications, such as paints or potting' compounds.
Possible economic restraints on the commercialization of bicyclic
polymers were discussed at the end of Chapter 5. If suitable polymers
can be identified, it will still be necessary to find economic synthetic
routes to these materials. This could be a major problem, except for
highly specialized applications.
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The use of bicyclic peroxides as polymerization initiators may
have some potential. Little work has been done with these compounds,
and they do show unusual stability. Unfortunately, a range of peroxides
with varying decomposition temperatures is already commercially avail-
able, and there may not be much incentive to develop another series of
compounds.
A possible method of making a micro-sized capacitor is described
in Chapter 5. The idea proposes to take advantage of the ultrathin
films that can be made with p-xylylenes. Fluorinated poly-p-xylylene
and a thin metal film deposited by a vapor deposition technique might be
used to make a small capacitor suitable for use at high temperature.
Unlike monomers and polymers, bicyclic polymer additives have not
been studied in an organized manner. As a consequence, this should be
an area with potential for further development. Compounds containing
bicyclo[2.2.Ijheptane and bicyclo[2.2.2]octane groups should be especially
useful. Bicyclic equivalents of presently commercial polymer additives
in particular might have similar properties to the non-bicyclic compounds
and be more stable at high temperatures. Bicyclic equivalents of dibutyl
and dinonyl phthalates might be particularly useful.
COOR ^-^ _ COOR
COOR
COOR COOR
COOR COOR
R = Butyl or Nonyl
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Trieresyl phosphate, triphenylphospite, and triphenyl phosphine
are three compounds that are presently used in polymers that are
designed for high temperatures. Bicyclic equivalents might offer even
greater thermal stability without greatly affecting the physical
properties of the polymer.
Medicinals
Bicyclic and cage compounds demonstrate a wide variety of medicinal
applications as parent drugs or as important drug components. In view
of the physiological activities of these compounds and the high poten-
tial for unknown effects, one should investigate these systems with
caution.
Interesting avenues of research may be found in such areas as anal-
gesics, antibacterials, anticancers and various other topics. For
example, one study that could be undertaken would be to study known
drugs using bicyclic groups in place of the existing aromatic systems.
A study of the changes in physiological effects of these modified com-
pounds may lead to new drug compositions or may even enhance the under-
standing of drug actions.
The slow hydrolysis of bicyclic esters could be useful in developing
timed-release drugs. Salicyclic acid substituted with the bicyclic
analogue might give long-lasting relief to arthritis victims. As another
example, some bicyclic compounds have been reported to be more potent
than meperidine (Demerol). These compounds might best be studied by
investigating the toxicological parameters. Similarly, systems that
show high analgesic activity with low toxicity or slow release proper-
ties might be investigated to determine what other derivatives of the
parent compound will show these properties.
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Synthesis of penicillin derivatives with activities superior to
natural compounds has proved to be a fertile avenue of drug research.
Bicyclic or cage penicillin compounds that demonstrate excellent acid
sensitivity, resistance to penicillinase, and slow intestinal absorption
could be expanded by searching out other three-dimensional, side-chain
derivatives with these beneficial properties.
Various arabinofuranosyloytosineadamantoate compounds have demon-
strated excellent potency as anticancer agents. Other "sugar" derivatives
might be investigated that demonstrate inhibitory actions and are also
suitable as depot agents.
Compounds that show increased activity or increased specificity
should be exploited. For example, anticholinergics with the 9-azabicyclo-
[3.3.l]nonane skeleton show enhanced activity when gem dialkyl groups
are introduced into the bicyclic skeleton. These compounds are more
active than atropine, scopolamine, and benactyzine, which are known anti-
cholinergics .
Selected antiinflammatory medicinals such as the quinuclidines are
more effective than known compounds but more toxic. An in-depth study
concerning the reduction of this toxicity by chemical means should
prove to be a valuable project.
Generally, in the other categories considered in this report, there
are few outstanding examples of medicinal superiority. A comprehensive
study does not seem to have been undertaken, however, and further work
might be worthwhile.
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Pesticides
With polychlorinated pesticides in general disfavor at the moment,
increased use of non-chlorinated pesticides can be expected. Although
it is difficult to visualize which types of compounds will be preferred,
bicyclic and cage compounds will undoubtedly find increased use.
One approach to the problem might be to synthesize bicyclic analogs
of known pesticides in order to modify the toxicity of the product:
Parathion is one example that is highly toxic and which might .be affected
by a switch to a bicyclic analog.
.P^TW^NOEt-cr \_/ * Eto' V_y 2
Parathion A bicyclic analog
The generally slow rate of hydrolysis of esters of bicyclic and cage
compounds suggests another area that might be worthwhile. It should be
possible to incorporate slow release characteristics into pesticide
composition by .making bicyclic esters. This property would make it
possible to have an effective pesticide that does not need to be applied
as often as present pesticides. Toxicity to humans might be lowered
by this technique also.
There is already evidence (see Chapter 8) that low levels of certain
herbicides can cause plant dwarfing and other effects. If the effective
concentration of the herbicide could be maintained at a relatively low
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level by making a bicyclic ester of the herbicide that would hydrolyze
slowly, then it might be possible to develop new horticultural techniques
for growing dwart plants for specific purposes.
Synthetic Lubricants
At the present time, there is a rapidly developing trend toward
the use of synthetic lubricants. This .trend is creating a demand for
temperature-resistant materials to form both the bulk of the lubricant
and as additives to improve specific characteristics. The unusual
thermal stability of many bicyclic and cage compounds suggest that
they should have a significant part in this emerging technology.
There is ample evidence (see Chapter 9) that this is true. Several
good diester lubricants have been reported that use a bicyclic nucleus
as part of the molecule. There are also several reports of bicyclic
compounds being used as lubricant additives.
At the same time, the literature in this area is not extensive.
No concerted effort seems to.have been made to exploit this area.
This situation suggests that there is a real opportunity to undertake
. a concerted attempt to find new bicyclic and cage compositions that
might be useful as synthetic lubricants or lubricant additives.
